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Background: Hypothalamic kisspeptin and neurokinin B (NKB) are central 
regulators of GnRH and thus gonadotropin (LH and FSH) secretion. Men and 
women with loss-of-function mutations in NKB-kisspeptin pathway show 
hypogonadotropic pubertal delay with reduced GnRH/LH pulsatility. Studies in 
patients with defects in NKB signalling suggest that kisspeptin is functionally 
downstream of NKB, although there are very limited data on the relevance of the 
NKB pathway in normal men or women, and no hierarchical data on this. The studies 
described in this thesis have investigated the interaction between these neuropeptides 
in the control of human reproduction in conditions of varying sex-steroid 
environment, and in states of fast and slow LH secretion (men, menopause, various 
stages across the menstrual cycle).  
Overall hypothesis: Pharmacological blockade of NKB signalling will decrease LH 
secretion by modulating GnRH/LH pulsatility, indicating the involvement of the 
NKB pathway in normal human reproductive function. It is also hypothesised that 
this will not abrogate the stimulatory kisspeptin response, revealing a functional 
hierarchy whereby NKB signalling is upstream of kisspeptin. 
Research strategy: A specific neurokinin-3 receptor antagonist (NK3R antagonist, 
AZD4901) was administered 40 mg twice daily orally for 7 days with and without 
kisspeptin-10 (KP-10) challenge. Response of reproductive hormones (serum and 
urinary where applicable) was measured. LH was sampled every 10 minutes for 8 
hours to assess LH pulsatility by blinded deconvolution.  
Results: 
Role of neurokinin B and kisspeptin in healthy men 
Six healthy men underwent LH pulsatility study pre-treatment and on day 7 of NK3R 
antagonist administration with iv KP-10 bolus (0.3 µg/kg) at 6 hours. NK3R 
antagonist reduced LH and testosterone secretion, whilst stimulatory LH response to 
KP-10 was unaffected. LH pulse frequency was unchanged by the NK3R antagonist 
but basal (nonpulsatile) and pulsatile LH secretion was markedly reduced.  
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Role of neurokinin B and kisspeptin in postmenopausal women 
Eleven postmenopausal women underwent LH pulsatility study pre-treatment and on 
day 7 of NK3R antagonist administration with iv KP-10 bolus (0.3 µg/kg) at 6 hours. 
NK3R antagonist decreased LH secretion. Basal (nonpulsatile) LH secretion also fell 
and while LH pulse frequency did not change in a group as a whole, it did fall in the 
8 of 11 postmenopausal womenwith hot flushes. These women reported a reduction 
in hot flush frequency (3.4±1.2 vs 1.0± 0.6 flushes/day with NK3Ra, p=0.008) and 
severity whilst on NK3R antagonist. LH response to KP-10 was minimal and 
unaffected by the NK3R antagonist.  
Role of neurokinin B across different phases of menstrual cycle  
The effect of NK3R antagonist on ovarian function was compared in early follicular 
(n=13), late follicular (n=6) and luteal phase (n=6) to no treatment control cycle.  
Early follicular: NK3R antagonist was commenced from cycle day 5-6. The diameter 
of the leading follicle was smaller than in controls at the end of treatment (9.3±0.4 vs 
15.1±0.9 mm, p<0.0001). Serum estradiol was also reduced and the endometrium 
was thinner. Although NK3R antagonist had no effect on LH pulse frequency, basal 
(nonpulsatile) LH secretion was decreased, suggesting that NKB modulates GnRH 
secretion. After stopping treatment, follicle development resumed and estradiol 
secretion increased thereby delaying the LH surge in 11/13 women (LH surge cycle 
day 22±1 vs 15±1, p=0.0006). The delayed LH surge and ovulation were confirmed 
by a similarly delayed rise in urinary progesterone and prolonged cycle length. 
NK3R antagonist did not affect luteal function. 
Late follicular: NK3R antagonist was administered from the emergence of a 
dominant follicle (≥12mm). Whilst there was an LH surge in all treated cycles, 
estrogen feedback was perturbed by the NK3R antagonist, as there was increased 
variation in the timing of LH surge compared to control cycle. NK3R antagonist had 
no effect on the growth of a dominant follicle and luteal function was unaffected.  
Luteal: NK3R antagonist was administered from day +2-3 of the disappearance of 
the dominant follicle. NK3R antagonist reduced the variation in the timing of peak 
estradiol secretion. Estradiol and progesterone concentrations remained unchanged, 
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suggesting that luteal function was overall unaffected by this treatment. No 
difference in mean LH was observed, although LH pulsatility was not assessed.  
Role of neurokinin B and kisspeptin in the mid-cycle LH surge 
A model of follicular phase (cycle day 9-11) administration of estradiol (200µg/day) 
to induce  LH secretion at 48 hours was used in twenty women, mimicking LH 
surge. In this model, KP-10 infusion (4µg/kg/hr for 7 hours) enhanced LH secretion, 
the response of which was directly correlated with estrogen concentration, indicating 
a role of kisspeptin in estrogen feedback. Pre-treatment with NK3R antagonist 
decreased LH pulse frequency and whilst the immediate LH response to KP-10 was 
unaffected, it blunted the duration of this response and abolished the relationship 
between estradiol and kisspeptin-induced LH secretion.  
Conclusions: These data indicate the role of NKB-KP pathway in regulating human 
reproductive function and that this is via the modulation of pulsatile GnRH secretion. 
Whilst NKB is predominantly proximal to kisspeptin, the hierarchy is more complex 
than simply linear in the control of human HPG axis. Manipulation of NKB-KP 
signalling has therapeutic potential in regulating GnRH/LH secretion in wide range 
of clinical settings, including contraception, sex-steroid dependent disorders and in 













Reproductive function is regulated by the brain hormone called Gonadotropin 
Releasing Hormone. This in turn stimulates Luteinising Hormone (LH) secretion 
from the pituitary gland at the base of the brain, which effects how ovaries and testes 
function in women and men. These hormones are released in bursts (pulses), which 
are essential for normal reproductive function. It is known that the frequency of burst 
of those hormones can be regulated by a novel brain hormone called kisspeptin and 
slowed down by a blocker of another hormone neurokinin B (NKB). However, the 
interaction between kisspeptin and NKB in the regulation of human reproduction is 
unknown. Abnormal secretion of those brain hormones might cause low levels of LH 
and therefore clinical problems such as a delay in puberty, or high levels of LH 
which may led to a condition such as Polycystic Ovary Syndrome (PCOS), causing 
infertility. Since the ability to control LH secretion bursts could be used to develop 
new treatments for various conditions of reproductive function, the aim of this study 
was to understand how these brain hormones interact and control LH bursts.  
The interaction between kisspeptin and NKB was tested in healthy women across 
varying stages of their reproductive life and in healthy men. During the study, 
kisspeptin was administered into a vein and NKB blocker was taken as a tablet twice 
a day for 7 days. LH was measured after taking a blood test and in women with 
periods, growth of eggs in the ovary was measured by ultrasound imaging.  
We found that in women after menopause and in men the blocker of NKB decreased 
LH levels. The NKB blocker also reduced the male hormone testosterone. 
Kisspeptin, on the other hand, increased LH levels in men where the frequency of 
LH bursts is characteristically slow. However this increase in LH levels was minimal 
in women after menopause (where LH burst frequency is fast). The effect of 
kisspeptin on LH levels was not affected by the NKB blocker, suggesting that 
kisspeptin effects on LH are ‘further down the pathway’ of the NKB system. The 
NKB blocker and kisspeptin also affected various aspects of LH release in bursts in 
those subjects, indicating that NKB and kisspeptin control reproduction by acting on 
the main hormone, Gonadotropin Releasing Hormone.  
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Postmenopausal women taking NKB blocker reported that the frequency of their hot 
flushes and night-time awakenings were reduced with this treatment, and the severity 
of their flushes decreased. In this group of women, blockage of NKB reduced the 
frequency of LH burst and since it is thought that menopausal hot flushes are related 
to the frequency of LH burst, there is a potential for NKB blockers to be used as new 
treatments for the management of those flushes.  
When administered soon after the period has started in healthy women, NKB blocker 
was able to delay the growth of the new egg.  This subsequently delayed the sharp 
rise in blood LH levels, which causes that egg to be released. After stopping 
treatment, normal egg growth and release occurred. When administered at the time 
when there is a large egg ready to be released, the NKB blocker caused a small delay 
in the growth of the egg and interfered with the timing of sharp LH rise. This 
suggests that the communication between the ovary and the brain was interrupted but 
not completely blocked. When administered soon before the period was due to start 
the NKB blocker had minimal effect on hormone levels. 
Also studied was how the sharp rise in LH that causes an egg to be released from the 
ovary is regulated by the NKB blocker, or brought on by kisspeptin in healthy 
women. Kisspeptin increased a rise in LH levels similar to levels seen at the time 
when egg is being released normally. The blocker of NKB did not abolish this LH 
rise but made it of a shorter duration. This indicates that NKB regulates how the 
brain controls egg growth in the ovary, the rise in LH levels and egg release. The 
blocker of NKB can affect those key events of human reproduction and may be 
applied to the development of new contraception.  
Taken together this data suggest that NKB and kisspeptin are key regulators of 
normal human reproductive function and that they act by controlling the key brain 
hormone Gonadotropin Releasing Hormone. The interaction between those 
hormones is a complex one. The ability to manipulate how NKB and kisspeptin 
function in the brain by their blockers or stimulators might be able to regulate the 
frequency of LH burst. This could be subsequently applied to various clinical 
settings, including delay in puberty, PCOS, menopausal hot flushes, and the 
development of new contraceptives.  
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Chapter 1.  Literature Review  
1.1 GnRH- the principal regulator of reproduction 
Gonadotropin Releasing Hormone (GnRH) is recognised as a key final mediator of 
endocrine, metabolic and environmental influences on reproductive function 
conveyed through the central nervous system.  Following the pulsatile secretion of 
GnRH into the hypophyseal portal circulation, it stimulates pulsatile LH and tonic 
FSH release from the gonadotropes of anterior pituitary, and thus regulates gonadal 
function and steroidogenesis. This functional unit is known as the hypothalamic-
pituitary-gonadal (HPG) axis. Pulsatile secretion of GnRH drives the fundamental 
events in human reproduction, such as onset of puberty and control of adult fertility, 
whilst changes in GnRH pulse pattern can lead to reproductive endocrine disorders 
and sterility.  
1.1.1 The discovery of GnRH, its isoforms and receptors 
GnRH 
The hypothesis that “nerve fibres from the hypothalamus liberate some humoral 
substance(s) into the capillaries of the primary plexus in the median eminence and 
that this substance is carried by the portal vessels to excite or inhibit the cells of the 
pars distalis” dates back to the monograph by Harris in 1955 (Harris. 1955), when 
mechanisms regulating hormonal secretion from the anterior pituitary were yet 
unknown. It was not until 1971, when GnRH was first isolated and sequenced from 
porcine and ovine hypothalami as a 10 amino acid peptide by the two independent 
groups of the Nobel laureates Andrew V. Shally and Roger Guilleman, respectively 
(Baba et al. 1971, Schally et al. 1971a). GnRH is a cleavage product of a larger 92 
amino acid precursor prepro-GnRH. It was a decapeptide that was initially termed 
Luteinizing Hormone Releasing Hormone (LHRH) or Luteinizing Hormone 
Releasing Factor (LRF) (Schally. 2000), but is now known as GnRH to reflect its 
stimulatory effect on both LH and FSH secretion (Schally et al. 1971b, Conn and 
Crowley. 1994).  
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GnRH isoforms 
The primary amino acid sequence of mammalian GnRH is not unique but spans for 
approximately 600 million years of evolution with over 20 isoforms identified in 
vertebrates (Maggi et al. 2016). GnRHs are named depending on the species in 
which they were first identified. GnRH was first discovered in mammal and is 
referred to as GnRH I (Miyamoto et al. 1984, Maggi et al. 2016). GnRH I regulates 
LH and FSH secretion, and this function will be discussed throughout the thesis. 
Another isoform was identified from chicken brain and is referred to as GnRH II 
(Miyamoto et al. 1984, Millar. 2003). GnRH II appears to be a neuromodulator of 
sexual behaviour (Chen et al. 1998, Millar. 2003). A third isoform was isolated from 
fish and is termed GnRH III (Sower et al. 1993). It is associated with the control of 
gametogenesis and sex-steroid production and has anti-proliferative effects, whilst in 
mammals has insignificant endocrine activity (Deragon and Sower. 1994).  
GnRH receptor 
The amino acid sequence of receptor for the ligand GnRH I (type I GnRH receptor) 
was first isolated from the mouse αT3-1 gonadotrope-derived cell line and then 
cloned from the pituitaries of several species, including humans (Fan et al. 1994). It 
belongs to the family of G-protein coupled receptors (GPCR) characterised by seven 
hydrophobic transmembrane domains (Maggi et al. 2016). Upon binding by GnRH, 
pituitary GnRH receptor couples to the G-protein subunit, activating phospholipase 
C and yielding secondary intracellular messengers, inositol triphosphate (IP3) and 
diacylglycerol (DAG). In turn, IP3 mediates calcium release, and DAG activates 
protein kinase C, which amplifies the downstream signalling cascade leading to 
gonadotropin synthesis (Cheng and Leung. 2005, Maggi et al. 2016). Conversely to 
episodic stimulation, continuous occupancy of GnRH receptor by its peptide, 
desensitises gonadotropes, suppressing gonadotropin and gonadal steroid secretion 
(Conn and Crowley. 1994), the feature of which is extensively applied in clinical 
management of sex hormone-dependent diseases and in assisted conception. In this 
thesis, the terms ‘GnRH’ and ‘GnRH receptor’ will be used instead of the GnRH I 
and its cognate type I GnRH receptor, respectively, when referring to the 
hypophysiotropic function of the decapeptide.  
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
Literature Review        3 
1.1.2 Neuroanatomy of GnRH network and related developmental 
disorders 
Neurodevelopment  
GnRH neurones originate in the nasal region, the medial olfactory placode, and 
during fetal development migrate along the scaffold of olfactory axons and terminal 
nerves into the olfactory bulb and to their final destinations within the hypothalamus 
(Schwanzel-Fukuda and Pfaff. 1989, Wray et al. 1989, Forni and Wray. 2015). The 
mechanisms regulating GnRH neurone migration involve the timed and coordinated 
expression of numerous cell adhesion molecules, matrix proteins, guidance cues, 
neurotransmitters, and growth and transcription factors (Forni and Wray. 2015). 
Defective GnRH neurone migration with olfactory dysfunction defines the Kallmann 
syndrome, where hypogonadotropic hypogonadism is associated with 
anosmia/hyposmia (absent or impaired sense of smell) (Kallmann et al. 1944, 
Schwanzel-Fukuda et al. 1989). These disorders are recognized as being oligogenic 
with complex genetic-environmental interactions that account for variable penetrance 
and interindividual phenotypic variation (Mitchell et al. 2011). Although the familial 
inheritance has been documented, the majority of cases are sporadic. To date genes 
that are required for GnRH neurone development, differentiation and function have 
been implicated in causing hypogonadotropic hypogonadism (Forni and Wray. 2015) 
and encode for factors including:  fibroblast growth factor 8 (FGF8) and its receptor 
(FGFR1) (Dode et al. 2003), heparin sulphate 6-O-sulphotransferase I (HS6ST1) and 
nasal embryonic LH releasing hormone factor (NELF) (Miura et al. 2004) involved 
in the embryonic differentiation of GnRH neurones; cell adhesion molecule anosmin-
1 (KAL1) (Legouis et al. 1991), chemotactic agent semaphorin 3A (SEMA3A) 
(Cariboni et al. 2011), G-protein prokineticin 2 (PROK2) and its receptor (PROKR2) 
(Pitteloud et al. 2007) essential for correct migration of GnRH neurones; 
sematophorin 3E (SEMA3E) (Cariboni et al. 2015) regulating the survival of GnRH  
neurones; neurokinin B (TAC3)-neurokinin 3 receptor (TAC3R) (Topaloglu et al. 
2009) and kisspeptin (KISS1) (Topaloglu et al. 2012)-kisspeptin receptor (KISS1R) 
(de Roux et al. 2003, Seminara et al. 2003) complexes, the upstream mediators of 
GnRH secretion; and GnRH (GnRH1) and the receptor (GnRHR1) itself (Bouligand 
et al. 2009, Chan et al. 2009b). 
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Distribution of GnRH neurone cell bodies 
There are approximately 1000-3000 hypothalamic GnRH neurones, depending on the 
species studied (Wray and Hoffman. 1986, Maggi et al. 2015). Owning to their 
olfactory origin, the GnRH cell bodies form a scattered continuum along their 
migratory pathway, although some species differences exist (Herbison. 2015). In 
humans, GnRH cell bodies or perikarya are diffusely scattered from the preoptic area 
(POA) though to the infundibular nucleus (homologue of the arcuate (ARC) nucleus 
in other species) of the medial basal hypothalamus, whereas in rodents the GnRH 
cell bodies reside predominantly in the POA (King and Anthony. 1984, Lehman et 
al. 1986, Schwanzel-Fukuda and Pfaff. 1989, Herbison. 2015).  
GnRH neurone projections to the median eminence 
GnRH neuronal projections are atypical in that they combine the characteristics of 
both dendrites and axons, which receive synaptic inputs and propagate action 
potential, respectively, and hence, have been termed as ‘dendrons’ (Herde et al. 
2013). They extend remarkable distances (2-3mm) from the GnRH cell body to the 
median eminence wrapping around each other and synapsing with adjacent GnRH 
neurones though numerous spine-like protrusions along the entire length of the 
dendron (Campbell et al. 2005, Campbell et al. 2009). These interconnections are 
likely to be functionally important in the synchronization of pulsatile GnRH release 
(Campbell et al. 2009). GnRH dendrons then break into numerous axons and 
terminal nerves upon their arrival at the principal site, the external zone of median 
eminence, where GnRH is secreted into the pituitary portal circulation, allowing 
delivery of the decapeptide to the gonadotropes of anterior pituitary. At the site of 
GnRH neurosecretion, GnRH neurones are in close proximity to the hypothalamic 
network of kisspeptin neurones (Clarkson and Herbison. 2006, Ramaswamy et al. 
2008, Hrabovszky et al. 2010), the anatomical distribution of which and their 
functional interaction with the GnRH system is described below.  
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1.1.3 GnRH pulsatility 
Pulsatile secretion of GnRH is the prerequisite for the acquisition and maintenance of 
normal adult reproductive function. The pattern of pulsatile GnRH secretion varies 
across the human lifespan, ranging from high pulsatility during the late stages of 
gestation and in the first year of life, though to quiescence during childhood, 
followed by nocturnal reactivation at puberty, culminating in sustained adult 
pulsatile GnRH secretion. In males, the frequency of GnRH pulses is approximately 
two hourly, whilst in females it is variable across the different phases of the 
menstrual cycle with a further surge mode of GnRH secretion mid-cycle (Maeda et 
al. 2010). Pulse mode refers to the episodic nature of GnRH release into the 
hypophyseal circulation with undetectable GnRH concentrations in portal blood 
between those pulses (Maeda et al. 2010). Pulsatile GnRH release drives ‘tonic’ 
gonadotropin secretion, necessary for reproductive function in both sexes, such as 
folliculogenesis, spermatogenesis and the synthesis of gonadal steroids (Plant. 
2015a). Surge mode of GnRH release, unique to females, reflects persistence of 
GnRH in the portal circulation, generating the pre-ovulatory LH surge to induce 
ovulation (Maeda et al. 2010).   
1.1.3.1 Pulsatile GnRH secretion 
Pulse mode of GnRH release 
The pulsatile nature of GnRH secretion in the primate was initially shown in the 
rhesus monkey by frequent sampling of the hypothalamic-pituitary stalk portal blood 
(Carmel et al. 1976). Disconnection of the vasculature links controlling pituitary 
function precluded those early experiments from simultaneous study of peripheral 
LH secretion. Although not yet directly demonstrated, the regulation of pulsatile LH 
secretion by the underlying GnRH pulsatility was postulated and strengthened by the 
findings that GnRH pulses were in close correlation with previously documented LH 
pulses in rhesus monkeys (Carmel et al. 1976), that GnRH pulsatility was associated 
with oscillations in LH levels in the pituitary blood sampled during transsphenoidal 
surgery in patients with pituitary adenomas (Antunes et al. 1978) and that 
gonadotropin secretion was abolished by an intravenous administration of antiserum 
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to GnRH in ovariectomised rhesus monkeys (McCormack et al. 1977). It was not 
until the early 1980’s, when the ability to sample hypothalamo-hypophyseal portal 
blood and maintain the pituitary function in conscious ewes was achieved, that the 
synchrony between the pulsatile discharges of GnRH from the hypothalamus and the 
pulses of LH in the peripheral circulation was demonstrated (Clarke and Cummins. 
1982).  
The need for intermittent GnRH stimulation of the gonadotropes for sustained LH 
and FSH secretion was elegantly demonstrated by further work from Knobil’s group, 
where in rhesus monkeys with hypothalamic lesions, abolishing endogenous GnRH 
and thus gonadotropin release, LH and FSH secretion was reinstated with an 
intravenous pulsatile GnRH infusion every hour (Belchetz et al. 1978). In contrast, 
continuous GnRH infusion suppressed this hypophysiotropic response (the process 
of desensitization), which again recovered when animals were switched from the 
continuous to pulsatile GnRH replacement (Belchetz et al. 1978). Furthermore, 
central role of pulsatile GnRH/LH secretion in the regulation of menstrual cycle and 
response to sex-steroid feedback was demonstrated in rhesus monkeys rendered 
hypogonadotropic and unresponsive to exogenous estradiol feedback by 
hypothalamic lesions, where pulsatile GnRH administration re-established normal 
ovulatory menstrual cycles (Knobil et al. 1980). Gonadal steroids also regulate the 
frequency of GnRH pulsatility, which is every 2-4 hours in intact rams, increased to 
a pulse every 70 minutes and every 36 minutes in short-term and long-term castrated 
rams, respectively (Caraty and Locatelli. 1988). 
Surge mode of GnRH release 
The surge mode of GnRH release was demonstrated by a massive increase and 
persistence of GnRH concentrations in the pituitary stalk blood of the proestus rat, 
correlating with the LH surge and ovulation observed in parallel studies of the same 
strain of rats (Sarkar et al. 1976). Whether GnRH/LH surge is a summation of high 
frequency and high amplitude pulses (Rahe et al. 1980, Gallo. 1981, Marut et al. 
1981, Norman et al. 1984) or continuous GnRH secretion into the portal circulation 
remains an ongoing debate (Moenter et al. 1992, Maeda et al. 2010). The latter is 
favoured by the observation that in sheep, a large amount of GnRH is released prior 
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the LH surge persisting beyond the end of the LH surge (Moenter et al. 1992). The 
GnRH surge is triggered by increasing estradiol levels across the late follicular phase 
of the menstrual cycle in spontaneously ovulating species, or in some species by 
coitus itself (Plant. 2015a).  
Detection of GnRH pulsatility 
The half-life of disappearance of exogenous GnRH from peripheral circulation in 
man is 3.6 minutes with virtually no GnRH present in the blood at the time of 
maximal gonadotropin stimulation (Arimura et al. 1974). Measurement of GnRH 
levels outside the portal system therefore cannot accurately reflect its hypothalamic 
secretion, and in humans, sampling of hypophyseal blood is unsound ethically and 
practically.  
LH pulses in the peripheral circulation remain a widely used and well-validated 
surrogate of hypophyseal GnRH pulsatility (the long half-life of FSH [274±45 
minutes in men] vs LH [approximately 20 minutes] makes FSH an unsuitable 
marker) (Urban et al. 1991). LH, FSH, Human Chorionic Gonadotropin (HCG) and 
thyroid-stimulating hormone (TSH) consist of two noncovalently linked 
polypeptides- α and β subunits. The β subunit is unique to each with hormone 
specific functional properties, and it is assay to LH β subunit that is used for 
detection of serum LH levels. The α subunit is conserved in all four hormones and 
the secretion of the uncombined subunit gives the name of free α subunit (FAS) 
(Corless et al. 1987). FAS has also been proposed as a marker of GnRH activity due 
to its short half-live (12-15 minutes) (Whitcomb et al. 1990). However, factors 
known to modulate gonadotropin secretion, such as starvation, can also alter TSH 
secretion, precluding FAS correlation with GnRH pulsatility (Samuels and Kramer. 
1996). Furthermore, TSH could interact with the human FSH receptor, such as seen 
in cases of precocious puberty associated with congenital hypothyroidism (Anasti et 
al. 1995).  
1.1.3.2 Pulsatile LH secretion 
The pulsatile nature of LH secretion was discovered shortly before the isolation of 
hypothalamic GnRH. In the course of validation of a radioimmunoassay for serum 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
Literature Review        8 
LH in rhesus monkeys, Knobil and co-workers reported intermittent rhythmic 
oscillations in circulating LH concentrations (Dierschke et al. 1970, Knobil. 1981). 
Further studies in those animals using frequent (10-30min) blood sampling via an 
indwelling cardiac catheter showed the frequency of those LH pulses to be 
approximately one hourly (Dierschke et al. 1970). The frequency of LH pulses was 
higher in ovariectomised rhesus monkeys compared to intact animas with similar 
findings reproduced in sheep, for the first time suggesting sex-steroid feedback in the 
regulation of LH pulse frequency (Dierschke et al. 1970, Bolt. 1971). LH secretion in 
pulses was soon thereafter demonstrated in other mammals, including humans 
(Katongole et al. 1971, Nankin and Troen. 1971, Butler et al. 1972, Gay and Sheth. 
1972, Yen et al. 1972).  
Gonadal activity is dependent on the frequency and the amplitude of LH pulses, and 
furthermore the variation of both parameters in that cycle in females. In males, LH 
pulse frequency approximately every 2 hours maintains spermatogenesis and 
testosterone secretion (Nankin and Troen. 1971). In pre-menopausal women, the 
frequency of LH pulses changes according to the stage of the menstrual cycle, being 
every 1-2 hours during early follicular phase, early luteal phase and mid-cycle surge 
while slower every 4 hours in the mid and late luteal phase (Yen et al. 1972). This 
change in LH pulse frequency is consistent across species (Foster et al. 1975, Baird. 
1978, Rahe et al. 1980, Sollenberger et al. 1990). The amplitude of LH pulses also 
changes from ‘minor oscillations’ in the late follicular phase to higher amplitude 
during the luteal phase (Yen et al. 1972, Santen and Bardin. 1973). Low LH pulse 
amplitude in conjunction with rising LH pulse frequency accounts for more than a 
doubling in LH concentration seen at the mid-cycle LH surge (Yen et al. 1972). 
Conversely, higher amplitude and lower frequency of LH pulses accounts for 
decreased LH levels during the luteal phase (Yen et al. 1972, Santen and Bardin. 
1973). Pulsatile LH secretion is the major stimulator of ovarian steroidogenesis.  
In addition to the frequency of LH pulses regulating ovarian function, the reverse 
was also shown in human, when in the absence of ovarian steroids in post-
menopausal women, LH pulse frequency is as high as during the follicular phase in 
pre-menopausal women but with high circulating LH concentration (Yen et al. 
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1972). It is now well accepted that estrogen can be both inhibitory and stimulatory to 
LH secretion depending on the phase of the menstrual cycle, whilst progesterone is 
inhibitory. Sex-steroids exert their feedback at the level of both the hypothalamus 
and the pituitary to modulate pulsatile GnRH/LH secretion. Estrogen acts 
preliminary to reduce pulse amplitude, while progesterone acts to reduce pulse 
frequency (Karsch. 1987).  
Those early studies above have discovered key paradigms in reproductive biology; 
the pulsatile nature of LH secretion and the sex-steroid feedback in regulating the 
frequency and amplitude of the periodic gonadotropin secretion. The novel finding of 
LH secretion in a pulsatile manner was proposed to be the consequence of then not 
yet correlated intermittent signals from the central nervous system to the pituitary by 
an LH releasing factor (Dierschke et al. 1970).   
1.1.3.3 Mechanisms of the GnRH pulse generator 
To coordinate thousands of neurones to discharge GnRH from the nerve endings into 
the hypophyseal portal circulation in pulse or surge mode simultaneously, some sort 
of neural timing mechanism must exist, and is referred to as the GnRH pulse 
generator or ‘circhoral clock’ (Maeda et al. 2010, Herbison. 2015, Plant. 2015a). 
Although the importance of the GnRH pulse generator has been recognised for years, 
its location, and the mechanisms by which GnRH neurones co-ordinate their activity 
remain incompletely understood (Maeda et al. 2010, Herbison. 2015, Plant. 2015a). 
Two mechanisms have been proposed for the GnRH pulse-generator; one is that 
pulsatility is intrinsic to GnRH neurones themselves, and other that a population of 
non-GnRH neurones within the mediobasal hypothalamus (MBH) target the 
downstream GnRH neuronal network to drive pulsatile GnRH secretion (Maeda et al. 
2010, Herbison. 2015, Plant. 2015a).  
GnRH pulse generator: the mediobasal hypothalamus 
The localisation of GnRH pulse generator to reside within the MBH comes from the 
famous ‘Halasz’s knife’ experiments in rats, where deafferentation of the MBH from 
the rest of the brain did not affect follicle development nor testicular structure, 
indicating that pulsatile GnRH/LH secretion is preserved (Halasz and Pupp. 1965). 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
Literature Review        10 
Subsequently, normal LH pulsatility was demonstrated following complete 
hypothalamic deafferentiation (Blake and Sawyer. 1974, Ohkura et al. 1991), and 
normal GnRH pulsatility was observed in fetal MBH transplants in adult rat (Ohkura 
et al. 1992). Recordings of the multi-unit electrophysiological activity (MUA) in the 
MBH preceding LH pulses further supports the existence of a hypothalamic GnRH 
pulse generator (Knobil. 1981, Thiery and Pelletier. 1981), although the cells 
generating those volleys of MUA could not be determined (Maeda et al. 2010). 
Whilst GnRH neurones are abundant in the primate MBH, they are sparse in the 
MBH of other species, suggesting MUA volleys may originate outside the GnRH 
neuronal network (Okamura et al. 2013). It was not until 2003 (de Roux et al. 2003, 
Seminara et al. 2003), when genetic studies in human populations identified a novel 
signalling peptide, kisspeptin, which by reciprocally interacting with other 
hypothalamic neuropeptides neurokinin B and dynorphin located within the MBH, is 
now considered as a prime candidate for GnRH pulse generation (Okamura et al. 
2013). The discovery of kisspeptin and its role in the regulation of pulsatile GnRH 
secretion will be discussed later in the chapter.  
GnRH pulse generator: the autonomicity of GnRH neurones 
There is a notion that GnRH pulsatility is intrinsic to the GnRH neurone itself. 
Immortalised GnRH-secreting GT-1 cells, derived from the mouse hypothalamus, 
exhibit pulsatile GnRH secretion in the culture medium (Martinez de la Escalera et 
al. 1992). Similarly, GnRH neurones cultured from the embryonic olfactory placode 
of the rhesus monkey demonstrated episodic calcium influxes and GnRH pulsatility 
in vitro (Terasawa et al. 1999a, Terasawa et al. 1999b) Furthermore, GnRH neurones 
themselves exhibit heterogeneous firing patterns, when recorded in GnRH-GFP 
transgenic rodents, using cell-attached electrodes in acute brain slices and 
anaesthetised animals (Lee et al. 2010, Constantin et al. 2013).  
Synchronisation of GnRH neuronal activity 
For GnRH to be released in fixed episodic manner, GnRH neurones require 
synchronised activation. Axo-dendritic and axo-somatic synapsing between the 
adjacent GnRH neurones is one possibility by which GnRH neurones achieve co-
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ordinated GnRH discharges, although the GnRH network is scattered throughout the 
hypothalamus, suggesting this would have to operate over significant distances 
(Witkin and Silverman. 1985, Herbison. 2015). Synchronisation of GnRH pulses 
may occur at the median eminence, the site where GnRH nerve terminals converge, 
and is supported by pulsatile GnRH release observed from the isolated rat median 
eminence in vitro (Rasmussen. 1993). Alternatively, the upstream ‘clock’ kisspeptin 
and its interrelated network may affect GnRH cells at the same time, resulting in 
simultaneous GnRH output (Okamura et al. 2013).  
1.1.3.4 Differential secretion of LH and FSH by GnRH pulse 
frequency 
The stimulatory effect of GnRH on gonadotropin secretion is not identical, with FSH 
being released in constitutive and LH in pulsatile manner (McNeilly et al. 2003). 
Administration of GnRH antisera in ovariectomised ewes rapidly abolished LH 
secretion with levels undetectable in 24 hours, whilst FSH secretion fell gradually 
and remained detectable (Caraty et al. 1984). A change in the frequency of GnRH 
pulsatile secretion is the key determinant of differential synthesis and secretion of 
pituitary gonadotropins and the ratio of LH and FSH levels across the different 
phases of the menstrual cycle. Transcription of LH and FSH β subunits is sensitive to 
pulsatile GnRH secretion (Haisenleder et al. 1991, Kaiser et al. 1997). Fast GnRH 
pulse frequency (1 pulse per 60-90 minutes) favours LH release, which is 
predominant over FSH in the late follicular phase necessary for ovulation, whilst 
slow GnRH pulsatility (<1 pulse per 2-3 hours) stimulates FSH secretion, which is 
dominant over LH in the luteal and early follicular stages of the menstrual cycle 
necessary for follicular development (Wildt et al. 1981). In the course of pubertal 
acquisition, FSH appears first in the circulation followed by LH, reflecting gradual 
acceleration of GnRH pulses, further supporting frequency-specific gonadotropin 
secretion (Burr et al. 1970, Sizonenko et al. 1970). Increasing the frequency of 
GnRH pulses above one pulse per hour similarly to continuous GnRH administration 
or an infusion of long-acting GnRH analogue, reduces pituitary responsiveness and 
extinguishes gonadotropin secretion (Wildt et al. 1981). Although it has no 
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physiological role, is used pharmacologically in clinical practice (Wildt et al. 1981). 
In contrast, altering the amplitude of GnRH pulses with constant pulse frequency has 
minimal regulatory effect on gonadotropic output (Wildt et al. 1981).  
1.1.3.5  Relevance of GnRH/LH pulsatility in health and disease 
High and low GnRH and thus LH pulse frequency is characteristic of both 
physiological processes and pathological conditions.  Fluctuation in pulsatile GnRH 
secretion is essential for normal pubertal development and in females, for ovarian 
function.  GnRH/LH pulsatility is low in patients with pubertal delay, hypothalamic 
amenorrhoea and hypogonadism in diabetes, whereas GnRH/LH pulsatility is 
enhanced in precocious puberty, polycystic ovary syndrome (PCOS) and menopause. 
(Berensztein et al. 2006) 
Pubertal maturation 
Sustained pulsatile GnRH secretion is observed during fetal life and in early infancy 
and is sufficient to stimulate gonadotropin and sex-steroid secretion, although 
ovulation and spermatogenesis are not established (Forest et al. 1974, Conte et al. 
1980, Waldhauser et al. 1981, Clark et al. 1984). To distinguish this latter 
phenomenon from true puberty, this phase is referred to as ‘mini-puberty’ (Plant. 
2015b). Gonadotropin levels are high during the first 3 months after birth, with LH 
and FSH decreasing gradually by age 6-9 months in boys, except FSH levels in girls 
that remain elevated until 3-4 years of age (Kuiri-Hanninen et al. 2014). This 
gonadotropin surge in associated with gonadal activation. In boys, testosterone peaks 
at 1-3 months but spermatogenesis is not initiated, as Sertoli cells do not appear to 
express androgen receptor (Berensztein et al. 2006). In girls, estradiol secretion is 
more fluctuant, possibly reflecting cyclical development and atrophy of follicles 
(Kuiri-Hanninen et al. 2014). After this postnatal HPG axis activity, pulsatile GnRH 
secretion becomes quiescent with stable and slow pulses during childhood, 
suppressing any activity of the gonads (Plant. 1980, Waldhauser et al. 1981). At the 
onset of puberty, nocturnal slow GnRH pulses initially stimulate FSH secretion and 
with acceleration of GnRH pulse frequency LH is secreted (Burr et al. 1970, 
Sizonenko et al. 1970). The regularity of GnRH and gonadotropin secretion becomes 
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sustained throughout day and night time, supporting sex hormone production and 
initiating gametogenesis (Dunkel et al. 1992, Plant. 2015b).  
Central mechanisms independent of the gonads appear to be responsible for 
switching off GnRH pulsatility and maintaining it in low stable state during infancy 
and then reawakening GnRH pulse generator at puberty (Plant. 2015b, Herbison. 
2016b). Agonadal children (Conte et al. 1980) and rhesus monkeys (Plant. 1980) 
experience the same pre-pubertal suppression of hypothalamic-pituitary-gonadal 
axis, and adolescent girls with Turner syndrome (45,X) show nocturnal gonadotropin 
secretion (Boyar et al. 1978). 
Premature or delayed reawakening of GnRH pulse generator is the central pathology 
associated with precocious and delayed puberty, respectively. Mechanisms involved 
in abnormal activation of the HPG axis include genetic (e.g. mutations in kisspeptin 
gene, Kallmann syndrome), endocrine (e.g. congenital adrenal hyperplasia), 
congenital, anatomical (e.g. tumours, trauma), iatrogenic (e.g. irradiation, 
chemotherapy, gonadectomy) and idiopathic causes (Abreu and Kaiser. 2016). 
Maintenance of ovarian cycle 
In women, GnRH/LH pulse frequency is lowest in the luteal phase, but increases 
during follicular and pre-ovulatory phases of the menstrual cycle (Yen et al. 1972, 
Santen and Bardin. 1973). Distortion of this finely tuned pulsatile GnRH/LH 
secretion can disrupt the ovarian cycle and give rise to endocrine conditions broadly 
categorised into those with pathologically low and pathologically high LH 
pulsatility.  
Low LH pulsatility states 
Slow GnRH pulsatility characterises hypothalamic amenorrhoea with preferential 
suppression of LH compared to FSH secretion and subsequently diminished ovarian 
follicular activity. The frequency of LH pulses in those women is low and 
comparable to luteal phase in normal women (Santen and Bardin. 1973, Reame et al. 
1985). Hyperprolactinaemia inhibits GnRH pulse rhythm resulting in lower LH pulse 
frequency but higher LH pulse amplitude than that observed in the follicular phase of 
women with ovulatory cycles (Sauder et al. 1984). Treatment with dopamine 
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agonists reverses both parameters and restores ovarian function and menses (Sauder 
et al. 1984). Pulsatile GnRH administration reinstates LH pulsatility in conditions of 
hypothalamic ovarian failure (Leyendecker et al. 1993). Opioid receptor antagonist 
(e.g. naltrexone) also increases LH pulse frequency in women with 
hyperprolactineamia (Cook et al. 1991) and in hypothalamic amenorrhoea, with 
ovulation and pregnancy documented in the latter (Wildt et al. 1993).   
High LH pulsatility states 
Compared to the follicular phase of the normal menstrual cycle, women with PCOS 
have higher serum LH concentrations (Yen et al. 1970). Increased LH pulse 
frequency and amplitude with little effect on FSH secretion in PCOS presumably 
reflects a similar pattern of GnRH pulsatility (Santen and Bardin. 1973, 
Waldstreicher et al. 1988). In addition to high LH pulse frequency, the pattern of LH 
secretion is irregular as indicated by high Approximate entropy (ApEn) (Veldhuis et 
al. 2001).  Abnormal dynamics of GnRH/LH secretion are one of the 
pathophysiological processes leading to hyperandrogenism and chronic anovulation 
characterising this condition. Obese women with PCOS appear to have lower LH 
pulse amplitude and overall serum LH concentrations compared to lean women with 
PCOS, reflecting a metabolic component of this heterogeneous disorder (Taylor et al. 
1997). Women with PCOS do not exhibit the normal cyclical variation in LH pulse 
frequency and have constant LH pulses at approximately one hourly. There are 
currently no licensed therapies aiming at normalisation of LH pulsatility. The first 
randomised controlled trial to date using a specific neurokinin B receptor antagonist 
in women with PCOS showed a reduction in LH pulse frequency and subsequently 
suppressed serum LH and testosterone levels (George et al. 2016). Whether this 
restores normal ovarian cyclicity remains to be determined.    
Menopause and aging 
Menopause is associated with increased GnRH and gonadotropin secretion following 
loss of ovarian activity. Elevated LH pulse frequency in postmenopausal women is 
similar to that seen in the late follicular phase, with net increase per pulse of LH 
approaching that during the mid-cycle LH surge (Yen et al. 1972).  The pattern of 
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high LH pulsatility lacks orderliness compared to premenopausal women and is 
consistent with LH secretion seen in aging men (Pincus et al. 1997, Keenan et al. 
2003a). Disordered LH secretion in aging men and women may be associated with 
diminished negative sex-steroid feedback (Veldhuis et al. 2008).  
Diminished GnRH secretion has been observed in early studies in aging men 
compared to young individuals (Winters and Troen. 1982). Although LH remains 
responsive to GnRH, the amount of LH secreted per pulse is diminished and 
hormone release is more disordered in aged men, resulting in declining testosterone 
production (Mulligan et al. 1999, Keenan and Veldhuis. 2001). A novel analytical 
method to reconstruct dose-response among reproductive hormones following GnRH 
receptor antagonist administration suggested testosterone feedback on GnRH/LH 
secretion to also be impaired in the elderly male, which may contribute to elevated 
GnRH/LH pulse frequency when compared to younger males (Keenan et al. 2006).  
1.1.3.6 Peripheral detection of LH pulsatility 
Since GnRH cannot be measured in the peripheral circulation, LH pulse frequency is 
used as a well-validated marker of GnRH pulsatility. However, there is no generally 
accepted method to objectively assess LH pulse frequency. The challenge in 
analysing hormone pulses arises in that hormone secretion patterns are often 
irregularly spaced in time, nonuniform in size and shape, noisy and superimposed 
upon a variable baseline with further alterations inflicted by physiological (e.g. age) 
and pathological (e.g. neuroendocrine tumours, obesity) processes and random 
effects, such as procedural inconsistencies (missing data, outliers) and measurement 
variability (Keenan and Veldhuis. 2016).  
Subjective pulse identification 
Early investigators identified LH pulses by marking its peaks in hormone plots 
obtained serially over extended intervals (Dierschke et al. 1970, Bolt. 1971). The 
first two studies of LH pulse frequency in humans defined LH peaks as a series of 
values consisting of two or more constant or decreasing concentrations followed by 
two or more higher levels (Nankin and Troen. 1971) in men, and in females, as an 
increase by 5mIU/ml followed by 5mIU/ml decrease in LH over two sampling points 
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(Yen et al. 1972). This technique of independent blinded scorers identifying and 
counting hormone peaks superimposed on marked variability in baseline LH 
secretion suffers from poor reproducibility (Merriam and Wachter. 1982).  
Threshold approaches for pulse detection 
Later work has applied some quantitative measures for detecting discrete peaks in 
hormone concentrations, specifying the threshold increase which is beyond the 
expected assay variability estimated by the standard deviation (SD) or the coefficient 
of variation (SD/ mean x 100%). The first of such threshold approaches for pulse 
analysis was the Santen and Bardin method, for which an increment of greater than 
20% from the nadir was accepted as a pulse (Santen and Bardin. 1973). These 
threshold definitions are however arbitrary and have no physiological significance 
attached to them.  Furthermore, the ability to detect broad LH pulses is limited by 
this approach. Administration of exogenous LH in gonadotropin-deficient men, has 
identified the disappearance of LH from the circulation to be in two phases: an initial 
‘fast half-life’ of mean 39 minutes, representing rapid hormone dilution upon 
secretion into peripheral circulation, and a second ‘slow half-life’ of mean 121 
minutes, indicating metabolic breakdown and excretion (Santen and Bardin. 1973). 
The half-life of LH secreted in a pulse is inversely related to the peak LH 
concentration, with high and narrow LH pulses having short half-life and broad small 
LH pulses having prolonged half-life (Santen and Bardin. 1973). Circadian 
fluctuations in size (peak) and shape (duration of deviation from the baseline) of LH 
pulses result in variable basal (nonpulsatile) hormone secretion and increasing 
hormone half-life, such as in uraemia and hepatic pathology, which elevates 
interpulse hormone concentration (Veldhuis et al. 1993, Veldhuis et al. 2008). 
Higher interpulse concentrations diminish the signal-noise ratio, and methods that 
rely on peak/baseline ratios are therefore less reliable in discriminating pulsatile 
secretion, especially when pulses are broad. For this reason detection of FSH pulses 
is more difficult than of LH, as the former has slower half-life (approximately 10.2 
hours) and higher basal secretion (Urban et al. 1991, Veldhuis et al. 2008). To take 
into account assay variability, to more accurately define basal hormone secretion and 
to detect broad pulses, Baird proposed the LH pulse to be a rise of at least four times 
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the SD over two consecutive samples, and basal LH secretion to be a mean of two 
preceding values (Baird. 1978).  
The Regional Dual-Threshold method has been proposed to overcome difficulties in 
pulse detection when hormone concentrations are low (e.g. in puberty) hence 
increasing the errors of hormone measurement and making fixed threshold methods 
above invalid (Velduis et al. 1986). Individual coefficients of variation are calculated 
for all samples using replicate LH assays (e.g. triplicate) at each data point (Velduis 
et al. 1986). Regional coefficients of variation are then calculated for a particular 
region of the data, the width of which is operator determined, and threshold multiple 
of the regional coefficient of variation for the upstroke and downstroke specified to 
detect pulses (Velduis et al. 1986).  
Cluster analysis technique searched for significant increases and decreases in data 
series (clusters of hormone concentrations) rather than relying on a single data-point 
to detect pulses (Veldhuis and Johnson. 1986). The significant increase in a cluster of 
hormone concentrations is compared to the pre peak nadir cluster and a subsequent 
significant decrease is compared to the post peak nadir cluster, thereby defining a 
pulse (Veldhuis and Johnson. 1986). An operator determined cluster size of peak and 
cluster size of nadir (Veldhuis and Johnson. 1986). This technique was advantageous 
in controlling for random variability by applying multiple-point criteria for peak and 
nadir detection and allowing a more consistent pulse detection, despite variable 
baseline hormone concentrations (Veldhuis and Johnson. 1986).  
Baseline strategies for pulse detection 
Pulse analysis methods employed so called baseline strategies, where computer 
algorithms identified pulses superimposed on an estimated baseline. Christian and 
colleagues partitioned blood hormone concentrations into inliers with low hormone 
levels representing baseline and outliers with abnormally high but random hormone 
levels representing pulses, which were then identified based on significant skewness 
of data (Christian et al. 1978). Whilst this approach could not accommodate 
circadian baseline changes, The Cycle Detector program was proposed to cope with 
irregular endocrine rhythms and defined a cycle (i.e. pulse) as two increases 
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separated by a decrease both of which are greater than operator determined threshold 
value (Clifton and Steiner. 1983). The PULSAR algorithm, on the other hand, 
calculated smoothened baseline incorporating circadian irregularities in baseline LH 
secretion and identified pulses based on both their amplitude as well as duration, 
allowing for detection of both narrow high pulses and broad low pulses (Merriam 
and Wachter. 1982). The program also factored in assay error and was able to 
identify clustered peaks (Merriam and Wachter. 1982). Those methods still lacked 
standardization and required an investigator to set arbitrary artificial 
assumptions/thresholds.  
Deconvolution analysis 
Deconvolution is to disentangle or unravel underlying secretion and/or elimination 
rates from the hormone-concentration profile. It 1) decomposes concentration data 
into an underlying secretion, which is composed of mass and shape of secretory burst 
and basal secretion (nonpulsatile or slowly varying); 2) determines elimination of 
previously secreted hormone and ongoing hormone secretion and elimination; and 3) 
takes into account random variability (host and assay) (Veldhuis et al. 2008, Keenan 
and Veldhuis. 2016). A predicted (reconvolution) curve is then constructed by 
simultaneously estimating pulse amplitude and hormone half-life to fit hormone data 
(Veldhuis et al. 2008, Keenan and Veldhuis. 2016).  
The first one of such approaches was the DETECT computer program. It was able to 
identify multiple overlapping peaks, evaluate average peak shape and estimate 
disappearance rate but assumed hormone secretion burst to be instantaneous (zero-
duration), which adds ‘noise’ to the basal secretion missing true positive peaks and is 
unlikely to represent physiological hormone secretion (Oerter et al. 1986).  
Deconvolution methods were further defined by the development of so-called blind 
deconvolution techniques to account for biological variability in half-lives among 
individuals (Veldhuis et al. 1987a, Keenan et al. 1998). This stemmed from previous 
deconvolution approaches (DETEC method), which used fixed half-life to calculate 
of secretion rates (Rebar et al. 1973, Oerter et al. 1986). However, the issue is that 
hormone half-lives and amplitude concentrations vary depending on physiological 
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(e.g. age, gender) and pathological (e.g. renal or hepatic impairment) status, and 
estimate kinetics from one cohort may not be representative of another (Veldhuis et 
al. 2008). Blind deconvolution estimates secretion rates and hormone half-lives 
simultaneously, which are unique for each individual and experimental context 
(Veldhuis et al. 1987a, Keenan et al. 1998, Veldhuis et al. 2008).  
The parameters of basal hormone secretion, size (mass) and shape of secretory burst, 
pulse frequency and hormone half-lives are all interdependent (Veldhuis et al. 2008). 
Any assumption about these parameters needs careful consideration when placed into 
a mathematical problem for correct computer-simulated outcome, as repeated 
analysis of the same data may generate different results. One of these assumptions is 
the shape or waveform of the hormone secreted, which impacts hormone half-life. 
An improvement on hormone secretory burst being instantaneous was the application 
of a Gaussian smoothing function to make hormone bursts symmetrical (Veldhuis et 
al. 1987a). However, this was arbitrary and risked overestimation of pulse frequency 
by not capturing delayed hormone half-life (Veldhuis et al. 2008). Direct sampling of 
pituitary blood every 30 seconds in conscious mares revealed LH secretory burst to 
be asymmetrical, where LH is secreted rapidly followed by a slow decline to the 
baseline (Irvine and Alexander. 1993). Accordingly, a flexible waveform gamma 
model was developed, which combines rapid initial Gaussian (symmetrical) hormone 
release with slow asymmetrical secretion to the baseline (Keenan et al. 2005, Keenan 
et al. 2006) hence accounting for variable secretory burst and half-life. In order to 
predict the true shape of the hormone secretory burst, a recent strategy is to identify 
independently the onset of hormone burst followed by mathematically verified 
methods, such as maximum-likelihood estimation (MLE) or Bayesian estimation to 
predict the secretion, elimination and variability parameters simultaneously on 
multiple possible sets of pulse-onset times generated (Keenan et al. 2005, Keenan et 
al. 2006, Liu et al. 2009, Keenan and Veldhuis. 2016). The most probable pulse-time 
set is then chosen using a statistical model-selection criterion, such as the Akaike 
information criterion (AIC) or Bayesian information criterion (BIC) (Liu et al. 2009). 
Efforts have also been made to better estimate hormone elimination upon its 
secretion into the bloodstream, which involves initial diffusion (rapid dispersion 
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within blood), advection (linear flow due to cardiac rhythm) and gradual elimination 
by metabolism or degradation (Veldhuis et al. 2008). Biexponential formulations 
using two half-lives more correctly model elimination kinetics compared to 
monoexponential ones using one half-life (Keenan et al. 2005). The advantage of the 
biexponential model is that by utilizing slow half-life it determines true baseline, and 
by using fast half-life it is able to accurately size the secretory burst amplitude, the 
former of which is otherwise overestimated and the latter underestimated in the 
model of one half-life thereby attenuating pulse detection (Veldhuis et al. 2008).  
Any deconvolution analysis for pulse detection requires validation, which can be 
achieved by comparing experimentally designed in vivo (true) and mathematically 
generated in silico (probable) pulses (Veldhuis et al. 2008, Keenan and Veldhuis. 
2016). This is illustrated by further work from the Veldhuis group, attempting to 
validate their automated deconvolution LH pulse detection procedure (Keenan et al. 
2003b, Keenan et al. 2005) using three different experimental contexts (the arcuate 
multiunit electrical activity and hypothalamo-pituitary portal GnRH pulses in 
ovariectomised rats and sheep, respectively, and LH infusion in GnRH antagonist 
treated men) and computer simulation (Liu et al. 2009). Sensitivity and specificity of 
this deconvolution algorithm were >90% with both experimental and simulated LH 
data (Liu et al. 2009).  Analysis of pulsatile hormone secretion in this thesis is based 
on this deconvolution approach, which has been kindly performed by Prof Veldhuis, 
blinded to data, at the Endocrine Research Unit at the Mayo Clinic (Rochester USA).  
Approximate entropy as a measure of secretory pattern orderliness 
Approximate entropy (ApEn) is not a part of the pulse detection method but is a 
complimentary statistic measure of the regularity of hormone secretion (Pincus. 
1991). ApEn is able to detect subtle changes in the orderliness of subpatterns in 
sequential measurements over time that is not apparent by alterations in pulse 
frequency and amplitude (Pincus and Keefe. 1992). It is calculated for any hormone-
concentration profile as a nonnegative number, with zero indicating perfect 
orderliness and larger values corresponding to a more random/irregular hormone 
secretion pattern (Pincus. 1991). ApEn statistic requires prior specification of r 
parameter, the threshold value for evaluating reproducibility, and m parameter, the 
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number of data points (window) over which the recurrence of the pattern is tested. It 
tests the likelihood that patterns within the threshold will remain within the threshold 
in the next comparison window (Pincus et al. 1999). Threshold value r is normalised 
against the standard deviation of each subject hormone-concentration profile and has 
been predetermined based on data series length. Threshold value r = 20% SD has 
been validated for data length of ≥ 60 samples with specificity and sensitivity of 
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1.2 Kisspeptin-the central modulator of GnRH secretion 
Since its Nobel Prize winning discovery, hypothalamic GnRH has been recognised 
as the highest hierarchical centre that initiates and controls reproductive function. 
The downstream effects of gonadotropin secretion and gonadal activity were 
attributed to GnRH pulsatility as the primary point that orchestrates the HPG axis. 
However, functional limitations in the GnRH neuronal network have been identified: 
in rats, GnRH neurones lack estrogen receptor (ER)-alpha, the principal receptor 
needed for estrogen feedback (Herbison and Theodosis. 1992). This prompted the 
search for an intermediary signalling pathway to mediate sex-steroid feedback and 
hence GnRH secretion. The hypothalamic neuropeptide kisspeptin seems to be 
providing this missing link as the key upstream regulator of GnRH secretion (Fig. 
1.1), following the discovery of its obligate role in human puberty fourteen years ago 
(de Roux et al. 2003, Seminara et al. 2003). Kisspeptin is now recognised as crucial 
in the onset of puberty, the regulation of sex hormone-mediated secretion of 
gonadotropins, and the control of fertility (Pinilla et al. 2012, Skorupskaite et al. 
2014). 
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Figure 1.1 The regulation of GnRH secretion by KNDy neurones and other central and 
peripheral regulators. 
GnRH mediates endocrine, metabolic and environmental cues on gonadotropin secretion. Kisspeptin 
is the upstream modulator of pulsatile GnRH secretion from the median eminence (ME). Kisspeptin 
neurones reside within the arcuate (rodent)/infundibular (human) nucleus and the rostral area of the 
hypothalamus, which is more species specific, being located at the pre-optic region (POA) in humans, 
but at the anteroventral periventricular nucleus (AVPV) in rodents. The arcuate/infundibular 
kisspeptin neurones co-express neurokinin B and dynorphin (KNDy neurones), which by expressing 
NK3R and kappa-opioid receptors autosynaptically regulate kisspeptin secretion, with neurokinin B 
being stimulatory and dynorphin inhibitory. Negative sex-steroid feedback is regulated by KNDy 
neurones within the arcuate/infundibular nucleus. The anatomical site for positive sex-steroid 
feedback shows species difference, with the infundibular nucleus in humans but the AVPV nucleus in 
rodents mediating this function. Adapted from Skorupskaite et al. (2014). 
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1.2.1 The discovery of kisspeptin gene and receptor 
The gene encoding kisspeptins, KISS1, was first described in 1996 as a suppressor of 
metastasis in human malignant melanoma (Lee et al. 1996). Transfection of KISS1 
cDNA into human malignant melanoma cells, C8161, suppressed their ability to 
metastasise when injected into the tail vein of athymic nude mice (Lee et al. 1996). 
To acknowledge the discovery of the gene in Hershey (Pennsylvania, USA), it was 
named after famous chocolate ‘Kisses’ produced in the town. The SS in KISS1 also 
refers to its function as a ‘suppressor sequence’. The KISS1 gene is expressed on the 
long arm of chromosome 1 (q32) composed of four exons, only the latter two of 
which are translated (West et al. 1998). It encodes a 145 amino acid peptide, which is 
cleaved to 54 amino acid sequence with further truncation to 14, 13 10 amino acid 
length peptides (West et al. 1998). Cleavage products belong to the RF-amide group 
and share a common C-terminal sequence of Arg–Phe–NH2 (Kotani et al. 2001).  
The orphan G-protein coupled receptor 54 (GPR54) was first described in the rat and 
then in human brain (Lee et al. 1999, Muir et al. 2001, Ohtaki et al. 2001), with 
subsequent linkage of kisspeptin as a ligand to its cognate GPR54, now known as 
KISS1R (Gottsch et al. 2009). KISS1R gene is localised to chromosome 19p13.3, 
where five exons encode 398 amino acid receptor (Muir et al. 2001).   
1.2.2 Nomenclature of kisspeptin gene, peptide and its receptor 
Since the discovery of kisspeptin-kisspeptin receptor signalling, different 
terminology has been used throughout the literature to describe the kisspeptin gene, 
protein and receptor. In this thesis, the nomenclature recommended by Gottsch and 
colleagues will be used to refer to kisspeptin and its receptor (Gottsch et al. 2009).  
1.2.2.1 Nomenclature of the KISS1 gene and mRNA 
Lee and colleagues named their newly discovered gene KiSS-1 (Lee et al. 1996). In 
the attempt to standardise nomenclature for the mouse, rat and human genome, 
Gottsch and colleagues have recommended the use of the symbol KISS1 for the 
human gene as per Human Genome Organization Gene Nomenclature Committee 
(HGNC) guidelines and Kiss1 for non-human kisspeptin gene (Gottsch et al. 2009) 
(Nomenclature. 2009). Accordingly italicised KISS1 mRNA and Kiss1 mRNA are 
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used to refer to the transcripts of the human and non-human gene, respectively 
(Gottsch et al. 2009).  
1.2.2.2 Nomenclature of the peptide 
The 54 amino acid protein was originally named ‘metastin’ to reflect its 
antimetastatic properties (Ohtaki et al. 2001). This 54 amino acid metastin and the 
shorter 14, 13 and 10 amino acid peptides are collectively referred to as kisspeptins 
given they are translated from the same KISS1 gene. Non-italicised version of the 
gene nomenclature would be an alternative to describe the protein product, namely 
KISS1 for humans and Kiss1 for other species (Gottsch et al. 2009).  The name of 
kisspeptin-54, kisspeptin-14, kisspeptin-13 and kisspeptin-10 are also used when 
referring to the specific length of the peptide.  Others have described kisspeptin 
based on the numerical sequence of amino acids cleaved the 145 amino acid 
precursor, with kisspeptin (68-121) referring to kisspeptin-54 and kisspeptin (112-
121) indicating kisspeptin-10. Since most authors report the bioactive fragment of 
kisspeptin used, Gottsch and colleagues have suggested referring to kisspeptin based 
on their size and abbreviate these to KP for the human and kp in non-human context 
(Gottsch et al. 2009).   
1.2.2.3 Nomenclature of the kisspeptin receptor 
The kisspeptin receptor has been referred to as AXOR12, hOT7T175, GPR-54, 
KISS1, KiSS1 and the metastin receptor. For more consistency, the HGNC denotes 
KISS1R for the human kisspeptin receptor gene, and mouse genome informatics has 
assigned Kiss1r to the once orphaned GPR-54 (Nomenclature. 2009) Similarly, 
Gottsch suggested the symbols of KISS1R mRNA and Kiss1r mRNA for the 
messenger transcripts of the kisspeptin receptor gene, and KISS1R and Kiss1r for the 
protein receptors in human and other species respectively (Gottsch et al. 2009).  
 
 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
Literature Review        26 
1.2.3 Discovery of the role of kisspeptin in reproduction 
The demonstration of the obligate role of kisspeptin-kisspeptin receptor signalling in 
human puberty was the finding that firmly established kisspeptin as a crucial 
regulator of reproductive function. In 2003 two independent groups almost 
simultaneously identified ‘inactivating’ point mutations and deletions in KISS1R that 
were associated with delayed pubertal maturation in patients with hypogonadotropic 
hypogonadism (de Roux et al. 2003, Seminara et al. 2003). Mutations were of both 
familial and sporadic origins. Genetic findings in humans were reinforced by 
engineering a Kiss1r deficient mice, which displayed a virtually identical phenotype 
to affected patients with no physiological changes appropriate for the normal 
pubertal development and low circulating gonadotropin and sex hormone levels 
(Funes et al. 2003, Seminara et al. 2003). A milder reproductive impact to Kiss1r 
deficient mice was subsequently observed in Kiss1 knock out mice (d'Anglemont de 
Tassigny et al. 2007, Lapatto et al. 2007). The pathway downstream of kisspeptin 
appears unaffected as demonstrated by secretion of gonadotropins in response to 
GnRH and kisspeptin administration in Kiss1r and Kiss1 mutant mice, respectively 
(Seminara et al. 2003, d'Anglemont de Tassigny et al. 2007). Conversely ‘activating’ 
mutations in the KISS1 and KISS1R genes have been identified in patients with 
central precocious puberty (Teles et al. 2008, Silveira et al. 2010) (see section 1.2.7 
Kisspeptin and puberty for more detail). Since the discovery of the reproductive role 
of kisspeptin, the field has acquired a wealth of information in understanding of 
relevant molecular biology, neuroanatomy and physiology, and has progressed to 
therapeutic manipulation of kisspeptin signalling in the clinical setting.  
1.2.4 Kisspeptin receptor signaling 
Kisspeptin receptor is a seven transmembrane domain G-protein coupled receptor 
(Muir et al. 2001). All kisspeptins can bind and activate kisspeptin receptor, but not 
the galanin or galanin-family peptides, despite the similarity of kisspeptin receptor to 
the galanin receptor (40% homologous) (Lee et al. 1999). The binding of kisspeptin 
receptor by its ligand activates phospholipase C (PLC) and recruits secondary 
intracellular messengers, inositol triphosphate (IP3) and diacylglycerol (DAG) (Muir 
et al. 2001, Liu et al. 2008, Constantin et al. 2009). IP3 mediates a biphasic increase 
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in calcium from the intracellular stores, with a rapid increase followed by a more 
sustained second phase (Min et al. 2014). To maintain this second phase and 
therefore sustain signalling, kisspeptin receptor trafficking involving internalization, 
recycling and recruitment from an intracellular pool is required (Min et al. 2014). 
Without receptor trafficking, the kisspeptin receptor undergoes desensitization 
following an initial acute phase (Min et al. 2014). Depolarisation of GnRH neuronal 
membrane is achieved by activation of transient receptor potential canonical 
(TRPC)-like channels and blockade of potassium channels, which are mediated by 
calcium influx and DAG (Zhang et al. 2008). DAG also activates Protein kinase C 
(PKC), which is associated with the phosphorylation of mitogen-activated protein 
kinases (MAPK), such as ERK1/2 and p38, which are also involved in mediating 
kisspeptin signalling (Kotani et al. 2001).  
1.2.5 Neuroanatomy of kisspeptin signalling  
The anatomical distribution of the kisspeptin neuronal network and the physiology of 
kisspeptin-kisspeptin receptor signalling have been studied in a number of species, 
including humans, with some species variation (Fig. 1.1). The focus in this section 
will predominantly be on human data, using animal findings in case of significant 
species variation or where human studies are lacking but there is potential 
translational application. 
1.2.5.1 Distribution of kisspeptin in humans differs from other 
species 
Distribution of kisspeptin cell bodies in the brain 
The existence of low levels of KISS1 mRNA was demonstrated in the human brain 
tissue by the quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) 
even before the role of kisspeptins in reproduction was discovered (Kotani et al. 
2001, Muir et al. 2001). Identification of the link between kisspeptin gene mutations 
and delayed puberty (de Roux et al. 2003, Seminara et al. 2003), sparked an interest 
amongst neuroendocrinologists, and in situ hybridization studies on the distribution 
of kisspeptin neuronal network in the human brain were carried out in autopsy 
samples from premenopausal and postmenopausal women, localising KISS1 
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expression to the infundibular nucleus (homologous to the arcuate nucleus in other 
species) only (Rometo et al. 2007). A more recent study by Hrabovszky’s lab has 
created a detailed anatomical map of kisspeptin signalling, localising the majority of 
kisspeptin cell bodies within the infundibular nucleus, in keeping with earlier human 
studies, but also identified a second dense population of kisspeptin cells in the rostral 
pre-optic area (POA) and a small number, probably an extension of the infundibular 
nucleus, in the infundibular stalk (Hrabovszky et al. 2010). 
Whilst localisation of kisspeptin neurones in the infundibular/arcuate nucleus is 
preserved across the species, the expression of kisspeptin perikarya in the rostral 
region shows interspecies variation (Clarkson and Herbison. 2006, Pompolo et al. 
2006, Ramaswamy et al. 2008, Clarkson et al. 2009b, Hrabovszky et al. 2010). 
Rodents have a specific rostral kisspeptin neurone population in the anteroventral 
periventricular nucleus (AVPV) and the periventricular nucleus (PeN), the 
continuum of this region being referred to as the rostral periventricular region of the 
third ventricle (RP3V) (Gottsch et al. 2004, Clarkson and Herbison. 2006, Clarkson 
et al. 2009b). In contrast to rodents, ruminants lack this well-defined RP3V 
population and have kisspeptin cell bodies scattered throughout the pre-optic region, 
confirmed by both immunocytochemistry and in situ hybridisation (Franceschini et 
al. 2006, Pompolo et al. 2006, Smith et al. 2007). No kisspeptin cell bodies were 
identified in the pre-optic area in castrated male rhesus monkey (Ramaswamy et al. 
2008), which compliments the expression of Kiss1 and Kiss1r in those hypothalamic 
areas detected in previous studies (Shahab et al. 2005, Shibata et al. 2007).  
The expression of kisspeptin transcripts and peptides in these areas is under the 
regulation of sex-steroid feedback. In general, estradiol in females stimulates 
kisspeptin expression in the AVPV nucleus and suppresses it in the arcuate nucleus 
(Smith et al. 2005a, Smith et al. 2006b, Herbison. 2008), suggesting that these are the 
loci of positive and negative feedback regulation respectively. The numbers of 
kisspeptin cells in the arcuate nucleus of female rodents appear to be two- to fourfold 
higher than in the RP3V (Goodman and Lehman. 2012). This is consistent with other 
mammals, where the arcuate kisspeptin population is readily observed and contains 
more kisspeptin neurones (Smith et al. 2007). Pubertal onset is also associated with 
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dramatic increase in the number of kisspeptin immunoreactive cell bodies in the 
AVPV/PeN region of both male and female mice and in Kiss1 expression in 
agonadal male and intact female monkeys through pre-pubertal to pubertal 
development (Han et al. 2005, Shahab et al. 2005, Clarkson et al. 2009a).  
Kisspeptin cell bodies are present in the other areas of hypothalamus and outside it: 
the dorsomedial nucleus in mice and sheep, but not the rat; the ventromedial nucleus 
of the hypothalamus in the sheep and rat, but not other species; the amygdala in 
rodents and the bed nucleus of the stria terminalis in rodents and rhesus monkeys 
(Clarkson and Herbison. 2006, Oakley et al. 2009, Lehman et al. 2010).  
Distribution of kisspeptin fibres in the brain  
Kisspeptin fibre projections broadly match the distribution of cell bodies across the 
species, which have been analysed using tract tracing with immunocytochemistry or 
multi-label immunocytochemistry. Dense network of kisspeptin fibres are found 
within the two anatomical sites of kisspeptin populations, the infundibular/arcuate 
nucleus and the region of POA/AVPV, and the site of GnRH neurosection, the 
median eminence (Clarkson and Herbison. 2006, Ramaswamy et al. 2008, Clarkson 
et al. 2009b, Hrabovszky et al. 2010). Whilst kisspeptin-immunoreactive fibres are 
present in other regions of the brain, for example the dorsomedial hypothalamic 
nucleus in all species, there is also species variation in kisspeptin axonal distribution: 
fibres are detected in the bed nucleus of the stria terminalis in all species except 
humans, in the ventromedial nucleus in humans and sheep, but not rodents, and in a 
variety of rodent forebrain structures, including organum vasculosum of the lamina 
terminalis and the medial and lateral septum (Clarkson and Herbison. 2006, Pompolo 
et al. 2006, Oakley et al. 2009, Lehman et al. 2010). 
Distribution of kisspeptin receptor in the brain 
Unlike the abundance of data on kisspeptin neurone localisation, studies on the 
neuroanatomical distribution of kisspeptin receptor are rather sparse, those using RT-
PCR do not provide information on the localisation of the receptor and lack 
specificity and validity for quantitative comparison, and those utilising in situ 
hybridisation focus predominantly on the detection of kisspeptin receptor in 
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particular cell type, especially GnRH neurones (Lehman et al. 2013). Even with 
these limitations in mind, Kiss1r mRNA is consistently localised within the pre-optic 
area and the mediobasal hypothalamus/arcuate nucleus using both RT-PCR in 
humans (Kotani et al. 2001, Muir et al. 2001) and monkeys (Shahab et al. 2005, 
Shibata et al. 2007) and in situ hybridisation in rodents (Irwig et al. 2004, Herbison 
et al. 2010) and sheep (Smith et al. 2009a, Li et al. 2012a). Localisation of Kiss1r 
mRNA in GnRH neurones provides evidence for those cells being direct targets of 
kisspeptin action. Over 90% of murine GnRH neurones express Kiss1r (Han et al. 
2005) with frequent co-localisation also observed in rats (Irwig et al. 2004) and non-
human primates (Shahab et al. 2005, Shibata et al. 2007). Kiss1r mRNA has been 
detected in the extra-hypothalamic regions of the brain such as hippocampus, 
amygdala and locus coerules (Lehman et al. 2013). Kiss1r is also found in the 
anterior pituitary in a number of mammals including humans, and in rats has been 
localised to gonadotropes (Kotani et al. 2001, Richard et al. 2008).  
Kisspeptin and GnRH neuronal networks overlap 
Kisspeptin axons form dense pericapillary plexuses in the human infundibular stalk, 
where GnRH is secreted into the hypophyseal portal circulation (Hrabovszky et al. 
2010). Axo-somatic, axo-dendritic and axo-axonal contacts between kisspeptin and 
GnRH axons were also demonstrated in the infundibular stalk, in keeping with data 
from rodents, sheep and monkeys, where kisspeptin and GnRH neuronal networks 
are in close proximity (Clarkson and Herbison. 2006, Ramaswamy et al. 2008, Smith 
et al. 2008a, Hrabovszky et al. 2010, Uenoyama et al. 2011). Furthermore, the 
appositions between kisspeptin and GnRH fibres have been shown to increase in 
mouse hypothalamus at the time of puberty (Clarkson and Herbison. 2006). These 
findings together with the localisation of Kiss1r mRNA in GnRH neurones indicate 
direct involvement of kisspeptin in the neurosecretion of this decapeptide (Irwig et 
al. 2004, Han et al. 2005, Messager et al. 2005). However, in humans as well as other 
species studied to date, not all GnRH neurones receive kisspeptin neurone contacts 
(Clarkson and Herbison. 2006, Ramaswamy et al. 2008, Smith et al. 2008a, 
Hrabovszky et al. 2010), suggesting that other neuropeptides and neurotransmitters 
are involved in regulation of GnRH secretion.   
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1.2.5.2 Kisspeptin neurones co-express other neuropeptides 
Kisspeptin cells are a heterogeneous population in that they co-localise with other 
hypothalamic neuropeptides and neurotransmitters (Fig. 1.1). A subpopulation of 
kisspeptin neurones co-expressing neurokinin B (NKB) and dynorphin A was first 
described by Goodman and colleagues in the ovine arcuate nucleus (Goodman et al. 
2007). The observation that the distribution and morphology of neurokinin B 
neurones in the infundibular nucleus in postmenopausal women was similar to that of 
kisspeptin neurones has suggested the expression of those neuropeptides to localise 
to the same cell (Rance et al. 1990, Rance and Young. 1991, Rometo et al. 2007). 
Immunocytochemistry has confirmed the expression of kisspeptin, neurokinin B and 
dynorphin in the human infundibular nucleus (Rometo et al. 2007, Rance. 2009, 
Hrabovszky et al. 2010), a phenomenon which is conserved across the species in the 
analogous arcuate nucleus in rats (Burke et al. 2006) , mouse (Smith et al. 2005a, 
Navarro et al. 2009) and monkeys (Ramaswamy et al. 2008). Neurokinin B and 
dynorphin are absent from the kisspeptin population in the pre-optic/RP3V. There is 
thus a population of infundibular nucleus (human) /arcuate (other species) neurones, 
which co-express all three neuropeptides, and these, are referred to as KNDy 
(Kisspeptin-Neurokinin B-Dynorphin) neurones (Cheng et al. 2010).  
In rats and sheep KNDy neurones co-localize with the glutamate transporter-2, the 
ligand of which has been implicated in mediating positive estrogen feedback in the 
GnRH/LH surge (Pompolo et al. 2003, Ciofi et al. 2006). However, the expression of 
glutamate receptor in KNDy cells is not yet elucidated (Ciofi et al. 2006, Lehman et 
al. 2010). Kisspeptin neurones in the RP3V in mouse also co-express tyrosine 
hydroxylase (the key enzyme in dopamine synthesis), met-enkephalin, GABA and 
galanin (Ferin et al. 1984, Smith et al. 2006b, Oakley et al. 2009). This differential 
expression of neurotransmitters suggests that two distinct populations of kisspeptin 
are phenotypically unique in both their molecular composition and functionality 
(Oakley et al. 2009). 
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1.2.5.3 Functional dimorphism of kisspeptin neurones 
KNDy neurones form direct contact with both GnRH cell bodies and dendrites in the 
preoptic area and the mediobasal hypothalamus and project to the median eminence 
in the sheep, rodents, rhesus monkeys and human (Krajewski et al. 2005, Ciofi et al. 
2006, Clarkson and Herbison. 2006, Ramaswamy et al. 2008, Dahl et al. 2009). The 
arcuate KNDy neuronal network is reciprocally interconnected, allowing for the 
synergistic neuroactivity of interlinked KNDy cells (Foradori et al. 2002, Burke et al. 
2006, Lehman et al. 2010) (Fig.1.1). This is achieved via the neurokinin B receptors 
and the kappa opioid peptide receptors (the receptor for dynorphin), which are 
expressed by KNDy cells (Krajewski et al. 2005, Navarro et al. 2009, Herbison et al. 
2010), but not the kisspeptin receptor, which predominantly co-localises with GnRH 
neurones (Irwig et al. 2004, Han et al. 2005, Shahab et al. 2005, Shibata et al. 2007, 
Herbison et al. 2010). This indicates that by autosynaptic communications between 
KNDy cells, the stimulatory action of neurokinin B and the inhibitory action of 
dynorphin achieve coordinate release of kisspeptin, which in turn controls the 
pulsatile secretion of GnRH and subsequently LH (Navarro et al. 2009).  
Kisspeptin-mediated GnRH secretion is sex-steroid dependent as inferred by 
frequent co-localisation of the nuclear estrogen receptor alpha (ERα), progesterone 
receptor (PR) and androgen receptor (AR) in kisspeptin as well as neurokinin B and 
dynorphin expressing cells otherwise absent from GnRH neurones (Ciofi et al. 1994, 
Goubillon et al. 2000, Foradori et al. 2002, Smith et al. 2005a, Franceschini et al. 
2006). There is species specificity in the subpopulation of kisspeptin neurones 
exerting negative and positive gonadal steroid feedback, described more fully below 
(1.4). Briefly, in humans, KNDy neurones and possibly additional neuromediators 
(e.g. glutamate) in the infundibular nucleus alone mediate both negative and positive 
sex steroid response (Rometo et al. 2007, Oakley et al. 2009), whereas in rodents 
KNDy neurones in the arcuate nucleus relay negative sex steroid signalling, but it is 
kisspeptin in the AVPV nucleus that responds to positive sex steroid feedback (Smith 
et al. 2005a, Smith et al. 2006b, Herbison. 2008). Although humans lack two distinct 
anatomical sites mediating negative and positive sex-steroid feedback, two separate 
neuronal pathways are likely to exist to exert different feedback loops.   
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1.2.5.4 Sexual dimorphism of kisspeptin neurones 
There is evidence for sexual dimorphism in kisspeptin pathways across species. 
Female hypothalami have significantly more kisspeptin fibres in the infundibular 
nucleus and the rostral periventricular zone compared to men (Hrabovszky et al. 
2010). Likewise there is marked sexual dimorphism in the numbers of kisspeptin cell 
bodies, of which there are more in the female infundibular nucleus but which are 
absent from the rostral periventricular zone in men (Hrabovszky et al. 2010). Similar 
sex differences in kisspeptin cell numbers have been reported in the arcuate nucleus 
of the male and female sheep (Cheng et al. 2010). Female rodents contain more than 
10-fold more kisspeptin neurones than males in the RP3V region, a difference that 
may be explained by pre-ovulatory positive estrogen feedback being unique to the 
female (Clarkson 2006, Kauffman 2007). Consistent with negative sex-steroid 
feedback operating in both sexes, sexual dimorphism in kisspeptin expression is not 
seen in the arcuate nucleus in this species (Clarkson 2006, Kauffman 2007).  
1.2.6 Kisspeptin and the regulation of GnRH secretion 
Kisspeptin is now recognised as having a central stimulatory role of the 
hypothalamic-pituitary-gonadal axis in both animal models and humans (Clarke and 
Dhillo. 2016). Upon binding to kisspeptin receptor on GnRH neurones, kisspeptin 
mediates pulsatile GnRH release from the median eminence into the portal 
circulation, which in turn stimulates the synthesis and secretion of LH and FSH from 
the gonadotropes of the anterior pituitary.  
1.2.6.1 Stimulatory effect of kisspeptin on gonadotropin secretion 
Kisspeptin effects on LH secretion 
Shortly after the discovery of the reproductive role of kisspeptin in genetic studies, 
the ability of kisspeptin to increase LH secretion was first demonstrated in rodents 
(Gottsch et al. 2004, Irwig et al. 2004, Matsui et al. 2004, Navarro et al. 2004a, 
Thompson et al. 2004). Intracerebroventricularly (IVC) administration of 1 nmol of 
both kp-54 and kp-10 in adult male mice significantly and equipotently increased 
orbital blood LH levels 30 minutes post kisspeptin injection (Gottsch et al. 2004). A 
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dose of kp-54 as low as one femtomole was able to elicit a significant LH response 
(Gottsch et al. 2004). Subsequently, the potency of kisspeptin in stimulating LH 
secretion was replicated in larger animals, including sheep (Messager et al. 2005, 
Caraty et al. 2007), gilts (Lents et al. 2008), goats (Hashizume et al. 2010), cows 
(Ezzat Ahmed et al. 2009) and monkeys (Shahab et al. 2005), where kisspeptin-
mediated LH secretion increased in the range of 2 to 25-fold from baseline.  
Kisspeptin exerts its stimulatory effects on LH secretion via the kisspeptin receptor 
as Kiss1r null mice fails to elicit LH response compared to a robust LH release in 
wild-type animal with intraperitoneal injections of kisspeptin (Messager et al. 2005). 
The Dhillo group was the first to take kisspeptin to man two years after its obligate 
role in human puberty was described. KP-54 was first administered in healthy men 
by intravenous infusion (4 pmol/kg/min for 30 minutes followed by half the initial 
rate for further 60 minutes) and resulted in a robust and dose-dependant increase 
(from 0.25 pmol/kg/min to 12 pmol/kg/min) in LH, and less marked rises in FSH and 
testosterone secretion (Dhillo et al. 2005). Subsequently, KP-54 was administered in 
women by subcutaneous bolus injection at doses ranging from 0.2 to 6.4 nmol/kg 
causing a dose-dependent increase in serum LH and FSH but not estradiol (Dhillo et 
al. 2007). The increase in LH was 7-fold more that for FSH, emphasizing the 
preferential effect of kisspeptin on LH secretion (Dhillo et al. 2007). First in human 
studies using KP-10 (1.5 μg/kg/hr [1.1 nmol/kg/hr] for 9 h) showed an increase in 
LH and also the frequency and amplitude of LH pulses in healthy men (George et al. 
2011).  
Potent LH-releasing effects of kisspeptins have been consistently observed in 
animals and in humans when kisspeptin is administered (Oakley et al. 2009, Pinilla 
et al. 2012, Skorupskaite et al. 2014, Clarke and Dhillo. 2016):  
1) by different routes (central in animals only: intracerebroventricular (icv) or 
intrahypothalamic; and systemic: intravenous (iv), subcutaneous (sc) or 
intraperitoneal (ip)); 
2) different types of exposure (single boluses or continuous infusion);  
3) in different isoforms (kisspeptin-54 and kisspeptin-10);  
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4) to males or females;  
5) in different stages of reproductive function, including early stages of postnatal 
development in rat, mouse and monkey (Han et al. 2005, Castellano et al. 2006a, 
Plant et al. 2006), various phases of the menstrual cycle (Roa et al. 2006, Dhillo et al. 
2007, George et al. 2012), lactation (Yamada et al. 2007) and ageing (Neal-Perry et 
al. 2009, George et al. 2012); 
6) in different disease models and in the IVF setting (Navarro et al. 2004b, 
Castellano et al. 2005, Castellano et al. 2006b, Plant et al. 2006, Jayasena et al. 2009, 
Jayasena et al. 2010, George et al. 2013, Young et al. 2013, Jayasena et al. 2014a, 
Jayasena et al. 2014b, Abbara et al. 2015). 
LH-releasing effects of exogenous kisspeptin administration in human health and 
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Figure 1.2 The stimulatory role of kisspeptin in healthy men and women.  
Kisspeptin potently stimulated LH secretion when administered in different isoforms (kisspeptin-54 and kisspeptin-10), by different routes (intravenous and 
subcutaneous) and protocols (continuous infusion or boluses) in men (filled squares) and across different phases of the menstrual cycle (filled circles). Note that 
stimulated LH may represent mean LH or peak LH (indicated by asterisk) concentrations depending on data reported in publications. LH levels were obtained from 
the relevant graphical data, if authors did not state exact values. 0% change in LH secretion indicates no statistically significant change in LH secretion reported 
whilst other percentage changes in LH secretion are statistically significant. iv, intravenous; sc, subcutaneous; BD, twice daily; COCP, combined oral contraceptive 
pill.  
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Figure 1.3 The stimulatory role of kisspeptin in human disease models. 
The stimulatory effect of kisspeptin on LH secretion in reproductive endocrine conditions characterised by low LH pulsatility. Stimulated LH represents mean LH 
as reported in publications. LH levels were obtained from the relevant graphical data, if authors did not state exact values. iv, intravenous; sc, subcutaneous; BD, 
twice daily; T2DM, type 2 diabetes mellitus; NKB, neurokinin B; NK3R, neurokinin 3 receptor.  
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Kisspeptin effects on FSH secretion 
In contrast to LH, the stimulatory effect of kisspeptin on FSH secretion is minimal 
and more variable in humans (Dhillo et al. 2005, Dhillo et al. 2007, George et al. 
2011, Jayasena et al. 2011, Chan et al. 2012, George et al. 2012, Narayanaswamy et 
al. 2016a), which is in concordance with data in rodents (Thompson et al. 2004, 
Navarro et al. 2005a). Compared with the rapid (within few minutes) and robust (up 
to 5-fold) LH response to kisspeptin, FSH release is of slower onset (approximately 
30 minutes onwards) and lower magnitude (up to 2-fold) (Thompson et al. 2004, 
Dhillo et al. 2005, Navarro et al. 2005a, Caraty et al. 2007, Dhillo et al. 2007, George 
et al. 2011, Jayasena et al. 2011, Chan et al. 2012, George et al. 2012). The 
stimulatory FSH response to centrally administrated kp-10 in rats is approximately 
100-fold less sensitive than for LH with half the maximal response of 4 pmol for LH 
and 400 pmol for FSH (Navarro et al. 2005a). The preferential secretion of LH to 
FSH in response to kisspeptin is likely to be related to kisspeptin-mediated increase 
in GnRH pulse frequency (as inferred by increased LH pulse frequency), with high 
GnRH pulsatility preferentially stimulating LH synthesis and secretion and low 
GnRH pulsatility favouring FSH release (McNeilly et al. 2003).  Furthermore, FSH 
secretion is also selectively regulated by gonadal peptides, particular the inhibins (de 
Kretser et al. 2002), acting at the pituitary.  
Gonadotropin response to kisspeptin is modulated by gonadal steroids 
When kisspeptin was first administered in healthy women, there was a marked 
difference in kisspeptin-induced LH and FSH secretion across the phases of the 
menstrual cycle (Fig. 1.2).  Gonadotropin response to exogenous KP-54 
(administered at the dose of 0.4 nmol/kg in a subcutaneous bolus) increased over two 
fold in the pre-ovulatory phase compared to the luteal and follicular phases of the 
menstrual cycle (Dhillo et al. 2007), suggesting that kisspeptin mediated LH release 
is dependent on the sex-steroid milieu. Similar enhanced gonadotropin-releasing 
effect in the pre-ovulatory phase was observed with KP-10 (Jayasena et al. 2011, 
Chan et al. 2012). In animal models, LH response to kp-10 also depends on the 
reproductive status with the highest rise in LH observed in the late follicular phase, 
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which is in concordance with the anatomical studies showing greatest expression of 
Kiss1 mRNA at the time of the LH surge in sheep (Smith et al. 2006b, Smith et al. 
2009b). Similarly to kisspeptin, intravenous GnRH at various stages of menstrual 
cycle in women elicited the greatest LH secretion during the pre-ovulatory phase and 
the smallest during the follicular phase, suggesting that kisspeptin mediates sex-
steroid action on gonadotropin secretion via GnRH pathway (Yen et al. 1973, Shaw 
et al. 1974, Nakano et al. 1975, Jewelewicz et al. 1977, de Kretser et al. 1978).  
Estradiol might be an important determinant of LH response to kisspeptin, given that 
kisspeptin is most effective during the phases of the menstrual cycle when serum 
estradiol levels are high. Indeed the LH response to subcutaneous KP-54 infusion for 
8 hours (0.3 and 1.0 nmol/kg/h) is positively correlated to estradiol levels in the early 
follicular phase in women with a 100 pmol/l rise in serum estradiol associated with 
1.0 IU/l increase in LH response at the higher dose (Narayanaswamy et al. 2016a). 
This is consistent with previous in vitro and in vivo reports where estrogen was 
shown to be important for kisspeptin-induced GnRH. In GnRH neuronal cell line, 
estrogen upregulated Kiss1 gene expression and enhanced kisspeptin-stimulated 
secretion of GnRH (Li et al. 2007, Novaira et al. 2009, Tonsfeldt et al. 2011). In 
pubertal monkeys, ovariectomy abolished KP-10 induced GnRH secretion, which 
was measured directly in the stalk-median eminence by microdialysis, and estrogen 
replacement reinstated kisspeptin-induced GnRH release (Guerriero et al. 2012).   
Somewhat different to the above, sex-steroid deficient postmenopausal women 
showed a greater AUC LH response to KP-10 than women taking combined estrogen 
and progesterone contraceptives and those in the early follicular phase of the 
menstrual cycle (George et al. 2012). It has been proposed that due to high 
endogenous kisspeptin activity in the follicular phase as a result of loss of negative 
estrogen feedback, the impact of exogenous kisspeptin is limited (Chan et al. 2012). 
These complex relationships suggest that, in addition to estrogen and progesterone, 
other mechanism may regulate kisspeptin sensitivity in different sex-steroid milieu 
and /or that kisspeptin-GnRH pathways are distinct between women with fluctuating 
gonadal steroids across the phases of the menstrual cycle, following estrogen-
depletion postmenopause and whilst taking exogenous steroids.  
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Comparison of the stimulatory effects of different kisspeptin isoforms 
Whilst the potency of kisspeptin to induce gonadotropin secretion has been evaluated 
in many different species using various isoforms, routes, regimens and doses, there 
are limited number of studies comparing kisspeptin effects using the same 
experimental conditions. Shorter and longer kisspeptin peptides may be distinct 
pharmacodynamically and pharmacokinetically. A recent study has for the first time 
compared the effects of KP-10, KP-54 and GnRH on the secretion of gonadotropins 
when administered at equimolar doses (0.1, 0.3 and 1.0 nmol/kg/h) by an intravenous 
infusion for 3 hours in healthy men (Jayasena et al. 2015a). Dose-dependent increase 
in both LH and FSH secretion was observed during the infusion of GnRH and to 
lesser extent during KP-10 and KP-54 infusions, with peak hormone concentrations 
achieved at the 0.3 nmol/kg/h dose for LH and 1.0 nmol/kg/h dose for FSH (Jayasena 
et al. 2015a). At the doses achieving maximal stimulation, AUC serum LH and FSH 
were 3-fold higher during GnRH infusion compared with KP-10 administration and 
2-fold higher than that with KP-54 (Jayasena et al. 2015a). Similarly, in male rats, 
intravenous bolus injection of GnRH (32.5 nmol/kg) evoked greater LH response 
than that induced by kp-10 (30 nmol/kg) administered repetitively at four boluses 
every 75 minutes (Tovar et al. 2006). GnRH potency over kisspeptin in stimulating 
gonadotropin secretion might be explained by suboptimal GnRH-releasing effect of 
kisspeptin since not all GnRH neurones are in apposition with kisspeptin neurones or 
express kisspeptin receptors (Irwig et al. 2004, Clarkson and Herbison. 2006, 
Ramaswamy et al. 2008, Smith et al. 2008a, Hrabovszky et al. 2010). This suggests 
that kisspeptin independent pathways may also regulate GnRH secretion (Chan et al. 
2009a). Although GnRH secretory nerve terminal are outside the complete blood-
brain-barrier in the median eminence (d'Anglemont de Tassigny et al. 2010), not all 
kisspeptin may penetrate into the hypothalamus (Jayasena et al. 2015a). 
Rodent studies suggest that full-length kisspeptin is more effective in stimulating 
gonadotropin secretion than shorter isoforms (Tovar et al. 2006, Pheng et al. 2009). 
When 3.0 nmol/kg of kp-52 (analogous to KP-54 in humans) and kp-10 was injected 
intravenously in male rats, a greater magnitude of LH secretion was achieved with 
the longer fragment (Tovar et al. 2006). Similarly, subcutaneous bolus injection of 
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kp-54 at 1 and 50 nmol significantly increased LH secretion in male rats when 
compared with kp-10 and kp-14 at equivalent doses (Thompson et al. 2006). 
However, a more detailed study compared the potency of intraperitoneal injection of 
mouse kp-10 and -52 and human KP-10 and -54 (at 0.1, 0.3, 1, 3, 10 and 30 nmol/kg 
for each peptide) on testosterone secretion in adult male mice, showing a dose-
dependent increase in testosterone concentrations with the same efficacy across the 
peptides (Mikkelsen et al. 2009). LH levels were not analysed in the study.  
Interspecies variability may account for distinct potency of various kisspeptin 
fragments  as well as differences in the dose and mode of administration. Whilst 
central (ICV) and peripheral (iv and ip) administration of kp-10 and kp-52 in male 
rats elicited comparable effects on LH secretion, that of peripheral administration 
was less protracted lasting less than 3 hours (Navarro et al. 2005b, Rance. 2009). 
Shorter stimulatory action of peripherally delivered kp-10 and kp-54 was also 
observed in sheep and monkeys (Shahab et al. 2005, Caraty et al. 2007) with 
generally longer response to intravenous injection than other routes of peripheral 
administration (Navarro et al. 2005b, Tovar et al. 2006, Caraty et al. 2007).  
KP-54 elicits a marked stimulatory effect on gonadotropin secretion when 
administered intravenously or subcutaneously in healthy volunteers and in women 
with hypothalamic amenorrhoea (Dhillo et al. 2005, Dhillo et al. 2007, Jayasena et 
al. 2009, Jayasena et al. 2014b, Jayasena et al. 2015a, Narayanaswamy et al. 2016c). 
In contrast, difference in KP-10’s ability to stimulate gonadotropin secretion has 
been observed with different routes of peripheral administration. Whilst intravenous 
KP-10 infusion stimulates LH secretion in men, women and patients with diabetes 
mellitus and with mutations in the neurokinin B pathway (Chan et al. 2011, George 
et al. 2011, Jayasena et al. 2011, Chan et al. 2012, George et al. 2012, George et al. 
2013, Young et al. 2013), subcutaneous injection of KP-10 failed to stimulate 
gonadotropin secretion in the early follicular phase in healthy women (Jayasena et al. 
2011), although subcutaneous administration of the shorter length peptide has not 
been evaluated in men, in other phases of menstrual cycle in women and in 
hypothalamic amenorrhoea.  
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Differences in KP-54 and KP-10 effectiveness might be explained by a much shorter 
plasma half-life of KP-10 of 4 min (Jayasena et al. 2011) compared to 27.6±1.1 min 
for KP-54 (Dhillo et al. 2005). Furthermore, sexual dimorphism in the 
responsiveness to KP-54 and KP-10 has been demonstrated with men generally 
showing greater stimulatory effect to both kisspeptin isoforms (Jayasena et al. 2011), 
discussed in more detail in section 1.2.6.7: Sexual dimorphism in response to 
kisspeptin. Comparison of the stimulatory action of various kisspeptin lengths is 
further complicated in that kisspeptin-induced gonadotropin secretion is dependent 
on gonadal steroid milieu (Dhillo et al. 2007, Smith et al. 2009b, Jayasena et al. 
2011, Chan et al. 2012, George et al. 2012).  
1.2.6.2 Direct and indirect actions of kisspeptin on GnRH neurones 
Direct action of kisspeptin on GnRH secretion 
Kisspeptin mediates its stimulatory role on gonadotropin secretion by acting directly 
on the hypothalamic GnRH pathway, evidence for which is mainly inferred from 
animal studies. In addition to anatomical data, the physiological role of kisspeptin in 
the regulation of GnRH secretion has been demonstrated in vitro and in vivo. 
Kisspeptin causes depolarisation of and increases in firing rate of GnRH neurones 
(Han et al. 2005, Zhang et al. 2008, Constantin et al. 2013); kisspeptin-induced 
GnRH secretion has been observed in hypothalamic explants and the median 
eminence (Thompson et al. 2004, Tovar et al. 2006); c-Fos immunoreactivity (a 
marker of neuronal activity) (Matsui et al. 2004, Han et al. 2005) and the expression 
of GnRH mRNA is upregulated within the cell bodies of GnRH neurones following 
the kisspeptin exposure (Novaira et al. 2009, Oakley et al. 2009).  
Temporal correlation between kisspeptin administration and GnRH secretion was 
first shown in sheep, where central infusion of KP-10 for 4 hours caused a parallel 
and dramatic increase in the cerebrospinal fluid GnRH content and peripheral LH 
and FSH concentrations (Messager et al. 2005). In a primate model, central infusion 
of KP-10 stimulated GnRH release in ovary-intact prepuberal and pubertal monkeys, 
when measured directly in the stalk-median eminence by microdialysis (Guerriero et 
al. 2012). In human setting, direct measurement of kisspeptin-induced GnRH 
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secretion is precluded ethically and to some extent mechanistically, and therefore 
GnRH-releasing effects in response to kisspeptin is inferred from indirect methods, 
such as assessment of LH pulsatility (1.1.3.2 Pulsatile GnRH secretion).  
Studies using kisspeptin antagonist further support the notion that kisspeptin 
mediates its action predominantly via the release of hypothalamic GnRH (Millar et 
al. 2010). Infusion of kisspeptin antagonist into the median eminence of prepubertal 
and pubertal female rhesus monkeys suppressed both GnRH secretion and pulse 
frequency, suggesting the role of kisspeptin in GnRH pulsatility (Roseweir et al. 
2009, Guerriero et al. 2012). Indirect evidence for the role of kisspeptin in regulating 
pulsatile GnRH secretion is further demonstrated by reduced LH pulse frequency 
with kisspeptin antagonist in the female rat and sheep (Li et al. 2009, Roseweir et al. 
2009, Smith et al. 2011).  Furthermore, reduced LH pulsatility was achieved with 
kisspeptin antagonist infusion at the arcuate nucleus but not the pre-optic area in rat, 
suggesting that kisspeptin modulates pulsatile GnRH secretion at the arcuate nucleus, 
thought to be the site of the GnRH pulse generator (Plant et al. 1978a). In contrast to 
kisspeptin, exogenous GnRH elicited a prompt LH release in Kiss1r knockout mice, 
suggesting that pituitary responsiveness is preserved and that and kisspeptin 
signalling to be proximal to GnRH (Seminara et al. 2003).  
The action of kisspeptin to be operating upstream of GnRH is elegantly demonstrated 
by abrogation of kisspeptin-induced LH secretion in response to GnRH antagonist. 
Rodents and agonadal male monkeys pre-treated with a potent GnRH receptor 
antagonist, acycline, failed to mount gonadotropin rise following an otherwise robust 
response to kp-54 and kp-10 administration, respectively (Gottsch et al. 2004, Matsui 
et al. 2004, Shahab et al. 2005). Passive immunisation of ovariectomised ewes with 
GnRH antiserum achieved consistent results with kp-10 failing to induce LH pulse 
and increase serum LH concentrations (Arreguin-Arevalo et al. 2007). Although 
there are no human studies administering kisspeptin antagonist or GnRH antagonist 
followed by kisspeptin, the direct action of kisspeptin on GnRH neurons is inferred 
from the consistent findings in other species, including nonhuman primates. 
 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
Literature Review        44 
Indirect action of kisspeptin on GnRH secretion 
In addition to direct stimulatory role of kisspeptin on GnRH neurones, kisspeptin 
appears to regulate GnRH secretion though its action on other intermediary 
signalling pathways, such as GABAergic (excitatory and inhibitory) and 
glutamatergic (excitatory) cells. In the female mice brain slices, blockade of γ-
animobutyric acid (GABA)A receptor (excitatory) and glutamate receptor reduced 
GnRH neurone firing response to kisspeptin-10 (Pielecka-Fortuna et al. 2008). This 
is consistent with rodent pre-optic kisspeptin neurones co-expressing GABA and 
galanin (Ferin et al. 1984, Smith et al. 2006b) suggesting the role of those 
neurotransmitters in mediating indirect actions of kisspeptin on GnRH secretion.  
Kisspeptin-independent GnRH secretion 
Kisspeptin-independent GnRH secretion is supported by neuroanatomical studies, 
showing that not all GnRH neurones express the kisspeptin receptor (Irwig et al. 
2004) and that the contacts between the GnRH and kisspeptin neuronal networks 
actually appear infrequent (Clarkson and Herbison. 2006, Ramaswamy et al. 2008, 
Smith et al. 2008a, Hrabovszky et al. 2010). Although humans with mutations in 
kisspeptin pathway show failure in pubertal development and infertility (de Roux et 
al. 2003, Seminara et al. 2003, Topaloglu et al. 2012), Kiss1 and Kiss1R knock-out 
mice exhibit partial sexual maturation with vaginal estrous phase in females and 
spermatogenesis in males, suggesting some GnRH activity (Chan et al. 2009a). To 
confirm that the partial sexual development in those mice is due GnRH secretion, 
administration of a GnRH antagonist, acycline, resulted in disrupted vaginal estrous, 
lower uterine and testicular weights, impaired spermatogenesis and low gonadotropin 
secretion (Chan et al. 2009a). These animals, however, do not undergo ovulation and 
are infertile, suggesting insufficient GnRH secretion (Lapatto et al. 2007).  
Studies using kisspeptin antagonists further suggest that pathways other than 
kisspeptin signaling are involved in the regulation of GnRH secretion (Millar et al. 
2010). Kisspeptin antagonist did not suppress basal LH secretion in gonadal intact 
and castrate rodents and sheep (Roseweir et al. 2009), when administered directly 
into the rat arcuate nucleus (Li et al. 2009) and in the pre-ovulatory LH surge studies 
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in rats (Pineda et al. 2010). Furthermore, basal GnRH secretion was also unaffected 
by the kisspeptin antagonist in pubertal female monkeys, although GnRH pulse 
frequency was reduced (Roseweir et al. 2009) as was LH pulsatility in female rats 
(Li et al. 2009). These findings indicate that basal LH secretion appears to be 
mediated by kisspeptin-independent pathways on GnRH neurones.  
Kisspeptin-independent GnRH secretion could be intrinsic to GnRH neurones 
themselves. Autonomous GnRH release in synchronous pulses has been observed 
from GnRH cell lines (Martinez de la Escalera et al. 1992). Ongoing GnRH secretion 
in the presence of defective kisspeptin signalling may reflect heterogeneity between 
GnRH neurones. The existence of two physiologically distinct subpopulations of 
GnRH neurones have been proposed in the prepubertal and pubertal mice; one that 
co-localises with Kiss1R mRNA and VGlut2 and is highly sensitive to kisspeptin but 
does not respond to glutamate receptor agonist; a second that is insensitive to 
kisspeptin but is activated by the glutamate receptor agonist (Dumalska et al. 2008). 
Neurotransmitters, other than kisspeptin, such GABA, galanin, glutamate, 
norepinephrine, neuropeptide Y and RF-amide-related peptides, have been 
implicated in modulating GnRH secretion, although evidence for their critical role is 
lacking for some (Herbison. 2015). Type I GnRH receptor transcripts have been co-
localised to the mice GnRH neurones, although the direct effects of GnRH on its 
neurone excitability remain unclear (Xu et al. 2004, Todman et al. 2005). The action 
of those neuromodulators upon GnRH neurones is reviewed in detail elsewhere 
(Herbison. 2015).  
1.2.6.3 Pituitary effects 
The direct action of kisspeptin at the pituitary gonadotrope remains debatable. The 
expression of both Kiss1 and Kiss1r genes have been detected in gonadotropes in a 
number of species, including humans, baboons, sheep, pigs and rats (Kotani et al. 
2001, Gutierrez-Pascual et al. 2007, Li et al. 2008, Richard et al. 2008, Smith et al. 
2008b). Kisspeptin is able to induce gonadotropin release from pituitary explants and 
cells in vitro, although its stimulatory effect on LH is modest compared to GnRH 
despite the use of kisspeptin concentrations well beyond those considered 
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physiological (Gutierrez-Pascual et al. 2007, Suzuki et al. 2008). Furthermore, 
kisspeptin has been detected (although in low levels) in the hypophyseal portal 
circulation in the sheep, suggesting that hypothalamic kisspeptin is transported in the 
portal blood to exert its action directly on the gonadotropes (Smith et al. 2008b). 
However, no fluctuations in kisspeptin levels have been observed in the portal blood 
to reflect changes in sex-steroid environment across the reproductive span (Smith et 
al. 2008b). In the hypothalamic-pituitary disconnected sheep, kisspeptin failed to 
induce LH secretion, suggesting that kisspeptin acts upstream of the pituitary (Smith 
et al. 2008b). This is further supported by the failure of kisspeptin to stimulate LH 
release in GnRH antagonist pre-treated monkeys (Gottsch et al. 2004, Irwig et al. 
2004). Whilst there is evidence to suggest direct action of kisspeptin on 
gonadotropes, it is clear that kisspeptin predominantly exerts its stimulatory role on 
LH and FSH secretion indirectly through GnRH (Gottsch et al. 2004, Irwig et al. 
2004, Smith et al. 2008b).  
1.2.6.4 Kisspeptin as GnRH pulse generator 
There is growing evidence to suggest that a population of kisspeptin neurones 
located in the hypothalamic arcuate nucleus constitutes the GnRH pulse-generator, 
which coordinates synchronised and episodic GnRH discharges from its neuronal 
terminals. In addition to kisspeptin making close associations with GnRH neurones 
at the median eminence and being a potent GnRH and LH secretagogue, there are 
anatomical and functional data in animals and humans supporting this notion.  
The arcuate kisspeptin neurones in GnRH pulse generating activity 
Although the MBH was argued to be the site for a GnRH pulse generating 
mechanism as early as 1980’s (based on the MUA recordings) (Knobil. 1981), 
kisspeptin neurones as the source of the GnRH pulse generator was not proposed 
until thirty years later, when in goats, rhythmical MUA volleys were recorded at 
close vicinity of the arcuate (part of the MBH) kisspeptin cells and in association 
with LH pulses (Ohkura et al. 2009, Wakabayashi et al. 2010). Importantly, pulsatile 
kisspeptin-54 release in association with GnRH pulses was detected within the MBH 
in monkeys (Keen et al. 2008). Whilst kisspeptin antagonists administered centrally 
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did not abrogate basal GnRH and LH secretion (Li et al. 2009, Roseweir et al. 2009, 
Pineda et al. 2010), the frequency of GnRH and LH pulsatility was suppressed (Li et 
al. 2009, Roseweir et al. 2009). It is plausible that kisspeptin is primarily involved in 
the regulation of pulsatile GnRH and subsequently LH release rather than the 
maintenance of basal gonadotropin secretion. This is consistent with the abolishment 
of LH pulsatility following direct kisspeptin antagonist infusion into the arcuate 
nucleus (but not the pre-optic area) in rats and sheep (Li et al. 2009, Goodman et al. 
2013), the proposed site of the GnRH pulse generator (Plant et al. 1978b). 
Furthermore, female rats bearing kisspeptin knockdown in the arcuate nucleus had 
suppressed LH pulsatility, indicating the role for kisspeptin within this area for pulse 
generation (Beale et al. 2014).  
In the studies using chronic subcutaneous kisspeptin administration to block 
kisspeptin-kisspeptin receptor signaling, MUA volleys remained unchanged despite 
complete suppression of LH secretion (Yamamura et al. 2014). Similarly, peripheral 
injection of kp-10 elicited LH response but did increase the amplitude or frequency 
of MUA recording in rats and goats (Kinsey-Jones et al. 2008, Ohkura et al. 2009), 
suggesting other cells/mechanisms than kisspeptin to be the GnRH pulse generator. 
However, kisspeptin neurones are deficient of kisspeptin receptors (Herbison et al. 
2010, Smith et al. 2011) and it is feasible that peripherally administrated kisspeptin 
analogues in the studies above did not affect the arcuate GnRH-pulse generator, but 
rather mediated their effects on the downstream kisspeptin receptor-expressing 
GnRH dendrons in the median eminence, which is outside the blood-brain-barrier. 
This may also be the case with antagonistic studies, where the precise location of the 
kisspeptin antagonism is unclear. Okamura and colleagues have debated whether 
kisspeptin is the intermediary mechanism which transmits the action potential from 
the pulse generator to GnRH neurones and mediates GnRH secretion at its terminals 
upon the entrance to the median eminence (Okamura et al. 2013). This is supported 
by the stimulatory role of kisspeptin and the inhibitory effect of kisspeptin antagonist 
on GnRH secretion from the median eminence in vitro and in vivo (d'Anglemont de 
Tassigny et al. 2008, Keen et al. 2008).  
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Effects of kisspeptin on GnRH pulse generator in humans 
In humans, studies aiming to delineate the role of kisspeptin in the control of GnRH 
pulse generator are more challenging and hence sparse. It has however been 
suggested that in men, kisspeptin can reset the hypothalamic clock that drives 
pulsatile GnRH secretion (Chan et al. 2011). Acute injection of KP-10 induced an 
immediate LH pulse and delayed the next endogenous LH pulse by approximately 2 
hours (Chan et al. 2011), the interval that would be observed between two 
consecutive endogenous LH pulses (Santen and Bardin. 1973). A refractory delay 
following kisspeptin-mediated LH pulse is unlikely since in some men an 
endogenous LH pulse occurred close to kisspeptin administration (Chan et al. 2011). 
The morphology of kisspeptin-induced LH pulses in healthy men (Chan et al. 2011) 
and GnRH-induced LH pulses in those with isolated GnRH deficiency (Pralong et al. 
1996) are similar, suggesting that kisspeptin generates LH pulse via a pulse of 
GnRH. Furthermore, KP-10 appears to induce prolonged GnRH secretion. In men, 
the morphology of kisspeptin-induced LH pulse was reproduced by a 17-minute 
infusion of GnRH (Chan et al. 2011). This is in concordance with the duration of 
kisspeptin-induced GnRH neurone depolarization ex vivo (Han et al. 2005, Pielecka-
Fortuna et al. 2008, Zhang et al. 2008).  
The GnRH clock resetting potential of kisspeptin shows sexual dimorphism as the 
same kisspeptin dosing protocol to that in men failed to achieve this in women across 
the different phases of the menstrual cycle (Chan et al. 2012). The authors suggested 
that the GnRH pulse generator in men operates differently to women and that it is the 
change in the sex steroid milieu across the menstrual cycle in the women that might 
be responsible for this discrepancy (Chan et al. 2012). This is consistent with early 
studies suggesting that in men, GnRH pulse generation is a renewal process 
adjustable to the last secretory phase, but may not operate in women in the luteal 
phase of the menstrual cycle (Butler et al. 1986, Santoro et al. 1988). Optogenetic 
stimulation of the arcuate kisspeptin neurones in female mice required higher 
frequency of activation to elicit LH pulses, which were still below the amplitude than 
that observed in males (Han et al. 2015). Sexual dimorphism in spontaneous 
electrical activity of the arcuate kisspeptin neurones has also been demonstrated in 
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mice (de Croft et al. 2012). The marked sex difference in the anatomy of the 
kisspeptin neuronal network in animals and humans may underlie gender specific 
mechanisms in generating GnRH pulses and may even determine changes in the 
frequency of GnRH secretion across the menstrual cycle.  
1.2.6.5 Effects of kisspeptin on LH pulsatility  
As GnRH secretion is pulsatile and kisspeptin is proposed to be an upstream GnRH 
pulse generator, the effect of kisspeptin on different aspects of pulsatility (as inferred 
by LH pulsatility) has been investigated. The stimulatory role of kisspeptin on 
pulsatile LH secretion has been demonstrated in animals and humans, data for the 
former of which is mainly inferred by studies using kisspeptin antagonism (see 
section 1.2.6.2 Direct and indirect actions of kisspeptin on GnRH neurones; 1.2.6.4 
Kisspeptin as GnRH pulse generator) whilst in humans using exogenous kisspeptin 
peptide itself (Pinilla et al. 2012, Skorupskaite et al. 2014, Clarke and Dhillo. 2016).  
The effect of kisspeptin on LH pulsatility was first demonstrated in humans 
following an intravenous infusion of KP-10 for 9 hours (1.5 µg/kg/hr [1.1 
nmol/kg/hr]), which in healthy men not only increased LH and testosterone secretion 
but has also enhanced the frequency and amplitude of LH pulses (George et al. 
2011).  This is in concordance with animal data, where kisspeptin antagonism 
potently suppressed the frequency of GnRH pulses in monkeys (Roseweir et al. 
2009) and LH pulses in rats (Li et al. 2009, Pineda et al. 2010) and sheep (Roseweir 
et al. 2009, Smith et al. 2011, Goodman et al. 2013), indicating that kisspeptin 
actions are via GnRH secretion and that kisspeptin modulates GnRH pulsatility.   
Interestingly, data from other investigators have not replicated increased LH 
pulsatility in response to an acute bolus of KP-10 injection in healthy male and 
female subjects (Chan et al. 2011, Chan et al. 2012), suggesting that a continuous or 
repeated administration of kisspeptin is needed to modulate GnRH and hence LH 
pulsatility given short half-life of KP-10 (Jayasena et al. 2011). In contrast, a single 
injection of KP-54 (0.3 nmol/kg [1.76 µg/kg] and 0.6 nmol/kg [3.55 µg/kg] 
subcutaneous) temporarily increased LH pulsatility in healthy women (Jayasena et 
al. 2013b). Although kisspeptin-54 remained detectable in serum for the duration of 
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the study, 4-hour post injection blood sampling period may not be sufficient to 
determine all the characteristics of LH pulsatility. Prolonged exposure to KP-54 had 
no effect on the frequency and amplitude of LH pulses when administered 
subcutaneously as an infusion for 8 hours (0.3 nmol/kg/hr and 1.0 nmol/kg/hr) 
(Narayanaswamy et al. 2016a) or as twice daily injection for a week in healthy 
women during the follicular phase (Jayasena et al. 2013a). Lack of kisspeptin 
response might reflect relatively low estradiol levels in the follicular phase given that 
kisspeptin-stimulated gonadotropin secretion is positively correlated to estradiol 
levels (Narayanaswamy et al. 2016a). In luteal-phase ewes, central kisspeptin 
infusion increased LH pulse frequency (Li et al. 2015). The effects of kisspeptin on 
LH pulsatility remain to be determined when administered during the pre-ovulatory 
or luteal phase of the menstrual cycle, when LH sensitivity to kisspeptin is 
heightened (Dhillo et al. 2007, Jayasena et al. 2011, Chan et al. 2012).  
The ability of kisspeptin to increase pulsatile LH secretion has also been 
demonstrated in human reproductive disorders of low LH pulsatility, including in 
hypothalamic amenorrhoea (Jayasena et al. 2014b), in hypogonadal men with type 2 
diabetes (George et al. 2013), and in defects in neurokinin B and its receptor (Young 
et al. 2013). It remains unclear as to whether kisspeptin administration can further 
enhance pulsatile LH release in states of high LH pulsatility in health, such as in 
postmenopausal women, and in disease, such as in PCOS.    
1.2.6.6 Chronic or continuous exposure to kisspeptin 
It is well established that continuing administration of GnRH desensitises the 
hypothalamic-pituitary-gonadal axis after an initial stimulation (Belchetz et al. 
1978), the phenomenon of which is applied clinically in the management of sex-
steroid dependent disorders and in IVF. Downregulation of gonadotropin-releasing 
hormone receptors and desensitization of gonadotropes is the mechanism by which 
GnRH analogue suppresses gonadotropin output (McArdle et al. 1987, Mason et al. 
1994). Given that pulsatile (i.e. non-continuous) kisspeptin secretion has been 
observed within the median eminence of the monkey (Keen et al. 2008), the potential 
of prolonged kisspeptin exposure to bring about desensitisation has been 
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investigated, but it appears to be less clearly demonstrable than that of continuous 
GnRH administration.  
Continuous administration of kp-10 (intravenous 200 µg/hr [154 nmol/kg] or 400 
µg/hr [307 nmol/kg] for 98 hours) to rhesus monkeys resulted in suppressed LH 
secretion, indicative of kisspeptin receptor desensitization (Ramaswamy et al. 2007). 
Similarly, the stimulatory effect of kp-54 on LH and testosterone secretion was lost 
after 2 days of continuous subcutaneous administration at 50 nmol/day in male rats 
(Thompson et al. 2006). The kisspeptin receptor has been shown to desensitise in 
vitro by uncoupling from its G-protein coupled complex and undergoing 
internalization (Pampillo et al. 2009). Consistent with this, repeated subcutaneous 
administration of KP-54 (6.4nmol/kg twice daily) for two weeks in women with 
hypothalamic amenorrhea resulted in an initial stimulation of LH and FSH secretion 
which was not maintained, indicating that chronic nonpulsatile exposure of 
kisspeptin causes tachyphylaxis in humans (Jayasena et al. 2009) (Fig. 1.3). In those 
women, LH response to GnRH administration after KP-54 injections was preserved 
and comparable to GnRH-stimulated LH secretion before kisspeptin treatment, 
indicating that desensitisation to kisspeptin was at the hypothalamus and upstream of 
the pituitary gland (Jayasena et al. 2009), which is consistent with animal data 
(Seminara et al. 2006). Whilst continuous kp-10 infusion reduced the frequency and 
amplitude of LH pulses in rhesus monkeys (Ramaswamy et al. 2007), this was not 
changed after kisspeptin treatment in women with hypothalamic amenorrhoea 
(Jayasena et al. 2009). This discrepancy may be explained by rapid recovery from 
kisspeptin exposure in the latter as assessment of LH pulsatility was 24 hours post 
final kisspeptin injection, and a protocol using more than 40-fold higher dose of 
kisspeptin and for longer period of time in the former.  Jayasena and colleagues have 
suggested there might be a dose-dependent window within which kisspeptin would 
sustain basal LH secretion and restore LH pulsatility. Intravenous KP-54 infusion at 
1 nmol/kg/hr for 10 hours in women with hypothalamic amenorrhea increased LH 
secretion to peak at 5 hours with a gradual decline thereafter (Jayasena et al. 2014b). 
Similarly, detectable LH pulses were diminished after 4 hours of 1 nmol/kg/hr of 
kisspeptin administration (Jayasena et al. 2014b). Lower doses of KP-54 
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(intravenous 0.01-0.3 nmol/kg/hr for 8 hours) showed no desensitisation, and there 
was overall increase in the mean peak number and secretory mass of LH pulses 
(Jayasena et al. 2014b).  
However other studies in healthy human subjects using infusions or repeated 
administration of kisspeptin have not provided consistent evidence for 
desensitization (Fig. 1.2). Kisspeptin-54 (6.4 nmol/kg) administered twice daily for a 
week advanced the menstrual cycle in healthy women (Jayasena et al. 2013a). The 
study did not continue KP-54 injections for 2 weeks to determine whether 
desensitisation would be observed as in women with hypothalamic amenorrhoea 
(Jayasena et al. 2009). It is possible that women with hypothalamic amenorrhoea are 
more sensitive to desensitisation by kisspeptin given that their immediate LH 
response to kisspeptin itself is greater than in follicular phase women, despite the low 
estrogenic environment. In healthy men, continuous KP-10 infusion at 4 µg/kg/hr 
(3.1 nmol/kg/hr) for 22.5 hours showed continuing stimulation of LH secretion, with 
no evidence of desensitisation (George et al. 2011) (Fig. 1.2). In contrast, LH 
secretion was not sustained in three healthy men during KP-10 infusion for 24 hours 
at 12 µg/kg/hr (9.2 nmol/kg/hr), the highest dose and the longest duration of infusion 
used in humans to date (Lippincott et al. 2013). However LH secretion remained 
well above baseline values at the end of infusion in contrast to marked 
desensitisation with KP-54 in women with hypothalamic amenorrhoea (Jayasena et 
al. 2009). It is yet to be determined if an infusion of kisspeptin for longer than 24 
hours would unlimitedly result in LH suppression to castrate levels or maintain it 
above baseline.  
Whilst continuous kisspeptin administration at high doses has the potential to induce 
desensitisation, intermittent administration sustains GnRH and LH pulsatility. In 
contrast to KP-54 administered twice daily for 2 weeks, the same dose of KP-54 (6.4 
nmol/kg) injected twice weekly sustained the secretion of gonadotropins for 8 weeks 
after a brief initial suppression (Jayasena et al. 2010) (Fig. 1.3). Intermittent 
administration of kisspeptin-10 in juvenile male monkeys (intravenously hourly for 2 
days) and juvenile female rats (intracerebroventricular twice daily for 5 days) caused 
precocious puberty, indicating that GnRH and LH were released in a pulsatile 
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manner, which is necessary for the physiological role of GnRH (Navarro et al. 
2004b, Plant et al. 2006). In a dose-finding study of bolus KP-10 injection in healthy 
men, the highest dose (3 µg/kg [2.3 nmol/kg]) elicited a sub-maximal response 
compared to lower doses, suggesting that kisspeptin-10 can cause desensitisation 
even with bolus administration (George et al. 2011). An alternative explanation for 
this observation is that kisspeptin at the higher dose kisspeptin-10 might have 
stimulated another RF-amine receptor, such as gonadotropin inhibitory hormone 
receptor, known to have inhibitory effect on GnRH and LH (George et al. 2011).  
These data suggest that while high doses of kisspeptin may induce desensitisation, 
evidence for tachyphylaxis in humans is inconsistent. There appears to be a fine 
balance in the ability of kisspeptin to upregulate or downregulate the hypothalamic-
pituitary-gonadal axis. The discrepancies between the studies might reflect the 
duration of kisspeptin administration (8-22.5 hours vs 2-8 weeks), lower doses of 
kisspeptin infused in the human studies compared those in primate, variation in the 
isoform of kisspeptin used, the mode of kisspeptin administration, differences 
between the human and animal models and even health status (healthy volunteers 
versus women with hypothalamic amenorrhea).  
Whilst tachyphylaxis caused by natural forms of kisspeptin is controversial, 
kisspeptin receptor agonist analogues, TAK-448 and TAK-683 are potent induces of 
desensitisation. Phase I clinical studies in healthy men showed that subcutaneous 
infusion of TAK-683 (0.01-2mg/day) (Scott et al. 2013) and TAK-448 (0.01-
1mg/day) (MacLean et al. 2014) for 2 weeks suppressed testosterone below 
castration levels, the latter of which also reduced testosterone and prostate specific 
antigen in patients with prostate cancer (MacLean et al. 2014). Kisspeptin analogues 
may be advantageous compared to the GnRH analogues widely used today in that the 
effect of kisspeptin analogues was more rapid and profound in suppressing the 
hypothalamic-pituitary-gonadal axis, thereby limiting the initial stimulatory phase of 
gonadotropin secretion prior to downregulation that is characteristic of therapies 
using GnRH agonists (Matsui and Asami. 2014). 
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1.2.6.7 Sexual dimorphism in response to kisspeptin 
Men and women display sexual dimorphism in their response to exogenous 
kisspeptin. Whilst kisspeptin potently stimulates the release of LH in men, the effect 
of kisspeptin is more variable in women and depends on the phase of the menstrual 
cycle (Fig. 1.2). The stimulatory potency of kisspeptin is greatest in the pre-
ovulatory phase and least in healthy women in the early follicular phase of the 
menstrual cycle (Dhillo et al. 2007, Jayasena et al. 2011, Chan et al. 2012), which is 
consistent with data in rats (Roa et al. 2006) and sheep (Smith et al. 2009b). This 
variability in women may therefore reflect changes in the activity of the 
hypothalamic kisspeptin system and in the pituitary sensitivity to GnRH, with the 
varying sex steroid environment playing a major role in regulating this, which is 
discussed in more detail in section 1.2.6.1 (Stimulatory effect of kisspeptin on 
gonadotropin secretion). 
The sexual dimorphism in the responsiveness of men and women has been elegantly 
illustrated using different isoforms of kisspeptin (Jayasena et al. 2011) (Fig. 1.2). 
Men respond to modest doses of both KP-54 and KP-10 and with broadly similar 
potencies of action on gonadotropin secretion when compared in equimolar doses 
(Dhillo et al. 2005, George et al. 2011, Jayasena et al. 2011, Jayasena et al. 2015a). 
In women, even the highest doses of KP-10 administered as an intravenous bolus (10 
nmol/kg), subcutaneous bolus (32 nmol/kg) or an intravenous infusion (720 
pmol/kg/min for 90 mins) failed to mount an LH response in the follicular phase 
(Jayasena et al. 2011). However in subsequent studies low-dose intravenous KP-10 
bolus (0.24 nmol/kg) stimulated LH secretion in the early follicular phase (Chan et 
al. 2012, George et al. 2012). The discordance in results may have been 
methodological- the former study had no baseline LH sampling as opposed to the 
latter two studies, which employed a 10-minute LH blood sampling for 3 (George et 
al. 2012) and 6 hours (Chan et al. 2012) prior to kisspeptin administration, allowing 
comparison of LH secretion before and after KP-10 administration within the same 
subject. Differential FSH response to kp-10 has been suggested in rodents, with the 
response being more prolonged in male rats (Pinilla et al. 2012). KP-54 is more 
consistent in inducing LH secretion when administered as an intravenous or 
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subcutaneous bolus or a subcutaneous infusion in the follicular phase (Dhillo et al. 
2007, Jayasena et al. 2011, Jayasena et al. 2013a, Jayasena et al. 2013b, 
Narayanaswamy et al. 2016a), suggesting that the response to the longer isoform of 
kisspeptin is substantially more robust, perhaps reflecting its longer half-life. This is 
consistent with studies in rodents where subcutaneous kp-54 stimulated LH secretion 
more potently in male rats compared to kp-10 (Thompson et al. 2006). Interestingly, 
it has been consistently found that in the pre-ovulatory phase both KP-54 and KP-10 
potently stimulate gonadotropin secretion (Dhillo et al. 2007, Jayasena et al. 2011, 
Chan et al. 2012).  
Sexual dimorphism has also been apparent in other aspects of kisspeptin signalling: 
there are marked differences in kisspeptin neurone abundance between males and 
females (Clarkson and Herbison. 2006, Kauffman et al. 2007, Cheng et al. 2010, 
Hrabovszky et al. 2010) (see section 1.2.5.4 Sexual dimorphism of kisspeptin 
neurones); spontaneous electrical firing of kisspeptin neurones is different in female 
to male mice (de Croft et al. 2012); female mice require higher frequency of 
stimulation to elicit action potential and LH secretion then males (Han et al. 2015); 
kisspeptin resets the hypothalamic GnRH clock in men but not in women (Chan et al. 
2011, Jayasena et al. 2011) (see section 1.2.6.4 Kisspeptin as GnRH pulse generator). 
This sexual variation in the anatomical distribution of kisspeptin pathway and many 
aspects of kisspeptin-kisspeptin receptor physiology may reflect sexually dimorphic 
roles of kisspeptin, notably in the generation of the pre-ovulatory LH surge, which is 
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1.2.7 Kisspeptin and puberty 
The obligate role of kisspeptin-kisspeptin receptor pathway in reproduction was 
established by genetic studies in human puberty undertaken simultaneously by two 
independent researchers, where ‘loss of function’ mutations in KISS1R were 
identified in patients with hypogonadotropic pubertal delay (de Roux et al. 2003, 
Seminara et al. 2003) (see section 1.2.3 Discovery of the role of kisspeptin in 
reproduction). Since these early reports, other ‘loss of function’ mutations in KISS1R 
have been reported (Tenenbaum-Rakover et al. 2007). A similar phenotype was later 
demonstrated in a large consanguineous family with all affected members bearing a 
homozygous mutation in KISS1 gene itself (Topaloglu et al. 2012).  
The clinical findings of kisspeptin as a crucial regulator of puberty have been 
supported by numerous studies in animals. Kiss1r and Kiss1 deficient mice display a 
phenotype of human normosmic idiopathic hypogonadotropic hypogonadism, 
although they show variable reproductive potential ranging from complete 
reproductive phenotype knock-out (Seminara et al. 2003, d'Anglemont de Tassigny 
et al. 2007) to partial sexual maturation, indicating residual activity of the HPG axis 
(Chan et al. 2009a). In general, the phenotype of the Kiss1r knock-out mice is more 
severe compared to the Kiss1 knock-out mice (Lapatto et al. 2007). Nevertheless, the 
reproductive abnormality appears to stem from the Kiss1-Kiss1r signalling as 
gonadotropin secretion is observed in response to kisspeptin and GnRH 
administration, respectively (Seminara et al. 2003, d'Anglemont de Tassigny et al. 
2007). A GnRH neurone specific Kiss1r knock-out mice displayed pubertal delay 
with low gonadotropin levels and external abnormalities, including microphallus and 
decreased ano-genital distance in males, suggesting that disruption of kisspeptin 
receptor signalling alters gonadal steroid synthesis and secretion (Novaira et al. 
2014).  Likewise, central administration of kisspeptin antagonist delayed vaginal 
opening (a marker of pubertal induction in rodents) and decreased uterine and 
ovarian weights in peripubertal female rats (Pineda et al. 2010) and inhibited 
pulsatile GnRH secretion in pubertal female monkeys (Roseweir et al. 2009). 
Conversely, ablation of Kiss1-expressing cells did not affect pubertal onset in female 
mice(Mayer and Boehm. 2011). This contrasts with impaired reproductive phenotype 
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reported in Kiss1 and Kiss1r deficient mice (Seminara et al. 2003, d'Anglemont de 
Tassigny et al. 2007, Lapatto et al. 2007, Chan et al. 2009a) and with complete 
absence of reproductive function in patients with inactivating KISS1 and KISS1R 
mutations (de Roux et al. 2003, Seminara et al. 2003, Topaloglu et al. 2012) and may 
indicate incomplete kisspeptin neuronal ablation.    
Mutations in kisspeptin signalling not only cause pubertal delay, but can also be 
associated with advancing pubertal onset. An ‘activating’ autosomal dominant point 
mutation in the KISS1R gene in an adopted girl with precocious puberty has been 
reported, although the inheritance could not be determined as the biological family 
was not available for genetic testing (Teles et al. 2008). To investigate this further, 
cells transfected with the mutant kisspeptin receptor showed slower desensitization 
and prolonged accumulation of inositol phosphate and phosphorylation of 
extracellular signal-regulated kinase, indicating extended intracellular signalling by 
the mutant kisspeptin receptor (Teles et al. 2008). Missense mutations have been 
subsequently described in the KISS1 gene in association with central precocious 
puberty (Silveira et al. 2010). Functional characterisation studies showed this mutant 
kisspeptin to be more resistant to in vitro degradation, suggesting that greater 
kisspeptin bioavailability might be accounting for the precocious puberty (Silveira et 
al. 2010). A cohort of Korean girls with precocious puberty appeared to have less 
frequent polymorphism in KISS1 gene that authors suggested might be otherwise 
protective against pubertal precocity (Ko et al. 2010) and had higher serum 
kisspeptin levels compared to healthy controls (Rhie et al. 2011). Interestingly, 6 
months of pubertal suppression treatment with GnRH agonist resulted in lower 
serum kisspeptin levels in girls with precocious puberty when compared to pre-
treatment levels (Demirbilek et al. 2012).  
In addition to human studies, anatomical and functional experiments in animals, 
including primates, implicate the role of kisspeptin in the onset of pubertal 
maturation. Hypothalamic expression of Kiss1 and Kiss1r mRNA is dramatically 
upregulated at puberty in rodents and primates (Navarro et al. 2004a, Han et al. 2005, 
Shahab et al. 2005, Clarkson and Herbison. 2006), and the percentage of GnRH 
neurones depolarising in response to kisspeptin increases from juvenile (25%) to 
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prepubertal (50%) to adult mice (over 90%), suggesting that GnRH neurones 
gradually acquire sensitivity to kisspeptin across puberty (Han et al. 2005). Kp-54 
secretion increased in association with the pubertal increase in GnRH, and 
furthermore kp-54 release was pulsatile at approximately 60-minute intervals at the 
onset of puberty in female monkeys (Keen et al. 2008). Kp-10 infusion hourly for 48 
hours in prepubertal male monkeys stimulated LH pulses that mimicked those 
induced by pulsatile synthetic GnRH administration (Plant et al. 2006) and were 
similar to LH pulses observed in castrated adult male monkey (Plant. 1982), 
suggesting GnRH-dependent kisspeptin signalling at puberty. Complementary to 
physiological changes linking kisspeptin and the onset of puberty, 
intracerebroventricular delivery of kisspeptin from postnatal day 26 to 31 induced 
precocious puberty in female rats, displaying advanced vaginal opening, increased 
uterine weighs and raised LH and estradiol secretion (Navarro et al. 2004b).  
Taken together these data support the hypothesis that during juvenile period reduced 
kisspeptin stimulatory tone initiates the prepubertal brake, resulting in GnRH 
quiesecence, and it is the upregulation of the arcuate kisspeptin expression and 
increased kisspeptin release in the peripubertal state that reactivates pulsatile GnRH 
secretion (Herbison. 2016a). In females, the later development of pre-optic 
kisspeptin neurone inputs to GnRH in the pubertal period allows the generation of 
the GnRH surge (Herbison. 2016a). Kisspeptin-kisspeptin receptor interaction 
appears to be a necessity to initiate and progress through the puberty, although the 
exact mechanism by which kisspeptin orchestrates and likely interacts with other 
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1.2.8 Kisspeptin and metabolism 
Reproductive function is influenced by metabolic status with both extremes of 
nutrition –starvation and obesity having a negative impact on reproduction across the 
species. Kisspeptin has been implicated as an intermediary link between energy 
homeostasis and reproduction by sensing energy stores and translating this 
information into the pulsatile GnRH secretion. Food-deprived rodents and non-
human primates show reduced expression of hypothalamic Kiss1 mRNA and low 
gonadotropin levels with pubertal arrest in the former (Castellano et al. 2005, Cota et 
al. 2006, Roa et al. 2009, Wahab et al. 2011). Kisspeptin administration was able to 
restore delayed vaginal opening and normalised low gonadotropin and estrogen 
levels associated with undernutrition in pre-pubertal rats (Navarro et al. 2004b, 
Castellano et al. 2005). However, testosterone response to peripheral kisspeptin 
injection was delayed and suppressed in mature male monkeys following 18- and 24-
hour fasting-induced metabolic deficiency (Wahab et al. 2008, Wahab et al. 2014), 
suggesting that fasting-induced suppression of the reproductive axis may involve 
decreased responsiveness to endogenous kisspeptin.  
Kisspeptin appears to mediate its role in energy homeostasis through interactions 
with leptin, the ‘satiety hormone’ of adipose tissue.  Leptin has been show to activate 
GnRH neurones (Quennell et al. 2009), and deficiency of leptin is associated with 
pubertal delay and hypogonadotropic hypogonadism in mice and humans (Chehab et 
al. 1996, Clement et al. 1998). Whist GnRH neurones lack the leptin receptor (Ob-
Rb), the arcuate kisspeptin neurones express this receptor, suggesting the role of 
kisspeptin in mediating the metabolic signals of leptin on the HPG axis (Smith et al. 
2006a). In animals subject to negative energy balance, low serum leptin levels results 
in decreased expression of Kiss1 mRNA (Castellano et al. 2005, Smith et al. 2006a, 
Wahab et al. 2011), which is subsequently upregulated by leptin (Smith et al. 2006a, 
Backholer et al. 2010). In sheep, this has been observed in both kisspeptin 
populations at the pre-optic region and the arcuate nucleus (Backholer et al. 2010). 
Interestingly, in leptin-deficient mice Kiss1 mRNA expression is not completely 
restored in response to leptin (Smith et al. 2006a). Partial recovery of kisspeptin 
signalling in response to leptin is consistent with 40% of kisspeptin neurones 
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localising to the leptin receptors and indicate the involvement of other mediators in 
suppressing kisspeptin pathway in leptin deficiency (Smith et al. 2006a). Indeed, 
mice with selective deletion of leptin receptor from kisspeptin neurones undergo 
normal pubertal maturation, sexual development and are fertile, suggesting that 
kisspeptin pathway is not critical for leptin signalling (Donato et al. 2011).  
Kisspeptin appears to replay the metabolic cues of other hypothalamic peptides. The 
arcuate kisspeptin neurones are in close association with neuropeptide Y (NPY) and 
pro-opiomelanocortin (POMC) neurones (Backholer et al. 2010). NPY is an 
orexigenic peptide, which decreases pulsatile LH secretion (Barker-Gibb et al. 1995), 
whilst POMC (a precursor for α-melanocyte-stimulating hormone (α-MSH)) is 
anorexigenic and stimulates the activity of kisspeptin and increases LH secretion 
(Backholer et al. 2009). Leptin receptor is also expressed by NPY and POMC 
neurones and may indirectly inform kisspeptin neurones on the body energy levels 
(Iqbal et al. 2001).  
Kisspeptin is also involved in mediating metabolic cues of gut hormones, in addition 
to adipose hormones, all of which interact with one another. For example ghrelin, the 
gut ‘hunger hormone’, is elevated under food-deprived conditions and is shown to 
decrease Kiss1 transcripts (Forbes et al. 2009). The role of gut and adipose hormones 
as regulators of energy homeostasis and their interaction with the reproductive axis is 
discussed in detail elsewhere (Comninos et al. 2014).   
Secondary hypogonadism has been observed in men with obesity and type 2 
diabetes, where decreased pulsatile GnRH secretion is thought to be the common 
factor (Dandona et al. 2008). However, the central cause of reproductive impairment 
appears to be upstream of GnRH as gonadotropin response exogenous kisspeptin 
administration is preserved in human diabetic patients and experimental diabetic 
animals (Castellano et al. 2006b, Castellano et al. 2009) (George 2013). A rat model 
of diabetes (streptazocin treated) display reduced levels of Kiss1 mRNA with 
subsequently low levels of circulating gonadotropins and sex steroids, which are 
corrected by kisspeptin (Castellano et al. 2006b, Castellano et al. 2009). Similarly, 
obese rats had decreased hypothalamic Kiss1 mRNA expression, low LH and 
testosterone levels, and suppressed kisspeptin-induced LH secretion (Sanchez-
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Garrido et al. 2014). This suggests that lack of stimulatory kisspeptin drive to the 
hypothalamic GnRH cells is a potential mechanism for the downregulation of 
reproductive axis seen with obesity and diabetes (George et al. 2010). Indeed, 
intravenous infusion of KP-10 (4 μg/kg/hr [3.1 nmol/kg/hr] for 11 hours) in 
hypogonadal men with type 2 diabetes increased the frequency and mass of LH 
pulses and LH and testosterone secretion (George et al. 2013) (Fig. 1.3). Low levels 
of leptin as opposed to insulin deficiency/resistance appears to be responsible for 
suppressed kisspeptin signalling in diabetes, as an administration of leptin and not 
insulin enhanced kisspeptin expression in the mouse hypothalamic cell line (Luque et 
al. 2007). Insulin receptors are expressed in the arcuate kisspeptin neurones, 
suggesting some role of insulin-kisspeptin interaction. Indeed, mice lacking insulin 
receptor from kisspeptin neurones showed signs of delayed puberty but otherwise 
normal adult reproductive capacity (Qiu et al. 2013). George and colleagues (George 
et al. 2010) have suggested that the mechanisms leading to suppression of kisspeptin 
signalling and subsequent hypogonadotropic hypogonadism in diabetes are multi-
factorial and include: upregulation of negative estrogen feedback (Schneider et al. 
1979); resistance to leptin seen in human obesity (Finn et al. 1998); insulin resistance 
and hyperglycaemia (Castellano et al. 2006b, Castellano et al. 2009); and 
inflammation, which is upregulated in hypogonadal men with diabetes (Dandona et 
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1.3 Neurokinin B- the upstream gatekeeper of kisspeptin-GnRH 
pathway 
The hypothalamic peptide neurokinin B (NKB) is now established as an essential 
regulator of pubertal acquisition and normal adult reproductive function across 
species, including humans. Neurokinin B is believed to act predominantly upstream 
of kisspeptin and signals via the neurokinin-3 receptor (NK3R) to mediate its 
stimulatory (although with some discordance in rodent data) effects on pulsatile 
GnRH and thus gonadotropin secretion. Co-expression of neurokinin B by the same 
functional neuronal network that also co-expresses kisspeptin and dynorphin (KNDy 
neurones) in the arcuate nucleus and their intimate interconnection to each other, 
indicates a complex interaction between the three neuropeptides and a degree of self-
regulation via the NK3R and kappa opioid receptor but not the kisspeptin receptor 
expressed within KNDy cells. Close apposition of KNDy projections to GnRH nerve 
terminal at the median eminence raises the possibility of this network being at the 
core of the GnRH pulse generator with NKB-NK3R signalling as an important 
component.  
1.3.1 Nomenclature and signalling  
Neurokinin B belongs to the tachykinin family peptides (10-11 amino acids), which 
share a common C-terminal amino acid sequence (Phe-X-Gly-Leu-Met-NH2) and 
include substance P, neurokinin A, neuropeptide K, neuropeptide γ, and hemokinin-1 
(Page. 2005). Neurokinin B is encoded by the TAC3 gene in humans, equivalent to 
Tac3 in non-human primates, cattle and dogs, and Tac 2 in rodents. Five out of seven 
exons of the TAC3 gene are first translated into the precursor preprotachykinin-B, 
which is then cleaved to proneurokinin B and finally to neurokinin B (Bonner et al. 
1987, Page et al. 2009). NKB/TAC3/Tac2 mRNA will be used when referring to the 
mRNA transcripts of this gene. 
The cognate receptor for neurokinin B is NK3R, encoded in five exon TACR3 gene 
in humans and Tacr3 in rodents (Almeida et al. 2004). NK3R belongs to the 
rhodopsin-like family of G-protein coupled receptor with seven hydrophilic 
transmembrane domains (Almeida et al. 2004).  Tachykinin family also has other 
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receptors, NK1R and NK2R for which substance P and neurokinin A are the 
preferential ligands, respectively, although each, including neurokinin B, can activate 
other three receptors (NK1R, NK2R and NK3R) (Regoli et al. 1994, Pennefather et 
al. 2004). Upon binding of neurokinin B to its NK3R, it can activate two intracellular 
signalling pathways- via phospholipase C, which recruits inositol triphosphate to 
increase calcium influx into the cells, and/or via adenylate cyclase to yield cAMP 
concentrations (Satake and Kawada. 2006).  
1.3.2 Neuroanatomy of NKB/NK3R pathway  
1.3.2.1 Distribution of NKB within the brain 
The distribution of NKB mRNA expressing neurones has been mapped in detail in 
the human hypothalamus and basal forebrain (Chawla et al. 1997). Neurokinin B 
neurones are predominately located in the infundibular nucleus (Chawla et al. 1997), 
which is conserved across species and localised to the arcuate nucleus (equivalent to 
the human infundibular nucleus) in rat (Marksteiner et al. 1992), mouse (Duarte et al. 
2006), sheep (Foradori et al. 2006), and monkey (Sandoval-Guzman et al. 2004).  
Small numbers of neurokinin B neurones are also scattered in other regions of the 
brain, including septal region, band of Broca, bed nucleus of the stria terminalis and 
amygdala in humans (Chawla et al. 1997) and rats (Marksteiner et al. 1992), 
although species difference exist, as for example expression of Tac2 mRNA in the 
rat hippocampus and olfactory bulb is absent in mice (Duarte et al. 2006).  
The key relevant feature of the infundibular/arcuate neurokinin B neurones is their 
co-localisation with kisspeptin and dynorphin in numerous species, including 
humans (Goodman et al. 2007) (see section 1.2.5.2 Kisspeptin neurones co-express 
other neuropeptides). Studies using dual immunocytochemistry and track-tracing 
have identified dense neuronal network of NKB/dynorphin in the rat arcuate nucleus, 
the axons of which are in close apposition to NKB/dynorphin cell bodies and 
dendrites, suggesting close communication between those neurones (Burke et al. 
2006). The arcuate neurokinin B neurones branch out to and are in close apposition 
to the GnRH terminals at the median eminence (Goubillon et al. 2000, Krajewski et 
al. 2005, Ciofi et al. 2006), and extend across it to the contralateral arcuate nucleus in 
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rats (Krajewski et al. 2010) as well as other regions of the brain, including the AVPV 
nucleus and the medial pre-optic area, the dorsomedial hypothalamus and the lateral 
hypothalamic areas (Burke et al. 2006, Krajewski et al. 2010, Rance et al. 2010).  
1.3.2.2 Distribution of NK3R within the brain 
NK3R is expressed in the arcuate nucleus and furthermore is present on 
NKB/kisspeptin/dynorphin cells (Krajewski et al. 2005, Navarro et al. 2009), 
suggesting that neurokinin B may exert feedback on reciprocally interconnected 
neurokinin B-expressing neurones in the regulation of kisspeptin and subsequently 
GnRH secretion. Generally, regions receiving the arcuate neurokinin B fibres in rat 
also express NK3R (Krajewski et al. 2005). NK3R-immunoteactivity was detected 
on GnRH terminals in the median eminence in rodents (Krajewski et al. 2005, 
Todman et al. 2005), suggesting direct action of neurokinin B on GnRH release. 
However, neurokinin B cells in rats did not take up intraperitoneally administrated 
aminostilbamidine, a retrograde tracer that does not cross the blood-brain-barrier, 
questioning their localisation and therefore function at the fenestrated capillaries at 
the median eminence having access to the blood-borne particles (Krajewski et al. 
2005). NK3R localisation to GnRH neurones has not been investigated in other 
species.  
1.3.2.3 Sexual dimorphism of neurokinin B neurones 
Similarly to the kisspeptin neuronal network, gender differences are present in the 
numbers and morphology of neurokinin B neurones. Ewes have increased numbers 
of neurokinin B neurones in the arcuate nucleus compared to rams and females 
androgenized prenatally, suggesting that this sex difference is influenced by 
testosterone early in development (Goubillon et al. 2000, Cheng et al. 2010). There is 
also sexual dimorphism in the distribution of neurokinin B axons in the rat arcuate 
nucleus, where in males, neurokinin B axons are in close proximity to the fenestrated 
capillaries in the median eminence, whereas in females, neurokinin B axons are more 
diffusely distributed (Ciofi et al. 2006). Postnatal development of the hypothalamic 
neurokinin B neuronal network is distinct in males and females in rats (Ciofi et al. 
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2007). Whilst in females, there appears to be progressive development in neurokinin 
B system (organised gathering of axons and increase in their numbers) from 
postnatal period (day 10) until puberty, they did not develop in males until puberty 
(day 40) (Ciofi et al. 2007). Furthermore, orchidectomy in prepubertal rats prevented 
and treatment with testosterone rescued masculine distribution of neurokinin B 
axons, whilst after estradiol administration the distribution of neurokinin B network 
was phenotypically female (Ciofi et al. 2007). In prepubertal ovariectomised female 
rats, testosterone exposure induced male-pattern of neurokinin B axon wiring (Ciofi 
et al. 2007). This shows that maturation of neurokinin B pathway is gender specific 
and furthermore is dependent on gonadal steroid exposure well beyond the perinatal 
period. Finally, the response of neurokinin B neurones to castration is different in 
prepubertal female and male rats. Ovariectomy was associated with an immediate 
increase in LH secretion and upregulation of the arcuate neurokinin B transcripts, 
whilst no changes were observed in LH levels and the expression neurokinin B in 
castrated juvenile males (Kauffman et al. 2009). This implies a gonadal-dependent 
suppression of the HPG axis before puberty in female rats but a different mechanism 












Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
Literature Review        66 
1.3.3 Discovery of the role of neurokinin B in reproduction 
Mechanistic studies: changes in NKB neurones in menopause in humans and 
animal models 
The role of neurokinin B in the reproductive axis was first suggested by 
neuroanatomical studies comparing the expression of neurokinin B in the 
hypothalamus of pre- and postmenopausal women (Rance and Young. 1991). In 
postmenopausal women, the subset of neurones in the infundibular nucleus was 
hypertrophied and expressed NKB mRNA and ERα mRNA (Rance et al. 1990, Rance 
and Young. 1991). Furthermore, there was marked increase in NKB mRNA 
expression of those hypertrophied neurones when compared to premenopausal 
women (Rance et al. 1990, Rance and Young. 1991). This suggests a role of 
neurokinin B in mediating negative estrogen feedback, whereby loss of steroid 
negative feedback with ovarian follicle exhaustion at the menopause results in 
heightened neurokinin B activity and high gonadotropin secretion.   
The involvement of neurokinin B in the control of the HPG axis was subsequently 
supported by animal findings, where ovariectomy increased and estrogen 
replacement reduced neurokinin B gene expression in monkeys (Abel et al. 1999, 
Sandoval-Guzman et al. 2004). In aging monkeys with low estrogen, resembling the 
human menopause, neurokinin B was unregulated in the arcuate nucleus (Eghlidi et 
al. 2010). Similarly, long-term (approximately 4 year) ovariectomy increased 
neurokinin B expression, which was reversed by estradiol treatment, whilst the 
expression of NK3R was not changed (Eghlidi et al. 2010).  
Clinical studies: hypogonadotropic hypogonadism due to NKB/NK3R mutations 
It was in 2009, when Topaloglu reported that loss of function mutations in the genes 
encoding neurokinin B (TAC3) and NK3R (TACR3) was associated with 
hypogonadotropic failure of pubertal progression in humans that firmly established 
the critical role of neurokinin B in normal function of the HPG axis (Topaloglu et al. 
2009). In cell culture, NK3R mutants had diminished ability to mediate intracellular 
calcium increase in response to neurokinin B (Topaloglu et al. 2009). Male patients 
with these mutations show microphallus, suggesting inadequate neurokinin B action 
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and testosterone secretion in utero (Topaloglu et al. 2009). Since then a number of 
cases of similar phenotype have been reported with NKB/NK3R mutations, both 
homozygous and hererozygous, with a suggested prevalence of 5.5% amongst 
patients with normosmic hypogonadotropic hypogonadism (Gianetti et al. 2010, 
Rance et al. 2010).  
In contrast to profound hypogonadotropic hypogonadism seen in patients with 
mutations in the neurokinin B pathway, rodents with genetic ablation of Tacr3 do not 
show GnRH deficient phenotype and are fertile (Kung et al. 2004). Tac2 
(homologous to human TAC3) knock-out mice have not yet been described. 
However, the expression of Tac2/Tacr3 was upregulated in the rat hypothalamus 
prior to pubertal maturation (Gill et al. 2012, Navarro et al. 2012), and 
intraperitoneal injection of neurokinin B agonist advanced pubertal onset as 
manifested with earlier vaginal opening and first estrus in female rats (Nakahara et 
al. 2013). Moreover, chronic central infusion of NK3R antagonist delayed the time 
of vaginal opening in pubertal rats, although this was not as effective as with 
kisspeptin antagonism (Pineda et al. 2010). This suggest that whilst neurokinin B is 
involved, it may not be critical for the pubertal maturation in rodents, further 
highlighting species difference in the neurokinin B and moreover, KNDy pathway.  
It is postulated that inability of neurokinin B to stimulate kisspeptin secretion in an 
autocrine and /or paracrine manner results in low GnRH pulse frequency with 
correspondingly low LH and gonadal steroid levels, but normal or near-normal levels 
of FSH typically seen in these patients. This pattern of gonadotropin secretion is 
reproduced by slow frequency of GnRH administration in rhesus monkeys (Wildt et 
al. 1981). Pulsatile administration of GnRH to adults with TAC3 and TACR3 
mutations normalised serum LH and sex steroids and in one female resulted in live 
birth (Young et al. 2010). This indicates that infrequent GnRH pulse pattern is at the 
core of defective NKB/NK3R signalling.  
Abnormal gonadotropin secretion in patients with mutations in the neurokinin B 
system appears to result from deficiency in the stimulatory action of kisspeptin on 
GnRH neurones. Indeed, continuous infusion of KP-10 (1.1nmol/kg/hr for 12 hours) 
in two patients with TAC3 and two patients with TACR3 mutations increased LH 
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response 2.5-fold and LH pulse frequency from none or very low (0.1 pulse/hour) to 
0.5 pulses/hour (Young et al. 2013) (Fig. 1.3), close to the normal pattern of 0.7 
pulses/hour seen in healthy men (George et al. 2011). This suggests that neurokinin 
B is essential for normal pulsatile GnRH secretion, and that the action of neurokinin 
B is upstream of kisspeptin. Overall, the LH response to kisspeptin was more limited 
and of lower LH mass per pulse than that observed in healthy men using the same 
kisspeptin administration regimen (George et al. 2011), consistent with a complex 
interaction of KNDy peptides rather than a linear hierarchy (Skorupskaite et al. 2014, 
Skorupskaite et al. 2016). Nevertheless, the significant increase in testosterone levels 
in male patients and estradiol levels in single female patient reflects an increase in 
LH and FSH following kisspeptin stimulation, although gonadal steroid levels were 
not corrected to the physiological range (Young et al. 2013). The authors explained 
partial restoration of gonadotropin and sex-steroid secretion in those patients by 
suggesting that while kisspeptin induces GnRH pulsatility readily, there is a delay in 
gonadotrope function which might be corrected with longer kisspeptin infusion and 
GnRH priming (Young et al. 2013). 
Interestingly, some patients with NKB/NK3R deficiency demonstrate reversibility of 
hypogonadotropic hypogonadism with pulsatile pattern of GnRH secretion in adult 
life after discontinuation of sex-steroid or gonadotropin replacement, including two 
spontaneous conceptions and a further woman with regular menstruation (Gianetti et 
al. 2010). It is possible that the phenotype is rescued by other tachykinins, such as 
substance P, which is co-expressed by ERα-positive neurokinin B neurones in the 
infundibular nucleus (Rance and Young. 1991). However, the reported rates of 
reversibility in patients with mutations in neurokinin B signalling of around 80% 
(Gianetti et al. 2010) and 15% (Topaloglu et al. 2009) are notably higher than the 
10% rate observed in a large cohort of other forms of normosmic hypogonadotropic 
hypogonadims cases (Pitteloud et al. 2005, Raivio et al. 2007). It is evident that 
NKB/NK3R pathway is a necessity for normal activation of HPG axis prenatally and 
at puberty, but once sexual maturation is achieved, neurokinin B signalling may not 
be required for sustained activity of the GnRH pulse generator (Topaloglu and 
Semple. 2011).  
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1.3.4 Effect of neurokinin B on GnRH and gonadotropin secretion 
1.3.4.1 Neurokinin B response on GnRH/ LH secretion and 
pulsatility 
Despite the critical role of neurokinin B in the onset of human puberty, its 
involvement in other aspects of reproduction is less clear. Administration of 
neurokinin B or a potent and selective NK3R agonist, senktide, has resulted in both 
stimulatory and inhibitory effects on LH secretion, depending on the animal model 
and gonadal status (Billings et al. 2010, Ramaswamy et al. 2010, Navarro et al. 
2011a). Initial studies in rodents suggested an inhibitory action of neurokinin B on 
LH secretion when injected centrally in ovariectomised rats (Sandoval-Guzman and 
Rance. 2004) and mice (Navarro et al. 2009). Decreased LH pulse frequency (a 
marker for GnRH pulsatility) by intracerebroventricular administration of senktide in 
rats suggests that neurokinin B alters pulsatile GnRH secretion (Grachev et al. 2012).  
In another study, neurokinin B had no effect on LH secretion when administered in 
intact mice or in hypothalamic explants from rats ex-vivo (Corander et al. 2010). 
Subsequently, NK3R agonist-induced LH secretion was demonstrated in female rats 
in both diestrus and proestrus (Navarro et al. 2011a). The effect of neurokinin B on 
LH secretion in rodents appears to depend on the level of circulating estradiol levels, 
as neurokinin B is inhibitory in the absence of sex-steroids (ovariectomised rats), but 
stimulatory in the presence of physiological levels of estradiol (intact or estrogen-
replaced ovariectomised rats) (Navarro et al. 2011a).  
The situation is however different in higher species, including non-human primates, 
where the stimulatory action of neurokinin B on LH secretion is more consistent. 
Central administration of neurokinin B and/or its receptor agonist dramatically 
increased LH secretion to levels close to those observed during the pre-ovulatory LH 
surge in ewes (Billings et al. 2010) and stimulated LH pulse frequency (Li et al. 
2015). Increased LH secretion was shown in the follicular phase and in anestrous 
ewes but not during the luteal phase, suggesting that response to neurokinin B is sex-
steroid dependent consistent with ERα-expressing NKB neurones (Billings et al. 
2010). Similarly, neurokinin B stimulated LH secretion in ovariectomised goats only 
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after pre-treatment with both estrogen and progesterone (Wakabayashi et al. 2010). 
Pre-treatment with GnRH receptor antagonist attenuated neurokinin B-induced LH 
discharges in agonadal prepubertal male monkeys, demonstrating that neurokinin B 
mediates its gonadotropic effects at or above the GnRH neurone (Ramaswamy et al. 
2010). Whilst neurokinin B elicits acute LH response, repetitive stimulation of 
neurokinin B pathway by an intermittent infusion of senktide (for 1 minute hourly 
for 4 hours), in contrast to kisspeptin, blunted LH secretion in agonadal juveline 
male monkeys, suggestive of tachyphylaxis (Ramaswamy et al. 2010). Kisspeptin 
stimulation of LH release was preserved following downregulation with repeated 
senktide administration, suggesting that desensitisation to neurokinin B is likely to 
occur upstream of kisspeptin/GnRH interactions (Ramaswamy et al. 2010, 
Ramaswamy et al. 2011).  Taken together, these data suggest sex-steroid modulation 
of neurokinin B action on LH secretion, and that it is upstream of and most likely via 
GnRH secretion, whereas discrepancies with rodent data may imply important 
interspecies variation in the neuroanatomical functioning of neurokinin B signalling.  
Neurokinin B was more recently administered to humans for the first time (Jayasena 
et al. 2014c). Perhaps surprisingly, intravenous infusion of neurokinin B (highest 
dose 5.12 nmol/kg/hr for 8 hours) had no effect on LH, FSH and sex-steroid levels, 
and did not alter the frequency and mass of LH pulses in healthy men and women 
even when examined across different phases of menstrual cycle (Jayasena et al. 
2014c). The discrepancy between human and animal findings might be explained by 
different doses (30 nmol/kg in monkeys versus 5.2 nmol/kg/hr in human) and routes 
of neurokinin B administration (central versus peripheral), variable sex-steroid 
feedback effects (intact versus post gonadectomy), species-specific action of 
neurokinin B and the interaction between the neurokinin B and other peptides of 
KNDy neurones (see section 1.3.4.2 The Interactions between KNDy neuropeptides).  
Studies using neurokinin B antagonism have further strengthened our understanding 
of the hypothalamic control of gonadotropin secretion by neurokinin B. Central 
infusion of an NK3R antagonist (MRK-08) had a powerful suppressive effect on LH 
secretion and abolished both the frequency and amplitude of LH pulses in 
ovariectomised ewes, suggesting that neurokinin B signalling is involved in the 
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regulation of pulsatile GnRH and therefore LH secretion (Li et al. 2015). Similarly, 
in castrate monkeys oral preparation of an NK3R antagonist (ESN364) supressed LH 
but not FSH secretion, indicative of preferential suppression of LH levels by reduced 
GnRH pulsatility (Fraser et al. 2015a). When administered in sexually mature female 
monkeys from menstrual cycle day 2 for 35 consecutive days, neurokinin B 
antagonism (using the drug ESN364) had no effect on basal gonadotropin secretion 
but delayed surge-like LH and FSH secretion and decreased ovarian hormone 
response, although not to castrate levels (Fraser et al. 2015a).  
In a recent randomised, double blinded, placebo-controlled clinical trial 
administering NK3R antagonist (AZD4901) in women with PCOS, 7 day 
administration of the highest dose of NK3R antagonist (40 mg oral twice daily) 
decreased LH secretion and subsequently circulating testosterone levels (George et 
al. 2016). NK3R antagonist interfered with GnRH pulse frequency as LH pulsatility 
was also reduced (George et al. 2016). Longer duration of treatment is required to 
establish the therapeutic application of neurokinin B antagonism in the treatment of 
hirsutism and potential resumption of menstrual regularity in PCOS. However, the 
inhibitory effect of neurokinin B antagonism on pulsatile GnRH/LH secretion has 
only been assessed when LH is hypersecreted and in disease models.  
During the preparation of this thesis, data on NK3R antagonism emerged in healthy 
men and women. NK3R antagonist (ESN364; 20, 60 and 180 mg on day 1) 
decreased LH but not FSH secretion in men and women and subsequently 
testosterone secretion in men, although this effect was very short-lived post dosing 
with both hormones recovering within 24 hours (Fraser et al. 2016). In women, there 
was no overall decrease in basal LH secretion during treatment started in the 
follicular phase for 21 days, but NK3R antagonist delayed the LH surge in some 
women, probably as a consequence of a delayed pre-ovulatory estradiol rise (Fraser 
et al. 2016). However, the mechanism by which neurokinin B antagonism suppresses 
sex hormones remains unclear and direct gonadal effects cannot be ruled out since 
TAC3/TACR3 and KISS1/KISS1R systems are expressed in the human ovary (Cejudo 
Roman et al. 2012, Garcia-Ortega et al. 2014). Although the action of NK3R 
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antagonist is consistent with slowing down the frequency of GnRH/LH pusatility, 
there are no data on this in states of high and low LH output in health. 
1.3.4.2 The interactions between KNDy neuropeptides 
It is now well accepted that kisspeptin, neurokinin B, and dynorphin of the same 
functional unit (KNDy neurones) in the human infundibular and the arcuate nucleus 
of other species interact to regulate GnRH and subsequently gonadotropin secretion, 
evidence for which is substantiated by both anatomical and functional data. In the 
only human study to date investigating the functional hierarchy of kisspeptin and 
neurokinin B, infusion of KP-10 was able to restore pulsatile LH secretion in men 
and women with inactivating mutations in neurokinin B (TAC3) and its receptor 
(TACR3), indicating that neurokinin B is functionally upstream of kisspeptin in 
regulating GnRH/LH secretion in humans (Young et al. 2013). This is supported by 
studies using Kissr1 knockout mice, which were unable to show a stimulatory effect 
of NK3R agonist senktide on LH secretion (Garcia-Galiano et al. 2012). Central 
administration of senktide in female rats was associated with a 10-fold upregulation 
in c-fos (a marker of neural activity) expression in the arcuate Kiss1 neurones as well 
as an increase in serum LH, suggesting that neurokinin B signalling can activate 
kisspeptin cells (Navarro et al. 2011a). Pre-treatment with NK3R antagonist 
abolished LH response to senktide but did not abrogate KP-10 induced LH secretion 
in GnRH primed juvenile male monkeys (Ramaswamy et al. 2010). Although NK3R 
is not widely expressed on GnRH neurones, its receptors are expressed by KNDy 
cells, where neurokinin B acts to regulate GnRH secretion (Krajewski et al. 2005, 
Navarro et al. 2011b). Current understanding is that the stimulatory neurokinin B and 
the inhibitory dynorphin via the cognate NK3R and the kappa opioid receptors 
expressed by KNDy cells autosynaptically coordinate the release of downstream 
kisspeptin, which through the kisspeptin receptor in turn drives the pulsatile secretion 
of GnRH and LH (Skorupskaite et al. 2014). 
To further investigate the KNDy hypothesis, a very recent study for the first time co-
administered kisspeptin, neurokinin B and naltrexone (an opioid receptor antagonist) 
in healthy men (Narayanaswamy et al. 2016c). Although all those treatments are 
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proposed to be stimulatory, divergent effects on gonadotropin secretion and pulsatile 
LH secretion were observed when they were co-administered. Generally, all 
kisspeptin (KP-54 0.1 nmol/kg/hr iv for 8 hours) and naltrexone (oral 50 mg) treated 
groups elicited pulsatile LH secretion, but those treated with neurokinin B (2.56 
nmol/kg/hr iv for 8 hours) had variable results (Narayanaswamy et al. 2016c) (Fig. 
1.2). Co-administration of neurokinin B limited the stimulatory effect of KP-54 on 
LH, FSH and testosterone secretion compared to KP-54 alone (Narayanaswamy et al. 
2016c). This phenomenon has been documented in limited animal studies, where co-
administration of neurokinin B with kisspeptin abrogated kisspeptin-induced GnRH 
secretion in hypothalamic explants from rats (Corander et al. 2010), although when 
injected centrally the stimulatory LH response to both neuropeptides was greater 
compared to kisspeptin alone (Corander et al. 2010). Incomplete access to the central 
nervous system with peripheral administration of neuropeptides may account for 
lowered response in the presence of neurokinin B, although the arcuate nucleus is 
thought to have some permeability to the blood-brain-barrier and its KNDy neurones 
project to the median eminence, which is outside this barrier. However, the 
expression GnRH1 and Kiss1r was downregulated by the intra-arcuate administration 
of senktide in rats (Grachev et al. 2012). There is a possibility that neurokinin B acts 
to inhibit kisspeptin-induced GnRH and subsequently gonadotropin secretion, in the 
situations where kisspeptin signalling is high (Narayanaswamy et al. 2016c).  
It has been postulated that the inhibitory effects of neurokinin B might be mediated 
by dynorphin. Dynorphin antagonism prevented senktide-induced suppression in LH 
secretion in ovariectomised rats with and without estradiol replacement (Grachev et 
al. 2012, Kinsey-Jones et al. 2012). However, no effect on gonadotropin secretion 
was observed with co-administration of naltrexone and neurokinin B in men 
(Narayanaswamy et al. 2016c). The inhibitory opioid action has also been implicated 
in the control of kisspeptin induced LH secretion. Naltrexone and kisspeptin 
treatment in men was the only combination that significantly increased the amplitude 
of LH secretion (Narayanaswamy et al. 2016c).  
Taken together is it clear that there is a complex interaction rather than a linear 
hierarchy between the neuropeptides associated with KNDy neurone function in the 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
Literature Review        74 
control of pulsatile GnRH secretion with further species differences operating at both 
anatomical and physiological levels. The KNDy system is highly sensitive to gonadal 
steroid status, which further modifies the signalling effects of those novel 
hypothalamic neuropeptides; this is discussed in more detail in section 1.4.1 Gonadal 
steroids.   
1.3.4.3 Neurokinin B and the GnRH pulse generator 
There are several lines of evidence to imply that infundibular/arcuate neurokinin B is 
a component of the GnRH pulse generating mechanism. The arcuate neurokinin 
B/kisspeptin/dynorphin neurones are the potential source of the multiunit volleys 
(MUA) of electrical activity that are associated with LH pulses, which are abolished 
by lesions in the arcuate nucleus in monkeys (Knobil. 1981). The role of neurokinin 
B on GnRH pulse generating activity was determined using MUA recording aimed at 
the arcuate KNDy neurones in estrogen-treated ovariectomised goats (Wakabayashi 
et al. 2010). A bolus of central administration of neurokinin B immediately evoked 
multiple MUA, lasting as long as 50 minutes after which spontaneous MUA volleys 
were re-established (Wakabayashi et al. 2010). Peripherally administrated senktide 
also induced MUA volleys and an accompanying pulse-like increase in LH secretion 
in ovariectomised goats (Yamamura et al. 2015). However, the efficacy of three 
neurokinin receptor-selective agonists was different with as little as 10 nmol of 
NK3R agonist potently inducing MUA volleys, whereas 100-fold higher doses of 
NK1R and NK2R agonist were effective in only some animals with no associated 
LH pulse observed in the absence of MUA (Yamamura et al. 2015). This suggests 
that the action of neurokinin B via the NK3R is predominantly involved in GnRH 
pulse generation, and the contribution of NK1R and NK2R is limited, if any, in goats 
(Yamamura et al. 2015). This is supportive by human data where inactivating 
mutations in TAC3 and TACR3 are associated with hypogonadotrpic hypogonadism 
and loss of LH pulsatility (Young et al. 2010).  
A model of GnRH pulse generation has been proposed, where neurokinin B from the 
arcuate KNDy neurones acts autosynaptically via the NK3R on the same neurones as 
well as the neighbouring and contralateral KNDy neurones to coordinate and 
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synchronise electrical activity. This would evoke kisspeptin discharges, released at 
the GnRH terminal in the median eminence, where KNDy neurones are known to 
project to, which induce GnRH secretion. At the same time inhibitory dynorphin 
would terminate neurokinin B and kisspeptin release, thereby creating a kisspeptin 
pulse, which would translate into a pulse of GnRH(Navarro. 2013, Okamura et al. 
2013). The involvement of dynorphin in the regulation of electrical KNDy neurone 
activity has also been demonstrated. Injection of dynorphin significantly increased 
the intervolley interval of the MUA, whereas kappa opioid antagonist was associated 
with decreased intervolley interval for the duration of the 2-hour infusion in 
ovariectomised goats(Wakabayashi et al. 2010).  
Changes in the frequency and amplitude of LH pulsatility by stimulating or blocking 
NKB/NK3R signalling further supports the role of neurokinin B in control of the 
pulsatile GnRH secretion (Fraser et al. 2015a, Li et al. 2015, George et al. 2016, 
Narayanaswamy et al. 2016c). Neurokinin B had no effect on the orderliness of LH 
pulses as measured by approximate entropy (ApEn) in healthy men, whilst kisspeptin 
resulted in more ordered and naltrexone in more disordered LH pulses 
(Narayanaswamy et al. 2016c). Nevertheless, it is possible that neurokinin B is 
involved in generating an initial impulse to GnRH secretion, and kisspeptin is the 
final pathway, which after integrating the signals of neurokinin B and dynorphin, 
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1.3.5 Neurokinin B and metabolism  
Given the involvement of the arcuate kisspeptin in conveying metabolic cues to the 
hypothalamus (see section 1.2.8 Kisspeptin and metabolism), it is reasonable to 
suspect that NKB/NK3R of the KNDy cells is also influenced by energy status in the 
metabolic regulation. Navarro and colleagues have studied metabolic influences on 
the neurokinin B control of puberty in rats. Animals subjected to 48 hours of fasting 
showed reduced Tacr3 and to a lesser degree Tac2 expression in their arcuate 
nucleus (Navarro et al. 2012). The NKB/NK3R pathway also appears to be more 
sensitive under fasting conditions with augmented LH response to senktide seen in 
pubertal rats (Navarro et al. 2012). Furthermore, repeated senktide administration 
was sufficient to induce vaginal opening and LH secretion in about half of the female 
rats with pubertal arrest secondary to malnutrition (Navarro et al. 2012).  
The situation is reverse in cases of high caloric intake, where high fat diet was 
associated with precocious puberty in female rats (Li et al. 2012b). This was thought 
to be a result of premature upregulation of neurokinin B signalling since the 
expression of Tac2 transcripts was increased in the arcuate nucleus, which in turn 
increased the frequency of LH pulsatility (Li et al. 2012b).  
The effects of positive and negative energy balance on NKB/NK3R signalling are 
pretty much identical to the findings of kisspeptin on gonadotropin secretion (see 
section 1.2.8 Kisspeptin and metabolism). The arcuate KNDy neurone therefore 
appears to be the center that integrates central and peripheral cues on the metabolic 
status and conveys it to control the reproductive function via pulsatile GnRH 
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1.3.6 Neurokinin 3 receptor antagonism by AZD4901 
Manipulation of the NKB signalling by antagonism of NK3R allows further 
exploration of a role of NKB in the regulation of reproductive function.  A specific 
NK3R antagonist AZD4901 has been used in studies described in this thesis. 
AZD4901 is a high-affinity antagonist of the human NK3 receptor (Malherbe et al. 
2011). It completely blocked neurokinin B agonist senktide induced calcium influx 
in human NK3R expressing Chinese hamster ovary cells (Malherbe et al. 2011).  
It was initially developed for schizophrenia in 2007–2010 (as AZD2624) but did not 
meet its developmental efficacy goals for that indication (Litman et al. 2014). This 
NK3R antagonist, however, reduced testosterone and to some degree LH 
concentrations in healthy male volunteers (Malherbe et al. 2011). Studies using 
AZD4901 were not pursued further, as at the time, a reproductive role for neurokinin 
B was yet to be elucidated (Topaloglu and Semple. 2011). Since then much evidence 
has accrued suggesting that NKB has a central role in regulating GnRH and thus LH 
pulsatility (Pinilla et al. 2012). 
Pharmacokinetic properties have been investigated in healthy men (Malherbe et al. 
2011). AZD4901 is quickly absorbed following oral dosing. The elimination half-life 
for the drug is approximately 8.5 hours (Malherbe et al. 2011, Litman et al. 2014). 
Both the area under the concentration-time curve and maximum observed 
concentration (Cmax) appears to be proportional to dose of AZD4901 with peak 
concentrations achieved at 1-8 hours  (Malherbe et al. 2011, Litman et al. 2014). 
Renal elimination of this NK3R antagonist was negligible. With multiple dose 
administration, steady state was achieved in 4 days, and there appears to be no 
difference in pharmacokinetic properties between females and males (Malherbe et al. 
2011). To date, there has been no clear demonstration of Cmax-related toxicity in 
humans receiving up to 80mg of AZD4901 and this is the highest dose yet 
administered to humans. Data obtained from healthy volunteers and in women with 
PCOS did not identify any safety or tolerability concerns (Malherbe et al. 2011, 
George et al. 2016).  
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1.4 Other regulators of GnRH and gonadotropin secretion 
1.4.1 Gonadal steroids  
The role of sex-steroids in the control of pulsatile GnRH and subsequently 
gonadotropin secretion in humans was proposed in early 1970s, when in healthy 
women across different phases of the menstrual cycle a variable pattern of 
gonadotropin release was observed with a pulse and a mid-cycle surge mode of 
LH/FSH secretion (Midgley and Jaffe. 1971). Subsequently, higher frequency of LH 
pulsatility was demonstrated in ovarian function deficient post-menopausal women 
compared to pre-menopausal women (Yen et al. 1972) with similar findings 
reproduced in ovariectomised sheep and monkeys (Dierschke et al. 1970, Bolt. 
1971).  
1.4.1.1 Estrogen, progesterone and testosterone feedback 
Estrogen feedback 
During the follicular phase of menstrual cycle, estrogen exerts negative feedback to 
limit GnRH activity and therefore LH secretion. However, in the late follicular 
phase, by yet unknown mechanisms negative estrogen feedback switches to positive 
estrogen action, culminating in the pre-ovulatory LH (and to a lesser extent FSH) 
surge needed for ovulation. Negative and positive estrogen control of gonadotropin 
secretion was initially demonstrated by variable duration of estrogen administration 
intramuscularly every 12 hours in the follicular phase women (Keye and Jaffe. 
1975). Short-term estrogen treatment (36 hours) inhibited, whilst prolonged estrogen 
treatment (132 hours) augmented LH and FSH response to GnRH (Keye and Jaffe. 
1975). Estrogen feedback modulates pulsatile GnRH and subsequently LH release. In 
post-menopausal women treated with intravaginal estrogen, LH pulse frequency 
decreased within 24 hours of estrogen treatment, then increased on day 5 and 10 of 
the study and declined thereafter (Veldhuis et al. 1987b). Similarly in men, estradiol 
infusion suppressed LH pulsatility and tamoxifen (a selective estrogen receptor 
modulator) had an opposite effect (Veldhuis and Dufau. 1987). Modulation of GnRH 
and gonadotropin secretion by estrogen is consistent with animal studies, where in 
rodents, intra-arcuate estrogen administration diminished LH pulse frequency 
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(Akema et al. 1984) and in monkeys, hypothalamic electrical activity was arrested 
with associated decreased in pulsatile LH secretion (Kesner et al. 1987), suggesting 
negative estrogen action on the hypothalamic GnRH pulse generator.  
Portal blood vessel sampling studies in sheep during positive estrogen feedback 
showed a gradual increase in the frequency and amplitude of GnRH pulses, which 
ultimately culminates in a prolonged GnRH surge (Clarke. 1993). Estradiol has been 
shown to generate GnRH/LH surge in a number of mammals but only when 
administered at sufficiently high levels for a prolonged period of time, which in ewes 
has been suggested to be of a minimum 7-14 hours (Karsch and Foster. 1975, 
Moenter et al. 1990, Evans et al. 1997).  
ERα is the predominant nuclear receptor involved in classical estrogen signalling via 
the estrogen response element (ERE) to alter gene transcription (Herbison. 2015). 
Mice deficient in ERα were unable generate positive feedback and a GnRH/LH surge 
(Glidewell-Kenney et al. 2007). On the other hand ERβ deficient mice were fertile, 
suggesting this isoform of estrogen receptor may not have a major role in mediating 
estrogen feedback (Lubahn et al. 1993, Krege et al. 1998).  
Progesterone feedback 
In the follicular phase in healthy women, administration of progesterone reduced LH 
pulse frequency, increased the amplitude of LH pulses and decreased mean LH 
secretion, a pattern of LH secretion that resembles that seen in the mid-luteal phase 
of the menstrual cycle (Soules et al. 1984). This suggests that progesterone mediates 
negative feedback on gonadotropin secretion during the luteal phase. PR knock-out 
mice showed elevated LH levels, although this could be suppressed by progesterone 
replacement, suggesting multimodal progesterone signalling possibly involving rapid 
non-genomic progesterone receptor isoforms, PRA and PRB (Chappell et al. 1997). 
Differential negative effect of ovarian steroids on pulsatile LH secretion is observed 
in sheep, with progesterone preferentially decreasing the frequency and estradiol the 
amplitude of LH pulses (Goodman and Karsch. 1980). Progesterone actions are 
estrogen-dependant as the suppressive effects of progesterone were lost in 
ovariectomised ewes but restored with estrogen replacement (Skinner et al. 1998): 
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this is analogous to the need for estrogen to induce progesterone receptors and 
responsiveness in the endometrium. The endogenous opioid dynorphin has also been 
implicated in mediating progesterone feedback on GnRH/gonadotropin secretion: 
progesterone increased dynorphin concentrations in the cerebrospinal fluid and 
upregulated the expression of hypothalamic preprodynorphin mRNA in 
ovariectomised ewes (Foradori et al. 2005).  
A role of progesterone in mediating positive feedback on GnRH/LH secretion has 
also been described. Progesterone advanced the onset and amplitude of estrogen-
induced GnRH/LH surge in ovariectomised rodents and monkeys (Clifton et al. 
1975). Furthermore, progesterone antagonist and centrally administered antibodies to 
progesterone receptor blocked GnRH and LH surge in rats, when measured 
simultaneously in the median eminence and peripheral blood, suggesting an obligate 
role of progesterone receptor in the estrogen-induced mid-cycle LH surge (Chappell 
and Levine. 2000).  
Testosterone feedback 
Hypogonadal men showed elevated LH pulse frequency and amplitude, both of 
which were suppressed with exogenous testosterone treatment, suggesting that 
testosterone or its metabolites exert negative feedback by slowing down pulsatile 
GnRH secretion (Matsumoto and Bremner. 1984). Similar pattern of LH secretion in 
response to testosterone were observed in castrated rats (Steiner et al. 1982), rams 
(D'Occhio et al. 1982) and monkeys (Plant. 1982). Testosterone can be further 
converted to its metabolite dihydrotestosterone (DHT) by the action of 5α-reductase, 
and suppression of LH secretion is comparable with both testosterone and DHT 
(Santen. 1975). Testosterone also undergoes aromatisation to estradiol, but whether 
this is required for the inhibition of LH secretion in men remains controversial. 
Santen has argued that since the effects of testosterone and estradiol infusion in 
healthy men are divergent, with 1) estradiol reducing the amplitude and testosterone 
the frequency of LH pulses and 2) estradiol blunting and testosterone preserving 
GnRH sensitivity, aromatisation is not required for hypothalamic negative androgen 
feedback (Santen. 1975). However, conversion of testosterone to estradiol might be 
required for the inhibitory effect of testosterone at the pituitary gonadotrope 
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(Pitteloud et al. 2008). In healthy men, the increase in LH secretion was less than in 
response to selective estrogen suppression by aromatase inhibitor alone compared to 
suppression of both estrogen and testosterone by aromatase inhibitor and 
ketoconazole treatment (Hayes et al. 2001), suggesting an additional action of 
aromatisation of testosterone to estadiol. To determine whether it is the pituitary or 
hypothalamic effects of testosterone that require aromatisation, healthy men and 
those  with hypogonadotropic hypogonadism on GnRH therapy were pre-treated with 
ketoconazole . Whilst testosterone suppressed high LH secretion in healthy men, 
estradiol and not testosterone decreased LH secretion in patients with 
hypogonadotropic hypogonadism, indicating that testosterone aromatisation is 
required for its action at the pituitary (Pitteloud et al. 2008).  
1.4.1.2 The site of sex-steroid feedback 
Pituitary sex-steroid action 
The site of estrogen feedback action was proposed to be the pituitary gland after 
experiments in rhesus monkeys, where following radio-frequency induced 
hypothalamic lesions to abolish gonadotropin secretion and responsiveness to 
estradiol positive feedback, normal ovulatory cycles were restored with intermittent 
GnRH infusion (Knobil et al. 1980). Similarly, intermittent GnRH administration 
resulted in ovulation in a patient congenital absence of GnRH (Kallmann syndrome) 
(Crowley and McArthur. 1980) and in pregnancies in women with hypothalamic 
amenorrhoea (Leyendecker et al. 1980). In men with idiopathic hypogonadotropic 
hypogonadism treated with GnRH, administration of estradiol and testosterone 
decreased LH and FSH secretion, indicating an inhibitory action of gonadal steroids 
at the level of pituitary (Bagatell et al. 1994). Estrogen induced suppression of LH 
secretion was also demonstrated from rat gonadotropes in culture (Emons et al. 
1986). Estradiol directly inhibits the transcription of FSHβ subunit gene by 
activating corepressor proteins that bind to the gene (Miller and Miller. 1996). 
Furthermore, estrogen suppresses FSH secretion indirectly by decreasing activin 
secretion (Herbison. 1998).  
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Hypothalamic sex-steroid action 
Estrogen feedback has been also demonstrated at the hypothalamic level, suggesting 
dual-site of sex-steroid feedback in the regulation of gonadotropin secretion. GnRH 
receptor antagonist suppressed gonadotropin secretion at lower doses during the mid-
cycle LH surge than during other phases of the menstrual cycle, suggesting that 
endogenous GnRH release might be diminished and/or pituitary sensitivity enhanced 
during the pre-ovulatory gonadotropin surge (Hall et al. 1994). Nevertheless, this is 
consistent with modulation of GnRH secretion by sex-steroid milieu across the 
menstrual cycle. The dual-site of estrogen feedback is further supported by 
administration of the aromatase inhibitor, anastrozole, which in healthy men 
increased LH pulse frequency suggestive of hypothalamic negative estrogen action, 
and in men with GnRH-treated hypogonadotropic hypogonadism increased 
gonadotropin secretion, suggestive of pituitary negative estrogen action (Hayes et al. 
2000). Hypothalamic positive estrogenic feedback is demonstrated by studies where 
estradiol implants in the medial pre-optic region generated an LH surge in rodents 
(Goodman. 1978). Similarly to estrogen feedback, testosterone also acts directly at 
the hypothalamus, as in healthy men, GnRH responsiveness on LH secretion was 
preserved following testosterone infusion (Santen. 1975), and testosterone decreased 
LH pulsatility following biochemical castration with ketoconazole (Pitteloud et al. 
2008). Taken together it appears that in males and females, gonadal steroids mediate 
gonadotropin secretion by acting at the level of both pituitary and hypothalamus, and 
this is supported by cognate sex-steroid receptor expression at those locations.  
1.4.1.3 KNDy neuropeptides in negative sex-steroid feedback 
In the face of GnRH neurones lacking (or expressing rather limited numbers of) sex-
steroid receptors, there is compelling evidence to suggest that ERα/PR/AR 
expressing KNDy neurones constitute this ‘missing link’ as mediators of negative 
and positive gonadal feedback to the hypothalamic GnRH neurones.  
Kisspeptin and neurokinin B of the infundibular/arcuate nucleus have been 
implicated in mediating negative estrogen action to suppress GnRH and subsequently 
gonadotropin secretion consistently throughout the species, including humans. In the 
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infundibular nucleus of postmenopausal women, kisspeptin neurones were 
hypertrophied, expressed more KISS1 mRNA and had more autoradiographic grains 
per neurone than premenopausal women, suggesting that these changes are 
secondary to the loss of estrogen feedback (Rometo et al. 2007). These hypertrophied 
neurones were ERα-positive and had upregulated expression of NKB mRNA with 
their neuroanatomical distribution resembling that of kisspeptin neuronal network, 
suggestive of the synergistic action of kisspeptin and neurokinin B in mediating 
negative estrogen feedback (Rance et al. 1990, Rance and Young. 1991). Similar 
adaptations to hypoestrogenic environment are seen in neurokinin B-kisspeptin 
neuronal network in animal studies. Kiss1 mRNA expression was enhanced 
following an ovariectomy in rodents, sheep and monkeys in the arcuate nucleus but 
not in more rostral areas, and this was suppressed with estradiol replacement (Smith 
et al. 2005a, Smith et al. 2005b, Rometo et al. 2007, Smith et al. 2007). Similarly, the 
expression of neurokinin B increased with ovariectomy and returned to almost 
undetectable levels with estrogen therapy in the arcuate nucleus in monkeys (Abel et 
al. 1999, Sandoval-Guzman et al. 2004). Antagonism of kisspeptin receptor 
abrogated the compensatory LH increase in castrated rodents, suggesting that intact 
kisspeptin signalling is required for estrogen to mediate its negative effects 
(Roseweir et al. 2009). 
Whilst negative estrogen feedback to reduce GnRH/gonadotropin secretion is 
mediated by suppressing kisspeptin and neurokinin B activity, the converse, 
inhibitory opioid component of KNDy system is upregulated. Dynorphin and its 
cognate κ opioid receptor are expressed by KNDy neurones, and dynorphin neurones 
co-localise with ERα and PR (Foradori et al. 2002, Foradori et al. 2006, Goodman et 
al. 2007, Navarro et al. 2009). Naloxone, an opioid receptor antagonist, increased 
serum LH levels in late follicular and luteal phases of the menstrual cycle (Quigley 
and Yen. 1980, Shoupe et al. 1985). However, this effect was only apparent in 
postmenopausal and oophorectomised young women following estrogen or 
progesterone replacement (Melis et al. 1984, Casper and Alapin-Rubillovitz. 1985, 
Shoupe et al. 1985). The opioid peptide dynorphin appears to mediate negative 
progesterone feedback by inducing changes in pulsatile GnRH secretion (Ferin et al. 
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1984, Karsch. 1987, Goodman et al. 2004). In luteal ewes, low LH pulse frequency 
(and inferred GnRH pulsatility) was increased with naloxone administration 
(Goodman et al. 2004).  
In contrast to women with menopause, the opioid antagonist naltrexone administered 
for 6 months increased LH pulse amplitude and plasma gonadal steroids in women 
with hypothalamic amenorrhoea with subsequent menstruation in some patients 
(Genazzani et al. 1995b). Lack of response to an opioid antagonist in 
postmenopausal women and those after oophorectomy may indicate the relative 
deficiency of dynorphin pathway in mediating negative sex-steroid feedback in the 
case of hypergonadotropic hypogonadim, in contrast to exaggerated dynorphin 
signalling contributing to the hypogonadotropic state in those with hypothalamic 
amenorrhoea. Indeed, the expression of prodynorphin mRNA is reduced in the 
infundibular nucleus in postmenopaual women (Rometo and Rance. 2008) and in the 
arcuate nucleus of ovariectomised ewes (Foradori et al. 2002, Foradori et al. 2006). It 
is however possible that there is a threshold maximum to which LH secretion can be 
induced, accounting for inability of opioid antagonist to further stimulate 
gonadotropin secretion in women with menopause, which is consistent with 
relatively small stimulatory effect of KP-10 in this group of women (George et al. 
2012).  
The situation appears to be distinct in rodents, where despite the co-localisation of 
KNDy neurones with both ERα and PR, dynorphin does not seem to mediate 
estrogen negative feedback (Navarro et al. 2009). Estradiol treatment inhibited the 
expression of dynorphin and kappa opioid receptor in ovariectomised mice, and 
dynorphin and its receptor knock-out mice had compromised increase in LH 
secretion following ovariectomy (Navarro et al. 2009). This highlights that although 
KNDy system is implicated in mediating gonadal feedback to the hypothalamus, 
species-specific pathways exist, and results from animal studies cannot be directly 
extrapolated to explain the physiology of KNDy signalling in humans.  
AR-expressing KNDy neurones have a role in relaying negative testosterone action. 
In castrated monkeys, testosterone induced suppression in gonadotropin secretion 
was accompanied by reduction in the expression of Kiss1 mRNA in the mediobasal 
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hypothalamus (Shibata et al. 2007), and this has been demonstrated in lower species 
(Irwig et al. 2004, Navarro et al. 2004a). Intracerebroventricular administration of 
kisspeptin antagonist abrogated LH rise associated with orchidectomy in rodents, 
further implicating the kisspeptin-kisspeptin receptor pathway in hypothalamic 
testosterone feedback (Roseweir et al. 2009).   
1.4.1.4 KNDy neuropeptides in positive sex-steroid feedback 
Estrogen feedback switches from negative to positive in the late follicular phase 
culminating in the GnRH/LH surge necessary for ovulation. However, the 
neuroendocrine mechanisms involved in this critical event have been unclear. 
Although negative sex-steroid feedback is mediated by KNDy neurones, their role in 
positive feedback of gonadal steroids is less consistent and mainly inferred from 
studies in rodents and sheep, which is further complicated by kisspeptin signalling 
being site and species specific.  
Recent data suggest the role of kisspeptin in mediating positive estrogen feedback in 
humans. KP-54 (subcutaneous in doses of 1.6 to 12.8nmol/kg) induced LH surge, 
which was sufficient to trigger oocyte maturation, when administered instead of a 
conventional human chorionic gonadotropin during an assisted conception cycle, 
with subsequent live term births reported (Jayasena et al. 2014a). Repeated follicular 
phase administration of KP-54 (subcutaneous 6.4nmol/kg twice daily for 7 days) 
shortened the menstrual cycle length in healthy women, indicating advanced LH 
surge (Jayasena et al. 2013a). The striking positive relationship between estradiol 
concentration in the late follicular phase and LH response to KP-54 infusion in 
healthy women lend further support for the involvement of kisspeptin in estrogen 
feedback (Narayanaswamy et al. 2016a). This is in keeping with data from animal 
studies. Exogenous kisspeptin administration advanced the LH surge in sheep, whilst 
antiserum/antagonist to kisspeptin receptor abolished LH peak in rats and sheep 
(Kinoshita et al. 2005, Caraty et al. 2007, Clarkson et al. 2008, Pineda et al. 2010). 
Positive feedback actions of estrogen specifically depend on the ERα in kisspeptin 
neurones, as mice with selective ERα ablation in kisspeptin cells failed to mount LH 
surges in response to estrogen challenge (Dubois et al. 2015). Although in humans, 
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ERα is abundantly expressed in kisspeptin neurones (Rance et al. 1990), the role of 
kisspeptin in physiological positive estrogen feedback in women is less clear. 
Hypothalamic kisspeptin population involved in positive estrogen feedback is 
species specific. In rodents the AVPV nucleus is the location of positive estrogen 
action, which is not matched in humans, other primates and sheep, where kisspeptin 
neurones in the infundibular/arcuate relay this function. In rodents, the expression of 
Kiss1 mRNA in the AVPV nucleus falls following ovariectomy, but increases after 
estrogen replacement and is at the peak during proestrus (Smith et al. 2005a, Smith et 
al. 2006b). Similarly, c-Fos (marker of neuronal activity) expression is at its highest 
during the LH surge in the AVPV kisspeptin neurones (Smith et al. 2006b). The 
AVPV nucleus as anatomical site for positive estrogen feedback in rodents is 
consistent with it receiving afferent fibres from the suprachiasmatic nucleus, the 
location of circadian clock, which coordinates the timing of LH surge (Khan and 
Kauffman. 2012). However, in sheep, which, like humans and other primates, have 
no homologous area to the AVPV nucleus, the expression of Kiss1 mRNA and c-Fos 
are dramatically enhanced during the pre-ovulatory LH surge in the arcuate nucleus 
(Smith et al. 2008b). The above evidence implies that rising levels of estrogen in the 
late follicular phase exert stimulatory role on kisspeptin secretion in the AVPV 
nucleus in rodents but the infundibular/arcuate nucleus in sheep and primates, and 
subsequently culminate in GnRH/LH surge. The reason for kisspeptin mediating 
positive estrogen feedback via two distinct anatomical sites remains unclear, but may 
solely reflect species difference.  
KNDy neurones of the infundibular/arcuate nucleus may have a role in mediating 
positive estrogen feedback in some species, including humans. Until very recently, 
subfertility seen in patients with mutations in NKB/NK3R signalling was the only 
indirect evidence linking neurokinin B to positive estrogen action (Topaloglu et al. 
2009). During the course of preparation of this thesis, a different NK3R antagonist 
(ESN364) was administered to normal women starting in the follicular phase for 21 
days (Fraser et al. 2016). NK3R antagonist delayed LH surge in some women with 
subsequent delay in luteal progesterone and prolongation of the menstrual cycle 
length (Fraser et al. 2016). Consistent with the involvement of neurokinin B in the 
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mid-cycle LH surge, NK3R antagonist abolished LH surge, ovulation and 
progesterone rise in intact monkeys (Fraser et al. 2015a). However, the mechanism 
by which neurokinin B antagonism interferes with the mid-cycle LH surge remains 
unclear as basal LH secretion was unaffected throughout the treatment in both 
women and female monkeys, and the effect of NK3R antagonist on LH pulsatility 
was not investigated in this setting (Fraser et al. 2015a, Fraser et al. 2016).  
In contrast, central infusion of the NK3R antagonist had no effect on the estrogen-
induced LH surge seen in ovariectomised ewes, which suggests that neurokinin B 
signalling might not be critical for positive estrogen feedback in this animal, further 
highlighting species difference in the mechanism generating GnRH/LH surge (Li et 
al. 2015). Unlike kisspeptin, neurokinin B expression did not change in 
ovariectomised ewes in response to a surge-inducing estrogen challenge (Goubillon 
et al. 2000) or across the estrous cycle (Li et al. 2015). Nevertheless, KNDy neurone 
activity is upregulated during the pre-ovulatory LH surge and following estrogen 
treatment in ewes (Smith et al. 2009a), and NK3R antagonist delayed the onset-to-
peak time of LH surge induced by estrogen challenge (Li et al. 2015). In keeping 
with this observation, NK3R agonist senktide increased LH secretion, resembling 
‘surge-like’ LH levels (Billings et al. 2010). This suggests that neurokinin B pathway 
is active at the time of estrogen-induced LH surge, but it may not be critical for this 
physiological event. Accordingly, KNDy neurones are not involved in the pre-
ovulatory LH surge in rodents based on their location in the arcuate nucleus only, but 
not the anteroventral periventricular (AVPV) nucleus, the site for positive estrogen 
action in this species (Burke et al. 2006, Goodman et al. 2007, Navarro et al. 2009). 
Other neurotransmitters may also contribute to kisspeptin-mediated LH surge. 
Glutamate is described in KNDy neurones and express ERα in the sheep arcuate 
nucleus, the site of positive estrogen feedback (Oakley et al. 2009). Similarly, 
tyrosine hydroxylase, galanin, neurotensin, met-enkephalin and cholecystokinin are 
expressed in the AVPV nucleus, the region specifically implicated in mediating 
estrogen positive feedback in rodents (Oakley et al. 2009, Porteous et al. 2011).  
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1.4.2 Endogenous opiates 
Endorphins, enkephalins and dynorphins are opioid peptides of their larger 
precursors acting via G-protein coupled μ, δ and κ opioid receptors. β-endorphin is 
the major opioid compound secreted by the hypothalamus, which in human brain has 
been localised to the infundibular nucleus (Wilkes et al. 1980). In healthy men, 
selective suppression of LH pulse frequency and amplitude by an infusion of DHT 
and estradiol respectively, was restored by naltrexone (opioid receptor antagonist), 
suggesting the interaction between the hypothalamic opioid pathway and sex-steroid 
feedback in the control of GnRH secretion (Veldhuis et al. 1984). The activity of 
GnRH neurones as inferred by Fos is upregulated following opioid antagonist 
treatment in the mediobasal hypothalamus in ewes and rams (Boukhliq et al. 1999). 
The inhibitory opioid tone changes across the menstrual cycle. Whilst naloxone 
(another opioid receptor antagonist) stimulated LH secretion in the late follicular and 
luteal phase of menstrual cycle in women, it has no effect in the early follicular phase 
(Quigley and Yen. 1980). This suggests that endogenous opiates are involved in 
regulating GnRH/LH secretion when sex-steroid levels are high. Thus opioid input is 
low during the menses to release the inhibitory break on gonadotropin secretion but 
is high during the luteal phase to suppress GnRH release. Estrogen-induced LH 
surges in ovariectomised ewes were delayed by specific μ-opioid receptor agonist 
(Walsh and Clarke. 1996). Endogenous opiates might mediate negative sex-steroid 
feedback on gonadotropin secretion. In luteal phase ewes, specific κ-opioid receptor 
antagonist increased LH pulse frequency, suggesting the role of dynorphin in 
mediating progesterone negative feedback (Goodman et al. 2004). In 
postmenopausal and oophrectomised women, naloxone infusion failed to elicit LH 
secretion unless estrogen, progesterone or both were replaced, suggesting that opioid 
activity is influenced by sex-steroids and that opioid signalling is diminished post 
menopause (Casper and Alapin-Rubillovitz. 1985).  
Abnormalities in opioid activity have clinical implications.  Inhibitory opioid tone 
might contribute to the hypogonadotropic hypogonadism seen in hypothalamic 
amenorrhoea since naltrexone treatment restored ovulation in some women (Wildt et 
al. 1993). Women with hypothalamic amenorrhoea have elevated circulating cortisol 
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levels, where corticotropin-releasing factor (CRF) might indirectly enhance 
suppressive opioid effects on GnRH secretion (Suh et al. 1988). Suppression of 
GnRH in hyperprolactinaemia might be mediated by endogenous opiates. In 
hyperprolactinaemic rats, low GnRH and LH secretion in the portal blood were 
associated with elevated levels of β-endorphin, the former of which were increased 
by naloxone (Sarkar and Yen. 1985). Anovulatory hyperprolactinaemic women were, 
however, unresponsive to naloxone treatment, but this may reflect deficiency of 
gonadal steroids since LH secretion increased in ovulatory women with 
hyperprolactinaemia (Larrea et al. 1995).  
1.4.3 Stress and glucocorticoids 
Reproductive function is highly sensitive to the situations of stress, including 
emotional (e.g. depression, restrain), physical (e.g. strenuous exercise), metabolic 
(e.g. hypoglycaemia) and pathological (e.g. eating disorders, acute and chronic 
illness), which are associated with transient suppression of pulsatile GnRH secretion 
and thus quiescence of the pituitary-gonadal axis (Li and O'Byrne. 2015). The 
pathway by which stressors downregulate the GnRH pulse generator is not entirely 
clear, but appears to involve numerous neuropeptides, including corticotropin-
releasing factor and arginine vasopressin (AVP). There is increasing evidence to 
suggest that stress neuropeptides mediate their action via kisspeptin signalling.  
1.4.3.1 Glucocorticoids 
Psychological and physical stress manifest as hypothalamic amenorrhoea in women, 
where circulating cortisol is elevated and LH pulse frequency is reduced, suggesting 
that activation of the adrenal axis inhibits GnRH pulse generator (Suh et al. 1988, 
Berga et al. 1989). Moreover, patients with anorexia nervosa have increased levels of 
CRF in their cerebrospinal fluid, which is normalised by weight gain (Kaye et al. 
1987). Although data is less abundant in men, strenuous military exercising was 
associated with raised circulating cortisol and suppressed gonadotropin and androgen 
levels (Opstad. 1992). Similarly, female monkeys exposed to a combination of 
psychological and physical stressors showed a range of responses, including 
suppression of gonadotropin secretion, reduced LH pulse frequency and cessation of 
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ovulatory cycles (Xiao et al. 2002, Bethea et al. 2013). The action of cortisol appears 
to be through the modulation of pulsatile GnRH secretion as glucocorticoid therapy 
suppressed GnRH pulse frequency in the hypophyseal portal blood in ewes (Oakley 
et al. 2009), and in women in the follicular phase LH pulse frequency was reduced 
(Saketos et al. 1993). It is possible that CRF mediates stress-induced suppression of 
gonadotropin secretion via kisspeptin signalling, since central CRF infusion in 
female rats reduced the expression of Kiss1 and Kiss1r mRNA in the pre-optic area 
and the arcuate nucleus (Kinsey-Jones et al. 2009). This is supported by co-
localisation of CRF receptor to kisspeptin neurone in both hypothalamic anatomical 
sites (Takumi et al. 2012).  
1.4.3.2 Inflammation 
Acute and chronic illness is not infrequently associated with hypogonadotropic 
hypogonadism and pubertal delay (van den Berghe et al. 2001). In animal studies, 
immune/inflammatory challenge on the reproductive system is investigated by the 
use of lipopolysaccharide (LPS), endotoxin secreted by gram-negative bacteria, 
which induces acute inflammatory responses resembling those of a bacterial 
challenge (Iwasa et al. 2008). LPS has been shown to suppress LH pulse frequency 
in a number of species and GnRH pulsatility in sheep when sampled directly in the 
hypophyseal portal blood (Battaglia et al. 1998, Xiao et al. 2000). CRF has been 
implicated in transmitting inhibitory effects of inflammation on reproductive axis 
since CRF receptor antagonism attenuated LPS-induced suppression of LH secretion 
in rats and monkeys (Li et al. 2006, Xiao et al. 2007). Furthermore, LPS 
administration in adult female rats decreased Kiss1 and Kiss1r mRNA expression in 
the pre-optic area and the arcuate nucleus and this was associated with suppression 
of pulsatile LH secretion, the latter of which was restored by an injection of 
kisspeptin (Iwasa et al. 2008, Kinsey-Jones et al. 2009). This suggests the role of 
kisspeptin in mediating decreased GnRH secretion in response to systemic 
inflammation.  
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1.4.3.3 Hypoglycaemia 
Insulin-induced hypoglycaemia is known to suppress pulsatile GnRH secretion in 
rodents, sheep and monkeys (Clarke et al. 1990, Chen et al. 1996, Cates and 
O'Byrne. 2000). Hypoglycaemic stress also reduced hypothalamic multi unit 
electrical activity and LH pulses, both of which were restored by glucose, suggesting 
that glycopenia and not insulin is the causative factor in suppression of the HPG axis 
(Chen et al. 1992, He et al. 1999). Similarly, in healthy men, LH and testosterone 
levels deceased in response to hypoglycaemia independent of the dose of insulin 
infused (Oltmanns et al. 2001). Hypoglycaemia induced suppression of gonadotropin 
secretion might be mediated via kisspeptin action of the GnRH. In female rats under 
hypoglycaemic stress, perturbation of pulsatile LH release was associated with 
downregulation of Kiss1 and or Kiss1r expression in the pre-optic area and the 













Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
Literature Review        92 
1.5 Overall hypothesis 
The overarching hypothesis of the work described in this thesis is that 
pharmacological blockade of neurokinin B signalling will decrease LH secretion and 
this will be attenuated by exogenous kisspeptin administration, revealing the 
functional hierarchy between these hypothalamic neuropeptides, whereby neurokinin 
B signalling is upstream of kisspeptin in modulating pulsatile GnRH secretion. This 
will be tested in conditions of varying sex-steroid environments, and in states of fast 
and slow pulsatile LH/GnRH secretion (men, menopausal women, early follicular, 
late follicular and luteal phases of the menstrual cycle and the mid-cycle LH surge).  
Aims 
 To determine the physiological role of neurokinin B in men and in different sex-
steroid milieu across the menstrual cycle in women; 
 To delineate the hierarchical contribution of kisspeptin and neurokinin B in states 
of slow LH secretion in health; 
 
 To delineate the hierarchical contribution of kisspeptin and neurokinin B in states 
of high LH secretion in health; 
 
 To determine the role of kisspeptin and neurokinin B in mediating estrogen 
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Chapter 2. Materials and Methods 
2.1 Ethical Approvals and Research Governance 
2.1.1 Approvals by ethics committee and local research and 
development bodies 
Clinical studies described in this thesis have been conducted in accordance with the 
principles of the International Conference on Harmonisation Tripartite Guideline for 
Good Clinical Practice (ICH GCP) and the Declaration of Helsinki. Studies 
undertaken were basic science proof of concept experiments, involving procedures 
with human participants and were not clinical trials of an investigational medicinal 
product (non-CTIMP). Clinical studies undertaking as a part of this thesis fell under 
the Disorders of Reproductive Endocrine Axis in Man (DREAM) study, which was 
approved by South East Scotland Research Ethics Committee (Ref: 09/S1101/67) 
and by NHS Lothian R&D (2010/R/RM/04). The study was sponsored jointly by The 
University of Edinburgh and NHS Lothian Health Board (Academic and Clinical 
Central Office for Research and Development, ACCORD). Funding for the study 
was obtained by a Fellowship awarded from the Wellcome Trust under the Scottish 
Translational Medicine & Therapeutics Initiative (STMTI) scheme.  
2.1.2 Informed consent 
All volunteers provided written informed consent. Potential participants received 
written and oral information, the former being in the form of ethically approved 
Participant Information Sheets. Oral explanation was provided by the Investigator 
covering all elements specified in the Participant Information Sheet/Consent form, 
and the Investigator took informed written consent. All potential participants were 
given sufficient time to consider the information provided and they were given every 
opportunity to clarify any points and, if necessary, to seek further information from 
the Investigator or an independent endocrinologist advisor, details of which were 
provided in the Information Sheets.  
2.1.3 Confidentiality and data protection 
All personal information was stored in a password-protected database on the 
University of Edinburgh computer separate from the main data collection. This 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
Materials and Methods        94 
database is accessed by the research team only. Personal information was only used 
to arrange subsequent visits etc. Participants were given a unique number, which was 
used to link personal information with study data. All laboratory specimens, 
evaluation forms, reports, and other study records were link-anonymised to maintain 
participant confidentiality.  Hard copies are held in a locked filling cabinet in a 
locked room in the Royal Infirmary of Edinburgh, while electronic data are stored on 
University of Edinburgh servers, which have a number of safety features including 
encryption. The study was conducted in adherence to NHS Lothian standards for 
data protection. No portable data storage device was used, except the secure devices 
provided by NHS. Published results will not contain any personal data that could 
allow identification of individual participants. 
2.1.4 Safety reporting 
All adverse events and serious adverse events were recorded by the Investigator. 
Upon assessment of seriousness, severity, causality and expectedness of any adverse 
events appropriate actions were taken, and any serious adverse events were reported 
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2.2 Recruitment of volunteers 
Subjects were recruited for different studies, and included healthy men and women, 
(both pre- and postmenopausal) (Table 2.1). 
2.2.1 Sample size 
6-12 healthy human volunteers were recruited into each study. Sample size is based 
on similar proof of concept mechanistic studies in our lab and by other colleagues, 
demonstrating statistically significant changes in reproductive hormone 
concentrations and changes in pulsatile LH secretion (George et al. 2011, Jayasena et 
al. 2011, George et al. 2012).  
2.2.2 Recruitment of healthy men and women 
Healthy men and premenopausal and postmenopausal women were recruited by 
email invitations (approved by research ethics committee) sent within the University 
of Edinburgh and the NHS Lothian Heath Board. Printed flyers were also displayed 
within the University of Edinburgh and the clinical areas. Depending on individual 
preference further information about the study was provided over the telephone, 
email or printed Participant Information Sheets. Once the potential volunteer was 
satisfied with the information provided, they were invited to attend for a screening 
visit. Inclusion and exclusion criteria are shown in Table 2.1.  
2.2.3 Screening for eligibility 
All subjects attended the Wellcome Trust clinical research facility at the Royal 
Infirmary of Edinburgh for their screening visit. At this visit informed written 
consent was signed. If volunteer was eligible based on the history and physical 
examination, their height, weight, blood pressure and heart rate was recorded and 
electrocardiogram was performed. Urinary pregnancy test was obtained as 
appropriate.  All volunteers had blood test taken, including full blood count, renal 
function, electrolytes, liver function, LH, and FSH with addition of estradiol in 
women and testosterone in men.  
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Participant group Inclusion criteria Exclusion criteria 
All volunteers a) a) Ability to consent 
b) Suitable veins for cannulation 
and/or repeated venepuncture 
a) Undiagnosed structural 
diseases/ previous surgery or 
radiation affecting 
hypothalamus or pituitary; 
b) Clinically significant cardiac, 
hepatic, renal, pulmonary, 
endocrine, neoplastic 
abnormalities; 
c) Uncontrolled hypertension or 
diabetes; 
d) Pregnancy/lactation; 
e) Concomitant use of 
cytochrome P450 inducers or 
inhibitors within 4 weeks of the 
screening visit; 
Healthy men a) Aged 18-45; 





a) Aged 18-45; 
b) Normal pubertal development; 
c) Regular menstrual cycle (25-35 
days); 
d) Using appropriate non-
hormonal contraception, including 
abstinence, condoms, sterilisation, 
vasectomy; 
a) Hysterectomy 
b) Bilateral or unilateral 
oophorectomy; 
c) Concomitant use of hormonal 
contraceptives within 8 weeks 
or antiandrogenic drugs within 




a) At least 12 months of 
amenorrhoea; 
b) FSH level above upper limit 
and estradiol level below lower 
limit of laboratory reference 
range; 
a) Taking HRT 
b) Taking aromatase inhibitors 
or selective estrogen receptor 
modulators 
Table 2.1 Subjects recruited into different studies, and inclusion and exclusion criteria used 
 
 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
Materials and Methods        97 
2.3 Hormones and drugs  
2.3.1 Kisspeptin-10 
Human Kisspeptin-10 (KP-10) was custom synthesized under GMP standards 
(Bachem GmBH, Weil am Rhein, Germany). 1 mg Kisspeptin-10 was dissolved in 5 
ml sterile normal (0.9%) saline immediately before administration.  
In healthy men and postmenopausal studies, Kisspeptin-10 was administered by an 
intravenous bolus at 0.3 µg/kg. The dose of KP-10 was selected based on a previous 
study administering KP-10 in healthy male volunteers (George et al. 2011). KP-10 at 
0.3 µg/kg was the lowest dose to cause maximal stimulation in LH secretion with no 
evidence of tachyphylaxis.  
In a model of the LH surge in healthy premenopausal women, KP-10 was 
administered as an intravenous infusion for 7 hours at 4 µg/kg/hour.  
2.3.2 NK3 receptor antagonist (AZD4901) 
The specific neurokinin-3 receptor (NK3R) inhibitor AZD4901, formulated as 20 mg 
tablets, was gifted by AstraZeneca, UK. In all studies, AZD4901 was administered as 
40 mg oral twice daily for 7 days.  
The dose of 40 mg twice daily was chosen as this is the highest yet administered to 
healthy volunteers, and showed efficacy in reducing LH secretion and LH pulse 
frequency in women with PCOS (George et al. 2016).  
2.3.3 Transdermal estradiol 
Two transdermal Evorel patches releasing 100 μg 17β estradiol each per 24 hours 
(Janssen-Cilag Buckinghamshire, UK) were used as exogenous estradiol treatment.  
2.3.4 Vehicle 
Sterile normal (0.9%) saline (Baxter Healthcare Ltd, Thetford Norfolk, UK) was 
used as vehicle. 
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2.4 Devices and imaging tools 
2.4.1 Intravenous infusion devices 
The syringe (20 ml BD Plastipak, Spain) and line (150 cm Sae-flo MD, Wescott 
Medical Limited, Durham) for infusion were first coated for 30 min with Kisspeptin-
10 to minimise peptide loss from adherence to the plastic. Infusion pumps (Alaris 
GH syringe pump, Cardinal Health, Rolle, Switzerland) designed to deliver low 
infusion rates were used for Kisspeptin-10 administration.  
2.4.2 Ultrasonography 
Transvaginal ultrasound scan (Xario 200, Toshiba, The Netherlands, 7.5MHZ 
frequency) was performed to measure largest follicle (mm), any follicles of ≥10 mm 
diameter, endometrial thickness and appearance of corpus luteum. The Investigator 
performed all ultrasound scans.  
2.5 Collection of samples 
2.5.1 Peripheral blood 
For single time point peripheral blood sampling, venepuncture was performed using 
green 21-gage butterfly needle (Sarstedt UK Ltd, Leicestershire). For infusion 
studies, blood samples were collected via an indwelling intravenous cannula 17-
gauge (B. Braun, Melsungen, Germany) inserted into the antecubital fossa under 
aseptic technique. After each samples drawn, 2 mls of normal saline was used to 
flush the cannula to prevent coagulation within the sampling system. Before each 
sample drawn, 2 mls of blood was discarded to avoid dilution of the sample from 
residual saline in the cannula.  
Samples for hormone analysis (LH, FSH, estradiol, inhibin B, progesterone and 
testosterone) were collected into vacuum serum tubes (S-Monovette, Sarstedt UK 
Ltd, Leicestershire). They were processed at the Clinical Research Facility by 
centrifugation at 4°C for 10 min at 3000 rpm. Serum was then separated into pre-
labelled aliquot tubes and frozen at -20°C or below until analysis. Safety samples 
(full blood count, renal function, electrolytes and liver function) were collected into 
vacuum serum tubes (S-Monovette, Sarstedt UK Ltd, Leicestershire) and processed 
by the NHS Lothian laboratory at the Royal Infirmary of Edinburgh.  
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2.5.2 Urine 
Urine samples for progesterone analysis were collected by participants into 7 ml 
bijous (Greiner Bio One, Stonehouse, UK) and frozen in a domestic freezer prior to 
batch transfer for storage in dedicated freezers at -20°C or below at the Queen’s 
Medical Research Institute until analysis.  
2.6 Analysis of samples 
LH, FSH, estradiol, inhibin B, progesterone and testosterone measurement 
Serum and urinary hormone assays were carried out by Dr Forbes Howie at the MRC 
Centre for Reproductive Health core immunoassay laboratory, except testosterone, 
which was assayed in the NHS Lothian laboratory at the Royal Infirmary of 
Edinburgh.  
LH and FSH concentrations were measured by an in-house ELISA as previously 
described (George et al. 2011). The inter-assay and intra-assays coefficient of 
variation (CV) for LH and FSH were <10%. Lower detection limit for LH was 0.2 
IU/l and for FSH 0.05 IU/l.  
17β-estradiol was performed on a Roche Cobas E411 immunoassay analyser (Roche 
Diagnostics, Burgess Hill, UK) using the manufacturer’s kits and controls according 
to their instructions. The lower limit of detection was 18.4 pmol/l.  The inter-assay 
CV was found to be <5% and intra-assays CV was 6.5%.  
The Inhibin B ELISA was an enzymatically amplified three-step sandwich assay 
from Beckman Coulter Inc. Brae, CA, USA.  According to the manufacturer, the 
lowest amount of inhibin B that could be detected with a 95% probability is 2.6 
pg/ml.  The inter-assay CV was <8% across the dynamic range of 10 to 950 
pg/ml.  Insufficient assays were performed to calculate an inter-assay CV but the 
manufacturer claim it is in the region of 6% at 100 pg/ml. All samples were analysed 
in one batch.  
Testosterone was measured by liquid chromatography-tandem mass spectrometry by 
NHS Lothian clinical laboratory according to their standard operating procedures. 
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Lower limit of detection was 0.3 nmol/l. The inter-assay and intra-assays CV were 
approximately 12%. 
Progesterone was measured by an in-house ELISA. The inter-assay CV for low and 
high progesterone pools respectively were 11.4 and 9.1% and the intra-assay CV 
were 8.9 and 5.6%.  The lower limit of detection was calculated at 0.1 ng/ml. 
Urinary progesterone concentrations were expressed as a ratio of the creatinine 
concentration measured colorimetrically. Creatinine was determined utilising a   
commercial kit (Alpha Laboratories Ltd.  Eastleigh, UK) adapted for use on a Cobas 
Fara centrifugal analyser (Roche Diagnostics Ltd, Welwyn Garden City, UK). 
Within run precision was CV < 3% while intra-batch precision was CV < 5%. 
All samples from each of the study visits were analysed together in one batch, in 
duplicate.  
LH pulsatility measurement 
Analysis of pulsatile LH secretion was kindly performed by Prof Johannes Veldhuis 
at the Endocrine Research Unit at the Mayo Clinic (Rochester USA). Analysis was 
performed blinded to treatment allocation. The number of LH pulses, secretory mass 
of LH per pulse, basal (nonpulsatile) and pulsatile (integral of dual amplitude and 
frequency regulation) LH secretion was identified by an established deconvolutional 
algorithm with cluster analysis (93% sensitivity and specificity) (Veldhuis et al. 
2008, Liu et al. 2009). ApEn was quantified as a measure of secretory regularity. 
Screening and safety bloods 
Full blood count, renal function, electrolytes and liver function tests were processed 
by the NHS Lothian clinical laboratory at the Royal Infirmary of Edinburgh 
according to their standard operating procedures. Results were reported on the 
computerised NHS Lothian TRAK system. 
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2.7 Statistical analysis 
Hormone data not normally distributed were log-transformed prior to statistical 
analysis, resulting in a distribution that approximated a normal distribution. Data 
were assessed for Gaussian distribution by Shapiro-Wilk normality test (for data 
points ≥7) or Kolmogorov-Smirnov test as appropriate (for data points <7).  
Mean and area under the curve (AUC) hormone concentration comparisons over 
time and between treatments were performed using analysis of variance (ANOVA) 
with repeated measures as appropriate followed by post hoc analysis with 
Bonferroni’s correction for multiple comparisons. Peak hormone concentrations and 
their peak menstrual cycle day were compared by Student’s paired t-test or Wilcoxon 
matched-pairs signed rank test. The null hypothesis of equal variation in cycle days 
was tested by Levene’s test for homogeneity of variance. Area under the curve for 
hormone concentrations during 6-8 hours of frequent sampling was calculated by 
trapezoid integration.  
The relationship between the timing of peak hormone concentration and treatment 
was assessed by chi-square test. Pearson correlation coefficient was computed to 
assess the relationship between estradiol concentrations and LH response to KP-10.  
Paired Student’s t-test (for parametric data) or Wilcoxon matched-pairs signed rank 
test (for non-parametric data) was used to assess changes in LH pulsatility, as 
appropriate. 
Data on follicle diameters and endometrial thickness were compared over time and 
between treatments using ANOVA with repeated measures as appropriate followed 
by post hoc analysis with Bonferroni’s correction for multiple comparisons. 
Additional expert input in statistical analysis was kindly provided by Cat Graham.  
Data are presented as mean ± SEM. Differences were regarded as significant at a 
two-sided p<0.05. The statistical software package GraphPad Prism (GraphPad, San 
Diego, California) was used for data analysis. 
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Chapter 3. Neurokinin B and Kisspeptin in the regulation of 
gonadotropin and testosterone secretion in 
healthy men 
3.1 Introduction 
Kisspeptin and neurokinin B (NKB) are hypothalamic neuropeptides now recognised 
as being key regulators of pulsatile GnRH secretion and thus central to the control of 
the human reproduction (Skorupskaite et al. 2014). Men and women with loss-of-
function mutations in kisspeptin, neurokinin B or their cognate receptors (KISS1R 
and NK3R) show reduced GnRH secretion and subsequently hypogonadotropic 
pubertal delay (de Roux et al. 2003, Seminara et al. 2003, Topaloglu et al. 2009, 
Topaloglu et al. 2012), whilst activating mutations in kisspeptin receptor are 
associated with precocious puberty (Teles et al. 2008).  
Whilst kisspeptin potently stimulates gonadotropin secretion (Dhillo et al. 2005, 
Chan et al. 2011, George et al. 2011, Jayasena et al. 2011, Jayasena et al. 2015a) and 
increases LH pulsatility in men (George et al. 2011), effects of exogenous neurokinin 
B administration are discordant. In animal studies both stimulatory and inhibitory 
actions of neurokinin B on LH secretion has been observed (Billings et al. 2010, 
Navarro et al. 2011a, Ramaswamy et al. 2011), whilst it had no effect on either 
reproductive hormone concentrations, nor LH pulsatility when infused for 8 hours in 
healthy men and women (Jayasena et al. 2014c). During the preparation of this 
thesis, NK3R antagonist ESN364 was administrated to human volunteers (Fraser et 
al. 2016). In women, there was no change in baseline gonadotropin secretion 
throughout the 21 day follicular phase administration of NK3R antagonist, but a 
delay in the LH surge was observed, likely secondary to a delay in the pre-ovulatory 
estradiol rise (Fraser et al. 2016). These findings are similar to those in intact adult 
female monkeys receiving the same NK3R antagonist (Fraser et al. 2015a). In men, 
NK3R antagonist suppressed LH and testosterone secretion, but not FSH (Fraser et 
al. 2016). However, this effect was temporary lasting only few hours post dosing 
with hormones returning to baseline within 24 hours and concentrations being no 
different after 10 days of treatment compared to pre-treatment values (Fraser et al. 
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2016). Antagonism of NK3R has been shown to decrease LH secretion and reduce 
the frequency of LH pulses in states of high LH output, such as in women with 
PCOS (George et al. 2016) and gonadectomised animals (Fraser et al. 2015a, Li et al. 
2015), indicating a role of neurokinin B in the regulation of pulsatile GnRH and thus 
LH secretion. However, the inhibitory action of neurokinin B antagonism on 
GnRH/LH pulsatility has not been investigated in states of slow LH secretion and in 
health. 
Kisspeptin and NKB are co-expressed by some neurones within the hypothalamus, in 
humans and other species, which also co-express the opioid dynorphin and have been 
termed KNDy neurones (Cheng et al. 2010). The interaction and functional hierarchy 
between kisspeptin and neurokinin B is largely inferred from studies in animal 
models. Kissr1 knockout mice were unable to mount a stimulatory effect of NK3R 
agonist senktide on LH secretion (Garcia-Galiano et al. 2012), and in juvenile male 
monkeys, KP-10 stimulated LH secretion after pre-treatment with the NK3R 
antagonist (Ramaswamy et al. 2011), suggesting the action of neurokinin B to be 
upstream of kisspeptin. In patients with inactivating genetic defects in NKB (TAC3) 
and its receptor (TACR3), showing slow GnRH secretion as inferred from low LH 
secretion (mean 0.1 pulses per hours) and near normal FSH, exogenous KP-10 
restored LH pulse frequency to normal (Young et al. 2013), providing further 
evidence that neurokinin B is functionally upstream of kisspeptin in the regulation of 
GnRH secretion. However, this is the only human study investigating the hierarchy 
of kisspeptin and neurokinin B and there are no studies looking at this in a 
physiological rather than disease model. 
The antagonistic effect of neurokinin B and its interaction with kisspeptin in the 
regulation of the male reproductive axis, a state of slow LH secretion, was therefore 
explored by the use of a specific NK3R antagonist.  
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3.2 Objectives 
The objectives of the study were, in healthy men: 
1) To determine the effect of NK3R antagonist on LH, FSH and testosterone 
secretion; 
2) To investigate the effect of NK3R antagonist on LH pulsatility; 
3) To determine if KP-10 stimulated LH secretion is abrogated in the presence 
of NK3R antagonist, thereby revealing the functional hierarchy of neurokinin 
B being proximal to kisspeptin. 
3.3 Methods  
3.3.1 Participants 
Six healthy men, aged 23-39 years were recruited to this study; all volunteers 
provided informed written consent. Subjects were eligible based on their inclusion 
and exclusion criteria (Table 2.1 Inclusion and exclusion criteria, Chapter 2), had 
normal physical examination, and full blood count, renal function, electrolytes, liver 
function and electrocardiogram were within normal limits.  
3.3.2 Study drugs 
The specific neurokinin-3 receptor (NK3R) inhibitor AZD4901 was administered 
orally at 40 mg twice daily. Kisspeptin-10 was administered by an intravenous bolus 
at 0.3 µg/kg and prepared as described in Chapter 2 (2.3.1 Kisspeptin-10).  
3.3.3 Protocol 
Investigation of the effect of NK3R antagonism on gonadotropin and testosterone 
secretion.  
A schematic representation of the protocol is shown in Figure 3.1. Volunteers were 
administered the NK3R antagonist for 7 days. Peripheral venous blood was sampled 
for spot LH, FSH and testosterone 24 hours before treatment (pre-treatment) and on 
days 2, 4, 6 and 7 of NK3R antagonist administration.  Once daily blood sampling 
was performed in the morning: during treatment, this was immediately prior to the 
next dose of NK3R antagonist, i.e. 12 hours after the previous dose.  
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Figure 3.1 Study protocol. 
6 healthy men were administered NK3R antagonist AZD4901 orally for 7 days. LH, FSH and 
testosterone were measured throughout the study. LH pulsatility was assessed during 10 minute blood 
sampling for 6 hours on the day before and on the last day of NK3R antagonist treatment. KP-10 was 
administered by intravenous bolus at 6 hours with further frequent blood sampling for 2 hours.   
Investigation of the effect of NK3R antagonist on LH pulsatility.  
On the pre-treatment day and on the last day of NK3R antagonist administration (day 
7) volunteers attended our clinical research facility for 8 hours. All visits commenced 
between 0800 and 0900 hours to avoid diurnal variation. Blood samples were 
collected via an indwelling intravenous cannula at 10 min intervals for 6 hours for 
assessment of LH pulsatility. The dose of NK3R antagonist was administered 
immediately prior to the start of sample collection (day 7). 
Establishment of the hierarchy between kisspeptin and neurokinin B on LH secretion.  
Kisspeptin-10 was administered at 6 hours of the pulsatility study described above 
with further 10 min blood sampling for 2 hours after administration.  
Safety profile. Safety blood tests including full blood count, renal function and 
electrolytes, and liver function were checked before commencing the NK3R 
antagonist, at the end of each 8 hour visit for frequent blood sampling and 2-3 weeks 
later.   
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3.3.4 Analytical methods 
Hormone assays, pulsatile LH secretion and safety blood tests were analysed as 
described in Chapter 2.  
3.3.5 Statistical analysis 
Mean LH, FSH and testosterone concentrations over time were compared using one-
way analysis of variance (ANOVA) with repeated-measures followed by 
Bonferroni’s post hoc correction for multiple comparisons. Area under the curve 
(AUC) of LH for each of the 8 hours of frequent sampling was determined by 
trapezoid integration on the pre-treatment day (control) and on day 7 of NK3R 
antagonist administration, and change in AUC LH during one hour pre KP-10 
injection and for 2 consecutive hours post KP-10 injection was calculated. 
Comparisons across both time and between treatments were performed using 
repeated-measures two-way ANOVA with Bonferroni’s multiple comparisons post 
hoc analysis. Paired Student’s t-test (for normally distributed data: basal and pulsatile 
LH secretion, mass per pulse, ApEn) or Wilcoxon matched-pairs signed rank test (for 
data that did not have a normal distribution: pulse frequency) was used to assess 
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3.4 Results 
3.4.1 NK3R antagonist decreases gonadotropin and testosterone 
secretion 
LH secretion decreased with NK3R antagonist administration (p<0.03), 
demonstrating a biphasic response: LH levels fell after 24 hours of treatment 
(4.5±0.6 IU/l pre-treatment to 1.7±0.2 IU/l day 2, p<0.05), then recovered (4.2±0.7 
IU/l day 4 and 3.7±0.7 IU/l day 6) but was again decreased on day 7 (2.5±0.6 IU/l vs 
pre-treatment, p<0.05) (Fig. 3.2A). To detect subtle changes in hormone secretion 
over time potentially overlooked by performing single time spot blood sampling, a 
more detailed analysis of LH secretion every 10 minutes for 6 hours post NK3R 
antagonist dose showed a decrease in AUC LH secretion throughout the 6 hour-
period on the last day of NK3R antagonist administration compared to pre-treatment 
(16.8±2.7 vs 8.7±1.5 IU/l over 6 hours with NK3Ra, p=0.0007, Fig. 3.2B). 
FSH secretion was also suppressed during NK3R antagonist administration 
(p=0.001), being significantly lower after 24 hours of treatment (3.6±0.3 vs 2.4±0.4 
IU/l, p<0.001) (Fig. 3.2C). FSH showed a comparable pattern to changes in LH over 
the following days, being significantly lower than pre-treatment on days 4 and 7 
(each p<0.05 vs pre-treatment) but not on day 6 of taking NK3R antagonist 
administration. 
Testosterone secretion declined rapidly in response to NK3R antagonist at 24 hours 
(18.4±1.6 pre-treatment vs 5.6±1.5 nmol/l, p<0.01) and was consistently suppressed 
for the remainder of the treatment period (p<0.05 day 4, 6 and 7 vs pre-treatment) 
(Fig. 3.2D). Serum testosterone recovered to pre-treatment in all subjects 2 weeks 
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Figure 3.2 LH, FSH and testosterone response to administration of NK3R antagonist in healthy 
men.  
(A) Mean LH concentrations during 7 days of NK3R antagonist treatment and (B) AUC LH during 6 
hours of 10 minute LH sampling pre-treatment and on day 7 of NK3R antagonist administration 
(n=6). Mean FSH (C) and testosterone (D) response to NK3R antagonist administration (n=6). Data 
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3.4.2 Effect of NK3R antagonist on pulsatile LH secretion in men 
LH pulse profile from all individual subjects before and after 7 days of NK3R 
antagonist treatment is shown in figure 3.3. The LH pulse frequency was unchanged 
by NK3R antagonist  (0.50±0.09 vs 0.47±0.07 pulses/hr, ns) (Fig. 3.4A). However 
consistent with suppressed LH secretion, other parameters of LH pulsatility were 
reduced. Both basal (nonpulsatile) and pulsatile mass of LH secretion were lower 
with NK3R antagonist treatment compared with pre-treatment day (Fig. 3.4 B-C, 
both <0.02). The secretory mass of LH per pulse (Fig. 3.4D) was not significantly 
changed. NK3R antagonist improved the orderliness of LH secretion pattern as 
assessed by approximate entopy (ApEn) (p=0.02) (Fig. 3.4E). ApEn is a statistical 
measure of the pattern of pulsatile LH secretion and not something that can be 
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Figure 3.3 Individual LH pulse profile. 
LH profiles sampled at 10 min intervals for 6 hours from 6 individual subjects (1-6) pre-treatment  
(black circles) and on day 7 of NK3Ra administration (red squares). 
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Figure 3.4 Analysis of 6 hour LH secretory pattern on day 7 of NK3R antagonist treatment 
compared to control pre-treatment day in healthy men.  
Mean LH pulse frequency (A), basal (nonpulsatile) LH secretion (B), pulsatile LH secretion (C), 
secretory mass of LH per pulse (D) and the relative orderliness/regularity of LH secretory pattern (E) 
on day 7 of NK3R antagonist treatment compared to pre-treatment day. Data are presented as mean ± 
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3.4.3 NK3R antagonist does not reduce kisspeptin-induced LH 
secretion 
To assess the hierarchical interaction between kisspeptin and neurokinin B in the 
regulation of LH secretion in men, an intravenous injection of kisspeptin-10 was 
administrated after 6 hours of blood sampling on pre-treatment day and on the last 
day of NK3R antagonist treatment (Fig. 3.5). KP-10 elicited a rapid increase in LH 
secretion (3.0±0.6 at 6 hours vs 4.8±0.5 IU/L at 7 hours, p<0.05 and AUC LH 
2.7±0.4 6 hours vs 5.2±0.5 IU/l hr 7 hours, p<0.01) (Fig. 3.5 A and B). The 
stimulation of LH secretion by KP-10 persisted in the presence of NK3R antagonist 
(mean LH and AUC LH for KP-10+NK3R antagonist: 6 hours vs 7 and 8 hours, all 
p<0.05; Fig. 3.5 A and B) and was similar to stimulated LH secretion after KP-10 
alone (AUC LH 7 and 8 hours KP-10: 5.2±0.5 and 3.9±0.4 vs 5.2±0.7 and 4.0±0.6 
IU/l hr with NK3R antagonist, ns). However, calculation of the LH response to KP-
10 as ΔAUC between hours 6 and 7/8 suggested that it was enhanced during NK3R 
antagonist treatment (KP-10 alone ΔAUC LH 7 and 8 hours: 2.5±0.2 and 1.2±0.2 vs 
3.8±0.5 and 2.5±0.4, KP-10 with NK3R antagonist, both p<0.05) (Fig.3.5C). This 
may reflect the lower LH concentrations with the NK3R antagonist at the time of 
KP-10 administration with similar LH concentrations after KP-10 injection. 
3.4.4 Tolerability and safety 
NK3R antagonist treatment was well tolerated. One man reported reduced libido 
whist on NK3R antagonist and this recovered after the completion of the study. 
Haematology and biochemistry safety parameters remained stable in all subjects 
throughout the study period.  
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Figure 3.5 LH response to KP-10 injection with and without 7 days of NK3R antagonist 
administration in healthy men.  
(A) Mean LH concentrations from 6 hours of frequent sampling; (B) AUC LH and (C) ΔAUC LH 
were compared over one hour (hour 6) before KP-10 administration, with 2 hours post KP-10 
administration (7 and 8 hours), with and without NK3R antagonist treatment during frequent blood 
sampling for LH every 10 minutes in the same 6 healthy men. Mean ± SEM. *, p<0.05; **, p<0.01; 
****, p<0.0001. 
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3.5 Discussion 
In the present study the role of neurokinin B and its interaction with kisspeptin in the 
regulation of GnRH and LH/FSH secretion was investigated in healthy men, where 
LH pulsatility is characteristically slow. Pharmacological blockade of NKB-NK3R 
signalling caused a rapid and marked decrease LH, FSH and testosterone secretion, 
although with a complex pattern of change over the week of treatment, whilst the 
stimulatory LH response to kisspeptin was maintained after 7 days of NK3R 
antagonist. NK3R antagonism did not affect the frequency of LH pulses in men, but 
other aspects of the pulsatile nature of LH secretion were markedly reduced. Taken 
together, these data show that NKB is important in the physiological regulation of 
GnRH/LH and testosterone secretion in men.  They support a predominantly 
hierarchical relationship whereby the action of neurokinin B is proximal to 
kisspeptin in the modulation of GnRH/LH secretion, as previously indicated in men 
with NKB/NK3R mutations (Young et al. 2013).  However, the pulse analysis 
suggests that the main effect of NKB on GnRH is through an overall reduction in 
both basal and pulsatile secretion without a change in pulse frequency, in contrast to 
the only previous data from women with PCOS, where an impact on pulse frequency 
was identified (George et al. 2016).  
These data demonstrate that in men, NK3R antagonist decreased LH secretion in a 
biphasic pattern, with significant reductions after 24 hours (day 2) and on day 7. 
Detailed 10-minute assessment showed suppression in LH secretion persisting for the 
duration of 6 hour sampling on day 7 of NK3R antagonist administration. Consistent 
with this being by suppression of GnRH secretion, NK3R antagonist also lowered 
FSH concentrations on day 2, 4 and 7 of treatment, albeit to a lesser extent than with 
LH secretion. FSH secretion is less sensitive to rapid changes in GnRH secretion, 
which may account for the slightly different profile of the FSH response to NK3R 
antagonism over the 7 days of treatment. A different NK3R antagonist, ESN364, 
suppressed LH secretion in ovariectomised ewe and castrate monkeys (Fraser et al. 
2015a, Li et al. 2015) but with only a transient 3 hour effect in normal men (Fraser et 
al. 2016) and did not affect FSH secretion in either men (Fraser et al. 2016) or 
castrate monkeys (Fraser et al. 2015a). There were no differences in reproductive 
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hormone concentrations on day 10 of ESN364 administration when compared to pre-
treatment levels in men (Fraser et al. 2016) and similarly, no change in LH secretion 
was observed with follicular phase administration of this NK3R antagonist in normal 
women or in intact female monkeys, although the LH surge was delayed (Fraser et 
al. 2015a, Fraser et al. 2016). This may reflect the greater effect on LH (and by 
inference GnRH) observed with NK3R antagonist AZD4901 used in our studies.  
Furthermore, Fraser and colleagues did not assess the effect of NK3R antagonist on 
pulsatile LH secretion to determine the nature of its effect on GnRH secretion.  
Sustained suppression of testosterone secretion was observed throughout the 7 days 
of treatment. Hitherto, this NK3R antagonist has been administered in states of high 
LH output and was shown to reduce both LH and testosterone secretion in women 
with PCOS (George et al. 2016). Although recovery of suppressed LH secretion with 
low testosterone levels on day 4 and 6 in the present study may indicate a direct 
gonadal effect of NK3R antagonist, and NKB-NK3R mRNA has been detected in 
human granulosa cells (Cejudo Roman et al. 2012, Garcia-Ortega et al. 2014), there 
are no data on this in human testes. The simultaneous decrease in serum LH and 
testosterone concentrations within 24 hours of treatment suggests a central role of 
neurokinin B in the regulation of GnRH/LH secretion, which is further supported by 
changes in the pattern of LH pulsatility. It seems likely that the initial fall in LH and 
testosterone levels caused a perturbation in testosterone negative feedback with a 
secondary recovery in LH secretion, with the suppressive effect re-established by the 
end of the week of treatment. It remains to be determined if this suppression would 
persist with prolonged antagonism of NKB-NK3R signalling.  
 The present study has shown for the first time that in normal men NK3R antagonist 
markedly reduced both basal i.e. nonpulsatile LH secretion and total amount of LH 
secreted in pulses, and the secretory mass of LH per pulses also trended downwards, 
contributing to overall lower serum LH concentrations by the end of the treatment. 
The regularity of LH secretory pattern and by inference GnRH secretion showed 
greater orderliness as indicated by reduced ApEn. In contrast to kisspeptin, which is 
a key modulator of GnRH/LH pulse frequency (George et al. 2011), NK3R 
antagonist did not alter the frequency of LH pulses in this study, although the ability 
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to detect a change in LH pulse frequency may have been limited by the small number 
of men studied here, and the short 6 hour duration of frequent sampling. Consistent 
with some aspects of our findings, infusion of neurokinin B ligand in men elicited no 
effect on LH pulsatility (Jayasena et al. 2014c). On the other hand NK3R antagonist 
has been shown to reduce LH pulse frequency in women with PCOS (George et al. 
2016) and in ovariectomised ewes (Fraser et al. 2015a, Li et al. 2015), although this 
was in state of fast LH pulsatility and in the animal studies NK3R antagonist was 
administrated centrally. Data on this in another state of high LH output- 
postmenopausal women- are presented in Chapter 4. Conversely, in the present study 
LH secretion was already low and there may be a threshold at which NK3R 
antagonist cannot suppress LH pulsatility further, accounting for the discrepancy 
observed, or a higher dose may be required. Moreover, inability to manipulate LH 
pulse frequency in men may reflect differences in male physiology in that changes in 
the frequency of LH pulses is not a prerequisite for normal testicular function, unlike 
its key role in regulating ovarian cyclicity (Filicori et al. 1986). Sexual dimorphism 
is well recognised in kisspeptin response, showing marked increase in LH with 
kisspeptin administration in men but variable response in women dependent on the 
sex-steroid milieu (Dhillo et al. 2007, George et al. 2012). Furthermore, the female 
hypothalamus has significantly more kisspeptin cell bodies and fibres compared to 
men (Hrabovszky et al. 2010), and there is a greater abundance of neurokinin B 
expressing neurones in ewes than rams (Goubillon et al. 2000), indicating gender 
differences in NKB-kisspeptin pathway. Lastly, loss of negative testosterone 
feedback is known to increase LH pulse frequency (Veldhuis et al. 2008), which may 
have balanced out the suppressive effect of NK3R antagonism on pulsatile LH 
secretion. Nevertheless, manipulation of pulsatile LH secretory pattern by the NK3R 
antagonist in this study, which is in concordance with stimulatory action of 
neurokinin B and inhibitory action of NK3R antagonist on LH pulses in animal 
studies (Fraser et al. 2015a, Li et al. 2015), supports the notion that neurokinin B acts 
centrally to modulate at least some aspects of pulsatile GnRH secretion and that there 
are complex neurokinin B/kisspeptin/GnRH interactions that result in the 
characteristics of the LH pulse.  
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
KP/NKB in states of slow LH secretion  117 
KP-10 stimulated LH secretion in the presence of NK3R antagonist in normal men, 
which lends further support to the overall hierarchy whereby neurokinin B signalling 
is functionally upstream of kisspeptin in GnRH/LH pulse generation. This is 
consistent with the only human study to date investigating the hierarchical 
contribution of these neuropeptides in disease rather than health model, where KP-10 
infusion restored pulsatile LH secretion in men and women with inactivating 
mutations in neurokinin B pathway (Young et al. 2013), and with equivalent results 
observed in animal studies (Ramaswamy et al. 2011, Garcia-Galiano et al. 2012). 
Although in the presence of NK3R antagonist, KP-10 stimulated LH concentrations 
were similar to those observed with KP-10 alone, there was some evidence that the 
KP-10 response was enhanced by the NK3R antagonist. This may reflect lower basal 
LH levels following pre-treatment with NK3R antagonist and perhaps a limit to the 
maximal KP-10 stimulatory effect.  Conversely, co-infusion of neurokinin B itself 
and KP-54 in healthy men, stimulated gonadotropin and testosterone secretion 
significantly less than with KP-54 alone and had no effect on LH pulsatility 
(Narayanaswamy et al. 2016b). As downregulation in GnRH and Kiss1r mRNA was 
observed with senktide administration in rats (Grachev et al. 2012), it was proposed 
that in the presence of high levels of kisspeptin, neurokinin B acts to inhibit GnRH 
and kisspeptin transcription to reduce the stimulatory action of kisspeptin on 
gonadotropins (Narayanaswamy et al. 2016b). Together, this evidence suggests a 
more complex interaction between kisspeptin and neurokinin B in the regulation of 
GnRH secretion, raising the possibility of neurokinin B being a gatekeeper, which 
exerts both stimulatory and/or inhibitory downstream actions on kisspeptin in 
response to negative sex steroid feedback.  
The present study has clear strengths in that a specific neurokinin-3 receptor 
antagonist was used, detailed LH pulse profiling was performed with blinded pulse 
analysis, and paired data was obtained for the control period and administration of 
NK3R antagonist. However, it is important to recognize that the sample size is small 
and a placebo control was not used. The limited suppression in the frequency of LH 
pulses by the NK3R antagonist might be due to the dose of AZD4901 being lower 
compared to doses used in animal studies. Direct comparison of human and animal 
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data requires caution since animal studies often use central administration of 
neuropeptides to delineate neurokinin B/kisspeptin/GnRH interaction. Peripherally 
administrated neuropeptides in this study may not have fully reached the 
hypothalamic regions of their action, although KNDy neurones send projections to 
the median eminence, which receives the portal circulation, and the arcuate nucleus, 
which have an incomplete blood-brain-barrier (Rodriguez et al. 2010).  
In summary, using healthy men to explore the role of neurokinin B in a physiological 
state of slow LH secretory pattern, these data show that NK3R antagonism resulted 
in suppression of both LH and FSH concentrations, and a sustained decrease in 
testosterone secretion, indicating an important role for neurokinin B in the regulation 
of the male HPG axis.  They show for the first time that a NK3R antagonist reduced 
some aspects of pulsatile LH secretion in men. Assessment of the interaction 
between neurokinin B and kisspeptin showed that LH response to kisspeptin was 
maintained in the presence of NK3R antagonist, supporting a hierarchical 
relationship of neurokinin B being predominantly proximal to kisspeptin. These data 
thus indicate that neurokinin B modulates GnRH/LH pulse generation in men but 
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Chapter 4. Neurokinin B and Kisspeptin in the regulation of 
gonadotropin secretion in postmenopausal women  
4.1 Introduction 
In chapter 3, the interaction between kisspeptin and neurokinin B in modulation of 
pulsatile GnRH/LH secretion was investigated in a state of slow LH pulsatility. In 
healthy men, neurokinin B signalling was found to be predominantly upstream of 
kisspeptin, which is consistent with the stimulatory kisspeptin effect seen in patients 
with loss-of-function mutations in neurokinin B (TAC3) and neurokinin-3 receptor 
(TACR3) (Young et al. 2013) and equivocal findings from animal studies 
(Ramaswamy et al. 2011, Garcia-Galiano et al. 2012). However, there are no data on 
the role of NKB in states of high LH output in human health: postmenopausal 
women provide a model to investigate this.  
Kisspeptin is a potent stimulator of LH secretion in men (Dhillo et al. 2005, George 
et al. 2011), the response in healthy women being variable and dependent on sex-
steroid milieu across different phases of the menstrual cycle with a direct positive 
correlation with estrogen concentrations (Dhillo et al. 2007, George et al. 2012, 
Narayanaswamy et al. 2015). The only study administering kisspeptin in estrogen 
deficient postmenopausal women has shown a rather limited LH response to both 
KP-10 and GnRH injection compared to women in the follicular phase or those on 
hormonal contraception (George et al. 2012). This suggests that kisspeptin might 
already be operating at its maximal capacity to increase GnRH pulsatility and 
subsequently LH secretion in response to loss of negative ovarian feedback in 
postmenopausal women. In keeping with this, hypothalamic expression of KISS1 and 
TAC3 mRNA are upregulated, and kisspeptin and neurokinin B neurones are 
hypertrophied in the infundibular nucleus of postmenopausal compared to 
premenopausal women (Sheehan and Kovacs. 1966, Rance et al. 1990, Rance and 
Young. 1991, Rometo et al. 2007). Similarly, the hypothalamic expression of those 
neuropeptides is increased following an ovariectomy in rodents, ewes and monkeys 
but restored with estrogen replacement (Rance and Bruce. 1994, Abel et al. 1999, 
Sandoval-Guzman et al. 2004, Navarro et al. 2009, Eghlidi et al. 2010). Whether this 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
KP/NKB in states of high LH secretion  120 
hypertrophy of kisspeptin and neurokinin B neurones and LH hypersecretion impact 
on the ability to manipulate the system is unknown.  
In states of high LH pulsatility, such as in women with PCOS, and in animals models 
of ovariectomised ewes and castrate monkeys, selective blockade of NK3R  with 
ESN364 or AZD4901 decreased the frequency of LH pulses, subsequently 
suppressing LH secretion and in women with PCOS lowering serum testosterone 
concentrations (Fraser et al. 2015a, Li et al. 2015, George et al. 2016). However, the 
inhibitory effect of such blockade on the NKB/KP/GnRH pathway and GnRH/LH 
pulsatility in high LH secretion in healthy women, such as post menopause, has not 
yet been explored.  
Withdrawal of estrogen and a compensatory increase in LH secretion in menopause 
is also accompanied by hot flushes in some women, the mechanisms of which remain 
unclear. Hot flushes are characterised by sudden onset of transient and intense 
sensation of heat associated with heat-loss response, including cutaneous 
vasodilation and sweating. A hypothalamic mechanism for this was first proposed 
almost 20 years ago, when using an ingestible thermometer small elevations in body 
core temperature were detected preceding most (65-76%) hot flushes (Freedman. 
1998). Hot flushes triggered by heat and exercise induced small increases in core 
body temperature, which in symptomatic postmenopausal women were acting within 
a lowered thermoregulatory threshold (0°C) for heat dissipation than in 
postmenopausal women who do not flush (thermoregulatory threshold (0.4°C) 
(Freedman. 1998), although these data have not been replicated.  
Studies involving blood sampling at frequent intervals have revealed the 
synchronisation of LH pulses with the onset of hot flushes in women (Casper et al. 
1979, Oakley et al. 2015). It is well established that pulsatile LH secretion is a 
marker of GnRH pulsatility, and functional links between pathways driving GnRH 
pulsatility and vasomotor symptoms have been proposed (Rance et al. 2013). KNDy 
neurones have been implicated as an important part of the GnRH pulse generator, 
they are sensitive to estrogen withdrawal and project to the thermoregulatory region 
within the median preoptic area (Krajewski et al. 2010), suggesting the role of KNDy 
signalling in the aetiology of flushes. Manipulation of high LH pulsatility in 
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postmenopausal women by a NK3R antagonist may therefore open new paradigms in 
the management of menopausal hot flushes. Consistent with the above is the 
demonstration that the administration of exogenous neurokinin B induced hot flushes 
in healthy premenopausal women (Jayasena et al. 2015b). Ablation of NKB-
expressing neurones reduced cutaneous vasodilation in rodents (Mittelman-Smith et 
al. 2012), and NK3R antagonist lowered body core temperature in sheep (Fraser et 
al. 2015a), whilst NK3R agonist senktide administered directly into the rat median 
preoptic area was associated with increased tail vasodilatation (Dacks et al. 2011). 
Collectively, these findings suggest the involvement of NKB signalling in vasomotor 
symptoms as well as GnRH/LH pulse generation, having potential for novel 
therapeutic application in the treatment of hot flushes.  Using a selective NK3R 
antagonist, the role of neurokinin B in the regulation of hypergonadotropic state in 
menopausal women and its interaction with kisspeptin was therefore investigated.  
4.2 Objectives 
The objectives of this study were in healthy postmenopausal women: 
1) To determine the effect of NK3R antagonist on LH and FSH secretion; 
2) To investigate the effect of NK3R antagonist on LH pulsatility; 
3) To investigate the effect of KP-10 on gonadotropin secretion and whether this 
response is preserved in the presence of NK3R antagonist, thereby revealing 
the functional hierarchy of neurokinin B being proximal to kisspeptin; 
4) To record changes in hot flushes in susceptible women during administration 
of NK3R antagonist. 
 
 
4.3 Methods  
4.3.1 Participants 
Eleven healthy postmenopausal women, aged 46-62 years and 2-20 years since 
natural menopause were recruited to this study; all volunteers provided informed 
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written consent. Subjects were on no hormonal replacement therapy and not taking 
any preparations for hot flushing. As the primary outcome was analysis of LH 
secretion, the presence or frequency of hot flushes were not inclusion criteria, and 
was reported in 8 of the subjects. Subjects were eligible based on inclusion and 
exclusion criteria (Table 2.1 Inclusion and exclusion criteria, Chapter 2), had normal 
physical examination, and full blood count, renal function, electrolytes, liver function 
and electrocardiogram were within normal limits.  
4.3.2 Study drugs 
The specific NK3R inhibitor AZD4901 was administered orally at 40 mg twice 
daily. Kisspeptin-10 was administered as an intravenous bolus at 0.3 µg/kg and 
prepared as described in Chapter 2 (2.3.1 Kisspeptin-10).  
4.3.3 Protocol 
Investigation of the effect of NK3R antagonism on LH and FSH secretion.  
Schematic presentation of the protocol is shown in Figure 4.1. Study design is 
similar to that used in healthy men (Chapter 3). Volunteers were administered the 
NK3R antagonist for 7 days. Peripheral venous blood was sampled for spot LH and 
FSH 24 hours before treatment (pre-treatment) and on days 2, 4, 6 and 7 of NK3R 
antagonist administration.  Once daily blood sampling was performed in the 
morning: during treatment, this was immediately prior to the next dose of NK3R 
antagonist, i.e. 12 hours after the previous dose. 
Investigation of the effect of neurokinin B on LH pulsatility.  
On the pre-treatment day and on the last day of NK3R antagonist administration (day 
7) volunteers attended our clinical research facility for 8 hours. All visits commenced 
between 0800 and 0900 hours to avoid diurnal variation. Blood samples were 
collected via an indwelling intravenous cannula at 10 min intervals for 6 hours for 
the assessment of LH pulsatility. The dose of NK3R antagonist was administered 
immediately prior to the start of sample collection (day 7).  
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Figure 4.1 Study protocol. 
11 healthy postmenopausal women were administered NK3R antagonist AZD4901 orally for 7 days. 
LH and FSH were measured throughout the study. LH pulsatility was assessed during 10 minute 
blood sampling for 6 hours on the day before and on the last day of NK3R antagonist treatment. KP-
10 was administered as an intravenous bolus at 6 hours with further frequent blood sampling for 2 
hours.  Women self-reported the frequency and severity of hot flushes and the interference of those 
flushes with daily activities throughout the study.  
 
Establishment of the hierarchy of kisspeptin and neurokinin B on gonadotropin 
secretion in postmenopausal women.  
Kisspeptin-10 0.3 µg/kg intravenous bolus was administered after 6 hours of the 
pulsatility study as above with further blood sampling for 2 hours every 10 min for 
LH and hourly for FSH.  
The role of neurokinin B in the modulation of flush symptoms.  
This formed the secondary outcome of the study. Subjects were not specifically 
informed that the study drug may reduce the experience of hot flushes. Subjects 
continued their usual lifestyle whilst taking part in the study, including intake of hot 
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drinks, caffeine, alcohol and spicy food. Subjects were asked to self-report any 
flushing symptoms (e.g. heat and sweating) and night-time awakenings, including 
their frequency and perceived severity (1 ‘mild’= heat sensation and no sweating; 2 
‘moderate’= heat and sweating, not causing disruption to activity; 3 ‘severe’ = heat 
and sweating, disrupting activity) by using ‘Hot Flush’ diaries for a week prior to 
study visits and whilst on NK3R antagonist treatment (Fig. 4.2). Subjects were 
encouraged to keep the diary with them at all times and record the flush and its 
severity after it occurred to minimise ‘retrospective monitoring’. Night-time 
awakenings were recorded in the morning. The subjective hot flush-related daily 
interference scale (HFRDIS) (Carpenter. 2001), covering the preceding 7 days, was 
completed by the subjects on the last day of pre-treatment period and upon the 
completion of NK3R antagonist (Fig. 4.2). HFRDIS is a 10-item scale allowing 
subjective assessment of the perceived affect of flushes on a number of activities of 
daily living and the quality of life (Carpenter. 2001). Subjects were asked to rate the 
bothersomeness of their hot flushes on each item of activity using the scale from 0 
(do not interfere) to 10 (completely interfere). 
Safety profile.  
Safety blood tests including full blood count, renal function and electrolytes, and 
liver function were checked before commencing the NK3R antagonist, at the end of 
each 8 hour visit for frequent blood sampling and 2-3 weeks after the treatment had 
finished. 
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Figure 4.2 ‘Hot Flush’ diary and Hot Flush-Related Daily Interference Scale questionnaire. 
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4.3.4 Analytical methods 
Hormone assays, pulsatile LH secretion and safety blood tests were performed as 
described in Chapter 2. The frequency of hot flushes was calculated as the mean 
number of hot flushes recorded in a 24-hour period and the mean number of night-
time awakenings as a result of those flushes (Freeman et al. 2011). Severity of hot 
flushes was calculated by selecting the highest severity rating for hot flushes for each 
subject in a 24-hour period and averaging the score for the week (Freeman et al. 
2011). For HFRDIS mean total score as well as individual item score were calculated 
(Carpenter. 2001).  
4.3.5 Statistical analysis 
Data were tested for normality by Shapiro-Wilk normality test. Mean LH and FSH 
concentrations over time were compared using one-way ANOVA followed by 
Bonferroni’s multiple comparisons post hoc analysis. Area under the curve (AUC) 
LH and FSH during 8 hours of frequent LH sampling (every 10 minutes) and FSH 
sampling (every hour) was determined by trapezoid integration on the pre-treatment 
day (control) and on day 7 of NK3R antagonist administration. Comparisons in AUC 
across time and between the groups were performed using repeated-measures two-
way ANOVA with Bonferroni’s multiple comparison post hoc analysis. AUC hourly 
gonadotropin response to KP-10 was not calculated for one of the eleven women, as 
full 2-hour sampling data post KP-10 injection was not obtained due to failure of 
indwelling intravenous cannulas and inability to secure further intravenous access.  
Parameters of LH pulsatility were compared by paired Student’s t-test (for normally 
distributed data: secretory mass per pulse, basal and pulsatile secretion, ApEn) or 
Wilcoxon matched-pairs signed rank test (for data that did not have a normal 
distribution: pulse frequency).   
Paired mean frequency of hot flushes and night-time awakenings were compared 
using Wilcoxon matched-pairs signed rank test. Mean flush severity scores (unpaired 
as score was set to missing on the day that hot flushes equalled zero) were compared 
using Mann-Whitney test. Total and individual item HFRDIS scores were compared 
by Wilcoxon matched-pairs signed rank test. Data are presented as mean ± SEM. 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
KP/NKB in states of high LH secretion  127 
4.4 Results 
4.4.1 NK3R antagonist decreases LH but not FSH secretion 
Analysis of single time point blood samples (with sampling before drug 
administration) showed that treatment with NK3R antagonist had a marginal 
suppressive effect on LH secretion (ANOVA p=0.008), lowering it on day 7 of 
treatment (pre-treatment 29.5±4.1 vs 24.4±3.8 IU/l day 7, p<0.05) (Fig. 4.3A) with 
no difference from pre-treatment on other sampling days. A more detailed analysis of 
LH secretion every 10 minutes for 6 hours pre-treatment and on day 7 of NK3R 
antagonist administration showed no difference in AUC LH (Fig. 4.3B). FSH 
secretion was unchanged by the NK3R antagonist (Fig. 4.3C). 
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Figure 4.3 Gonadotropin response to administration of NK3R antagonist in healthy 
postmenopausal women.  
(A) LH concentrations during 7 day course of NK3R antagonist treatment (blood samples taken once 
daily) and (B) AUC LH during 6 hours of 10 minute LH sampling pre-treatment and on day 7 of 
NK3R antagonist administration. (C) FSH response to NK3R antagonist. Data are presented as mean 
± SEM. * p<0.05 vs pre-treatment.  
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4.4.2 NK3R antagonist modulates pulsatile LH secretion in 
postmenopausal women 
An example of an LH pulse frequency profile is shown in figure 4.4 (A). Consistent 
with reduced mean LH secretion on day 7 of treatment, deconvolutional analysis 
showed that the NK3R antagonist decreased basal (i.e. nonpulsatile) LH secretion 
(p=0.006), although LH pulse frequency did not change with NK3R antagonist in the 
group as a whole (0.8±0.1 vs 0.7±0.1 pulses/hr, ns) (Fig. 4.4 B and C). Secretory 
mass per LH pulse was increased with NKR3 antagonist treatment (p=0.01) (Fig. 
4.4D) with no overall effect on total amount of LH secreted in a pulsatile manner 
(Fig. 4.4E) and there was no change in ApEn, the orderliness of LH secretory pattern 
(Fig. 4.4F).  
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Figure 4.4 Analysis of 6 hour LH secretory 
pattern on day 7 of NK3R antagonist 
treatment compared to control pre-treatment 
day in healthy postmenopausal women. 
Illustrative LH pulse profile from one subject 
(A) undergoing 10 minute blood sampling for 
LH for 6 hour with no NK3R antagonist 
treatment (black circles) and on day 7 of NK3R 
antagonist treatment (red squares). LH pulse 
frequency (B), basal (nonpulsatile) LH secretion 
(C), mass of LH per pulse (D), pulsatile LH 
secretion (E) and the relative 
orderliness/regularity of LH secretory pattern 
(F) on day 7 of NK3R antagonist treatment was 
compared to pre-treatment day in all 
postmenopausal women (n=11). Data are 
presented as mean ± SEM. *, p<0.05; **, p<0.01. 
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4.4.3 KP-10 does not elicit gonadotropin response with or without 
NK3R antagonist  
Intravenous KP-10 was administered at 6 hours of frequent sampling, with 2 hours 
sampling thereafter.  KP-10 had no effect on LH and AUC LH and FSH secretion in 
postmenopausal women, and this response was not affected by the NK3R antagonist 
treatment (Fig. 4.5).  
 
Figure 4.5 LH, AUC LH and AUC FSH response to KP-10 injection with and without NK3R 
antagonist in postmenopausal women. 
Mean LH (A) and AUC LH (sampling every 10 minutes) (B) and AUC FSH (sampling every hour) 
(C) were compared over one hour before KP-10 administration (i.e. at 6 hours) with 2 hours post KP-
10 administration, before and after 7 days of NK3R antagonist treatment during frequent blood 
sampling (n=10). Data are presented as mean ± SEM. 
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4.4.4 NK3R antagonist reduces self-reported postmenopausal hot 
flushes 
Hot flush frequency, severity and interference with daily activities were recorded in 
the 8 of 11 postmenopausal women experiencing these symptoms, for 7 days pre-
treatment and whilst on NK3R antagonist. These women reported a reduction in hot 
flush frequency (3.4±1.2 to 1.0±0.6 hot flushes/day with NK3Ra, p=0.008) and 
night-time awakenings as a result of those flushes (1.6±0.3 to 0.4±0.2 
awakenings/night with NK3Ra, p=0.008) whilst on NK3R antagonist (Fig. 4.6 A and 
B). There was also an improvement in the severity of flushing symptoms from 
moderate (heat and sweating, not causing disruption to activity) to mild (heat and no 
sweating) (mean severity 2.1±0.2/3 vs 1.4±0.1/3 with NK3Ra, p=0.03) with the 
NK3R antagonist (Fig. 4.6C). The time-course of changes in day-time hot flushes 
across 7 days of NK3R antagonist administration was analysed (p<0.0001), showing 
significantly lower hot flush frequency on the 2nd day of treatment (p<0.05 vs 
baseline) and thereafter each day for the remainder of NK3Ra administration (p<0.05 
at day 3-7 vs baseline) (Fig. 4.6D). Night-time awakenings as a result of those 
flushes also showed a rapid decrease in frequency with the NK3R antagonist and 
were reduced throughout treatment (p=0.0003) (Fig. 4.6E).  
 NK3R antagonist reduced total hot flush-related daily interference scale (HFRDIS) 
score (31.3±7.7 vs 9.0±4.7, p=0.008), indicating significantly reduced interference of 
hot flushes with daily function (Table 4.1). The highest mean interference rating was 
noted for sleep, which was improved by the NK3R antagonist (6.4±0.8 vs 1.1±0.6, 
p=0.008). Whilst all other individual HFRDIS items also showed a reduction in the 
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Figure 4.6 Differences in the frequency and severity score of menopausal hot flushes pre-
treatment and during 7 days of NK3R antagonist administration.  
Response to NK3R antagonist is shown for individual postmenopausal women for the frequency of 
day (A) and night-time (B) hot flush and their severity (C) over 7 days before and during NK3R 
antagonist administration. Time-course in the reduction of day (D) and night-time (E) hot flush 
frequency over 7 days of NK3R antagonist administration is compared to pre-treatment period. Data 
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Hot Flush Interference Pre-treatment (n=8) NK3Ra (n=8) p value 
Total Hot Flush-Related Daily 
Interference Scale (HFRDIS) Score 
31.3 (7.7) 9.0 (4.7) 0.008 
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Table 4.1 Differences in hot flush-related daily interference scale scores pre-treatment and 
during 7 days of NK3R antagonist administration.  
Total and individual item HFRDIS scores in 8 postmenopausal women are shown. Data are presented 
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4.4.5 NK3R antagonist decreases LH pulse frequency in 
postmenopausal women with hot flushes 
Figure 4.7 (A and G) shows examples of LH pulse frequency profile of a 
postmenopausal woman reporting hot flushes and one not having such symptoms. 
Although LH pulse frequency was not affected by the NK3R antagonist in a group as 
a whole (Fig. 4.4), in a secondary analysis of the 8 of 11 women with self-reported 
symptomatic hot flushes, NK3R antagonist reduced both basal LH secretion (p=0.03) 
and the frequency of LH pulses (1.0±0.1 vs 0.7±0.1 pulses/hr, p<0.05) (Fig. 4.7 H 
and I). The mass of LH per pulse was increased (p=0.04), although pulsatile LH 
secretion remained unchanged (Fig. 4.7 J and K). The orderliness (ApEn) of LH 
secretory pattern was unaffected by treatment in those with flush symptoms (Fig. 
4.7L).  
4.4.6 Tolerability and safety 
NK3R antagonist was well tolerated with no subject discontinuing the treatment 
during the study, and no adverse effects were reported during KP-10 administration. 
Haematology and biochemistry safety parameters remained stable in all subjects 
throughout the study period.  
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Figure 4.7 Comparison of LH secretory pattern with and without NK3R antagonist treatment in 
healthy postmenopausal women as a group and in those experiencing hot flushes only.  
Illustrative LH pulse profile from two subjects (A with no flushes, G with flushes) undergoing 10 
minute blood sampling for LH for 6 hour with no NK3R antagonist treatment (black circles) and on 
day 7 of NK3R antagonist treatment (red squares). LH pulse frequency (B and H), mean basal 
(nonpulsatile) LH secretion (C and I), mass of LH per pulse (D and J), pulsatile LH secretion (E and 
K) and the relative orderliness/regularity of LH secretory pattern (F and L) on day 7 of NK3R 
antagonist treatment was compared to pre-treatment day in all postmenopausal women (n=11) and in a 
subgroup of women reporting hot flushes (n=8). Note that data in left panel is taken from Fig. 4.4 for 
the ease of pulsatile LH secretion comparison between all women versus those with subjective hot 
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4.5 Discussion 
This study has investigated for the first time the role of neurokinin B and its 
interaction with kisspeptin in the regulation of GnRH and LH secretion in a state of 
high LH pulsatility in health, the postmenopausal woman. Selective blockage of 
NKB signalling had only a very limited suppressive effect on LH secretion as 
assessed on daily sampling with no detected effect on FSH release. Blood sampling 
during NK3R antagonist administration was performed before the morning dose, i.e. 
12 hours after the previous treatment and may have missed subtle changes in 
gonadotropin secretion. The importance of the sampling schedule is indicated by the 
significant effect of the NK3R antagonist on parameters of pulsatile LH secretion, 
which were measured over 6 hours immediately following drug administration.  The 
NK3R antagonist reduced basal LH secretion, demonstrating the involvement of 
NKB signalling in the regulation of the hypergonadotropic state in postmenopausal 
women.  The effect of NKB on pulsatile GnRH secretion is further supported in a 
subgroup of women experiencing hot flushes where a reduction in LH pulse 
frequency was identified. These women also reported a marked reduction in flush 
symptoms whilst on NK3R antagonist consistent with a link between GnRH/LH 
pulsatility and vasomotor symptoms (Rance et al. 2013). 
These data show that in postmenopausal women NK3R antagonist preferentially 
decreased LH but not FSH secretion. This pattern of effect of NK3R antagonist is 
consistent with data from patients with inactivating mutations in NKB pathway who 
display reduced LH levels but near normal FSH secretion, likely mediated through 
decreased GnRH pulse frequency (Young et al. 2013). While the present study has 
shown that in postmenopausal women high LH output can be altered by the NK3R 
antagonist, LH pulse frequency in the group as a whole, the proportion of total LH 
secreted in pulses and the regularity of LH secretion were not affected. Mass of LH 
secreted per pulse was increased with the NK3R antagonist, although this may be 
due to LH pulses merging in postmenopausal women without return to basal 
secretion thereby giving an apparent greater LH secretory mass per pulse. However, 
the LH response in this study is in contrast to the only previous data from a high LH 
output state in humans, which is in women with PCOS, where the frequency of LH 
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pulses was decreased by the NK3R antagonist after 7 days administration at the dose 
used here (George et al. 2016) and similar findings in ovariectomised ewes using a 
different NK3R antagonist MRK-08 (Li et al. 2015). Duration and/or dose of NK3R 
antagonist administration in this study may have contributed to the limited 
suppressive effect seen on LH/GnRH secretion in contrast to hypogonadotropic 
hypogonadism observed in patients with loss-of-function mutations in NKB and its 
receptor (Young et al. 2013) or NK3R antagonist administration for 4 weeks in 
women with PCOS (George et al. 2016). Additionally, pulsatility analysis in high 
frequency states can be challenging, with discrimination of discrete pulses difficult. 
Inability to manipulate high LH secretion by the NK3R antagonist in menopausal 
women may reflect estrogen depletion, and high activity of the NKB pathway. 
Increased expression of hypothalamic TAC3 mRNA after ovariectomy in animal 
models is restored with estrogen replacement (Rance and Bruce. 1994, Abel et al. 
1999, Sandoval-Guzman et al. 2004, Navarro et al. 2009, Eghlidi et al. 2010), and 
sex-steroid receptors are known to localise to the NKB perikarya (Rance et al. 1990, 
Rance and Young. 1991), clearly supporting a role of estrogenic feedback in the 
regulation of NKB signalling. It seems plausible that loss of negative estrogen 
feedback following the menopause impedes the ability to manipulate the 
NKB/KP/GnRH pathway as readily as in other states. Although LH secretion was 
reduced with the NK3R antagonist in an animal model of menopause, the 
ovariectomised ewes (Li et al. 2015) and in castrate monkeys (Fraser et al. 2015a), 
treatment was administrated centrally, and species difference precludes direct 
comparison of the result, especially since there is anatomical variation in pathways 
mediating sex-steroid feedback between the humans and other mammals (Smith et al. 
2005a, Smith et al. 2006b, Rometo et al. 2007, Herbison. 2008).  
The lack of KP-10 effect on gonadotropin secretion seen in this study is consistent 
with previous data showing minimal LH response to both KP-10 and GnRH injection 
in postmenopausal women as opposed to women in the early follicular phase of the 
menstrual cycle or taking hormonal contraceptives (George et al. 2012). This further 
highlights the role of sex-steroid feedback in the control of hypothalamic 
neuropeptide signalling. It seems likely that due to loss of negative estrogen 
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feedback post menopause, the kisspeptin system is already operating at its maximum 
to increase GnRH and LH secretion with little scope for further a stimulatory effect 
of exogenous kisspeptin. This is supported by hybridization histochemistry showing 
that in the postmenopausal infundibular nucleus kisspeptin neurones are 
hypertrophied, their number is increased, and they have increased expression of both 
KISS1 and TAC3 mRNA (Sheehan and Kovacs. 1966, Rance et al. 1990, Rance and 
Young. 1991, Rometo et al. 2007). The absence of an effect of KP-10 on LH alone or 
in the presence of NK3R antagonism precludes clear analysis of the hierarchical 
relationship between kisspeptin and NKB in the postmenopausal women. It would be 
of interest to repeat the experiment in postmenopausal women taking estrogen 
replacement. 
Interestingly, the NK3R antagonist reduced LH pulse frequency in postmenopausal 
women reporting hot flushes only, despite the smaller sample group. It is however 
unclear as to whether NKB acts to modulate GnRH/LH pulsatility specifically in 
those experiencing flush symptoms, as larger groups would be required to explore 
this more robustly. In this study, postmenopausal women were not recruited based on 
their hot flushes and statistical comparisons between those with and without flushing 
were not feasible since there were only 3 women in the latter subgroup. Small 
sample size may have impacted overall effect seen on LH pulsatility. It is however 
possible that the NKB pathway is somewhat different and is enhanced in women 
with hot flushes, thereby being more responsive to suppression by the NK3R 
antagonist.  
The finding that all postmenopausal women with symptomatic flushes (8/11) 
reported a reduction in the frequency of total and night-time hot flushes whist on 
NK3R antagonist and an improvement in their severity from moderate to mild is a 
striking and novel finding. The response to NK3R antagonist in the reduction of 
flush symptoms was also a rapid one, with a significant fall in both day time and 
night time symptoms after only 2 days of treatment. The NK3R antagonist also 
reduced the interference of those flushes with daily activities. The present data 
implicate NKB as a key link between sex-steroid deficiency and hot flushes, as 
proposed from studies in animal models (Rance et al. 2013). In premenopausal 
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women neurokinin B itself administered as an intravenous infusion over 30 minutes 
induced the sensation of heat, which was accompanied by increased heart rate and 
skin conductance, resembling events associated with menopausal hot flushes 
(Jayasena et al. 2015b). Moreover, a recent genome-wide association study has 
localised single-nucleotide polymorphisms associated with vasomotor symptoms to 
the neurokinin 3 receptor locus (TACR3) (Crandall et al. 2016). Reduced cutaneous 
vasodilation in rodents with ablation of NKB-expressing neurones (Mittelman-Smith 
et al. 2012) and lowered body core temperature in NK3R antagonist treated sheep 
(Fraser et al. 2015a) lend further support for the involvement of NKB signalling in 
hot flushes. Reduction in the frequency of LH pulses by the NK3R antagonist 
observed here suggests the mechanism of flushes to be tied to the hypothalamic 
control of pulsatile GnRH secretion, although the degree of fall in LH pulsatility was 
much less than the fall in hot flush frequency. This is consistent with studies showing 
the synchronization of LH pulses with hot flushes in women (Casper et al. 1979, 
Rance et al. 2013, Oakley et al. 2015). Although these data support the involvement 
of NKB in vasomotor symptoms, it remains possible that separate pathways exist 
mediating hot flushes and those associated with pulsatile GnRH/LH secretion, with 
both involving NKB regulation.  
The limitation of the absence of a placebo group in the present study is 
acknowledged, as well as the small number of women studied. Placebo has been 
shown to reduce hot flushes by 20-30% within 4 weeks of treatment and in 15% of 
women experiencing symptomatic flushes (Sloan et al. 2001, Boekhout et al. 2006). 
In contrast, NK3R antagonist treatment in this study was associated with 
approximately 70% reduction in hot flushes over only 7 days of treatment and in all 
8 women reporting hot flushes. Subjective reporting of hot flushes is currently the 
most accurate method for detection and assessment of those flushes and is the 
method of choice in clinical studies in the field (Guttuso et al. 2012, Sievert. 2013, 
Joffe et al. 2014). Objective assessment of menopausal hot flushes, such as using 
skin conductance monitors would have reinforced the findings but was not 
performed in this study. This group had a lower hot flush frequency than is generally 
the case in studies specifically investigating therapies for that condition (Carpenter. 
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2001), reflecting recruitment criteria not specifying the presence of or a minimum 
flush frequency.  Whether NK3R antagonist has a therapeutic potential in the non-
steroidal management of hot flushes remains to be established. Nevertheless, the 
findings above form a strong basis for this. 
In summary, a state of high LH secretory pattern in postmenopausal women is 
relatively refractory to manipulation by the NK3R antagonist and kisspeptin but 
effects on LH pulsatility were demonstrated. The absence of a response to 
kisspeptin-10 precluded investigation of the relationship between the NKB and 
kisspeptin pathways in the postmenopause. We have shown that NK3R antagonist 
reduced subject reported menopausal hot flushes and reduced the frequency of LH 
pulses in those women. These data demonstrate that NKB signalling is involved in 
the regulation of LH secretion in the hypergonadotropic state of the menopause and 
provide indirect evidence linking vasomotor symptoms and high GnRH/LH pulse 
frequency to the NKB pathway. Although our data are based on small numbers and 
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Chapter 5. Neurokinin B in the regulation of ovarian function 
in healthy women in the early follicular phase of 
menstrual cycle 
5.1 Introduction 
In Chapter 3 and 4, the role of NKB in states of slow and high LH pulsatility was 
investigated. In healthy men and postmenopausal women NKB action was found to 
be through GnRH secretion by modulating its basal i.e. nonpulsatile release with no 
effect of the frequency of LH/GnRH pulses in those groups. Whilst changes in 
pulsatile LH/GnRH secretion had a marked effect on serum LH and testosterone 
levels in men, manipulation of the NKB/GnRH/gonadotropin pathway was rather 
refractory in postmenopausal women. This suggests that sex-steroid feedback is 
important in modulating downstream effects of NKB on GnRH secretion, although 
sex-specific differences in the importance of the NKB pathway may also be relevant, 
given the differences in the number of NKB expressing neurones (Goubillon et al. 
2000), their fibre distribution (Ciofi et al. 2006) and postnatal development of 
hypothalamic NKB neuronal network (Ciofi et al. 2007) in males compared to 
females. However, the involvement of NKB in GnRH/LH pulsatility with the 
varying sex-steroid milieu across the menstrual cycle in healthy premenopausal 
women has not yet been explored. 
NKB is a key modulator of GnRH and hence gonadotropin secretion, as loss-of-
function mutations in genes encoding neurokinin B (TAC3) and neurokinin-3 
receptor (TACR3) result in hypogonadotropic pubertal delay (Topaloglu et al. 2009). 
However, the converse stimulatory effect of NKB on gonadotropin secretion was not 
seen in the only human study to date administering NKB as an intravenous infusion 
over 3 hours during the follicular, pre-ovulatory and mid-luteal phases of the 
menstrual cycle in healthy women (Jayasena et al. 2014c). Data from animal studies 
are also inconclusive with both stimulatory and inhibitory effects of NKB reported 
(Billings et al. 2010, Navarro et al. 2011a, Ramaswamy et al. 2011). In rodents, 
neurokinin B decreased LH secretion in ovariectomised animals (Sandoval-Guzman 
and Rance. 2004, Navarro et al. 2009), but in intact male mice had no effect on LH 
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secretion (Corander et al. 2010), whereas in diestrus and proestrus female rats NK3R 
agonist induced LH secretion (Navarro et al. 2011a), suggesting the action of 
neurokinin B to be dependent on circulating sex-steroids. In higher species, the 
stimulatory role of neurokinin B on LH secretion is more consistent and has been 
observed in ewes (Billings et al. 2010, Li et al. 2015), goats (Wakabayashi et al. 
2010) and monkeys (Ramaswamy et al. 2010).  
Similarly to patients with inactivating mutations in the NKB pathway (Topaloglu et 
al. 2009), studies involving selective blockade of NK3R have been more consistent 
in demonstrating a suppressive effect on LH but not FSH secretion. When 
administrated to gonadectomised ewes, the NK3R antagonist (ESN364 and MRK-
08) decreased LH secretion and pulse frequency (Fraser et al. 2015a, Li et al. 2015) 
with similar findings observed in women with PCOS administered AZD4901, a 
condition also characterised by high LH pulse frequency (George et al. 2016). 
Administration of the NK3R antagonist ESN364 throughout the follicular phase in 
intact female monkeys inhibited estradiol secretion, with no LH surge or subsequent 
rise in serum progesterone (Fraser et al. 2015a), suggesting the role of NKB in 
regulation of female reproduction. Follicle development was not assessed in this 
study, but antagonism of NK3R was associated with reduced ovarian weight and 
absence of normal cyclical changes seen in the uterine mucosa, the effects which 
were reversible upon discontinuation of NK3R antagonist (Fraser et al. 2015a). 
However, the role of NKB in regulating gonadotropin secretion and ovarian function 
in healthy women was then unknown, and this study was designed to determine this 
in premenopausal women.  
During the preparation of this thesis, data on the effects of the NK3R antagonist 
ESN364 administered in healthy women for 21 days initiated early in the follicular 
phase were published (Fraser et al. 2016). NK3R antagonist in those women 
decreased estradiol secretion and affected the LH surge, which was variably delayed 
but not completely abolished (Fraser et al. 2016). As a result of the delayed LH 
surge, progesterone rise was inhibited and menstrual cycle length was also 
prolonged, although no significant changes in follicle development were observed 
(Fraser et al. 2016). The NK3R antagonist did not affect basal LH levels and changes 
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in GnRH/LH pulsatility were not investigated. The mechanisms by which NK3R 
antagonist regulates ovarian function therefore remain unclear. NK3R has been 
localised to human granulosa cells (Cejudo Roman et al. 2012, Garcia-Ortega et al. 
2014, Garcia-Ortega et al. 2016). The effects of NK3R antagonism on LH pulsatility 
and ovarian follicle development was therefore determined in premenopausal women 
during the follicular phase of the menstrual cycle to investigate the possible 
contribution of NKB signalling to the regulation of follicle development.  
5.2 Objectives 
The objectives of this study were to investigate the effect of NK3R antagonism in the 
follicular phase in healthy women on: 
1) gonadotropin and ovarian hormone secretion; 
2) LH pulsatility; 
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5.3 Methods  
5.3.1 Participants 
Thirteen healthy premenopausal women, aged 27-41 years and with regular 
menstrual cycles (25-34 days) based on medical history were recruited into the study; 
all volunteers provided informed written consent. Subjects were not taking any 
hormonal contraception nor had a copper intrauterine device in situ. They were 
eligible based on inclusion and exclusion criteria (Table 2.1 Inclusion and exclusion 
criteria, Chapter 2), had normal physical examination and negative urine pregnancy 
test. Full blood count, renal function, electrolytes, liver function and 
electrocardiogram were within normal limits.  
5.3.2 Study drugs 
The specific neurokinin-3 receptor (NK3R) inhibitor AZD4901 was administered 
orally at 40 mg twice daily.  
5.3.3 Protocol 
Investigation of the effect of NK3R antagonism on gonadotropin and ovarian 
hormone secretion.  
Schematic presentation of the protocol is shown in Figure 5.1. Volunteers were 
administered the NK3R antagonist for 7 days starting on cycle day 5-6. All women 
had a no treatment control cycle, and a treatment cycle, the order of cycles being 
randomised. Peripheral venous blood was sampled for spot LH, FSH, inhibin B and 
estradiol immediately before treatment (pre-treatment), on days 2, 4 and 6 of NK3R 
antagonist administration, in the morning following the last dose and then every 2-4 
days until ovulation was confirmed by transvaginal ultrasonography. Ovulation was 
defined either by the last day on which the pre-ovulatory follicle was seen or 
appearance of a corpus luteum. In the control cycle interval blood sample timing was 
equivalent to that in the treatment cycle. Once daily blood sampling was performed 
in the morning: during treatment, this was immediately prior to the next dose of 
NK3R antagonist, i.e. 12 hours after the previous dose. Urine was collected daily for 
progesterone until the next menstrual period.  
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Figure 5.1 Study protocol. 
13 healthy women were administered the NK3R antagonist AZD4901 orally for 7 days from cycle 
day 5-6. Reproductive hormones were measured and transvaginal ultrasonography was performed 
throughout the study.  Urine samples were collected daily until the next menstrual period. LH 
pulsatility (n=8) was assessed during 8 hours of 10 minute blood sampling on day 6 or 7 of NK3R 
antagonist administration or equivalent day of the control cycle. Reproductive hormones and 
ultrasound scan findings were compared to the control cycle, the order of cycles being randomised. 
LMP, last menstrual period; NMP, next menstrual period; TV USS, transvaginal ultrasonography; 
BD, twice daily. 
Investigation of the effect of NK3R antagonism on follicle development and 
endometrial thickness.  
Transvaginal ultrasonography was used to measure the diameter of the leading 
follicle, any follicles of ≥10 mm in diameter, endometrial thickness and appearance 
of corpus luteum. Ultrasound scans were performed with the same schedule as 
assessment of reproductive hormones. 
Investigation of the effect of NK3R antagonism on LH pulsatility.  
Assessment of LH pulsatility was performed in 8 of the 13 women. On day 6 or 7 of 
NK3R antagonist treatment volunteers attended the clinical research facility for 8 
hours. All visits commenced between 0800 and 0900 hours to avoid diurnal 
variation. Blood samples were collected via an indwelling intravenous cannula at 10 
min intervals for 8 hours. The dose of NK3R antagonist was administered 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
NKB in different sex-steroid milieu  148 
immediately prior to the start of sample collection. In control cycle, frequent 
sampling was performed on cycle day 10-12, i.e. on the equivalent cycle day to that 
in the treatment cycle.  
Safety profile.  
Safety blood tests including full blood count, renal function and electrolytes, and 
liver function were checked before commencing the NK3R antagonist, after the 
treatment had finished and 2-3 weeks later.  
5.3.4 Analytical methods 
Hormone assays, analysis of pulsatile LH secretion and safety blood tests were 
performed as described in Chapter 2. 
5.3.5 Statistical analysis 
Data were assessed for Gaussian distribution by Shapiro-Wilk normality test (for 
data points ≥7) or Kolmogorov-Smirov test as appropriate (for data points <7).  
Baseline characteristics between the control and NK3R antagonist-treated cycles 
were compared by Student’s paired t-test (for normally distributed data: LH, FSH, 
estradiol, follicle size) or Wilcoxon matched-pairs signed rank test (for data that did 
not have a normal distribution: menstrual cycle day). Hormone concentrations and 
ultrasonography data were compared throughout 7 days of NK3R antagonist 
treatment and between the control and treatment groups using repeated measure two-
way ANOVA followed by Bonferroni’s multiple comparisons post hoc analysis. 
Peak serum hormone concentration, size of the pre-ovulatory follicle and their peak 
cycle timing were compared by Student’s paired t-test. Urinary progesterone 
concentrations, normalised to creatinine concentrations, were available for 11 
women. Mid-luteal (i.e. LH surge +7 days) urinary progesterone levels and cycle 
length were compared by Student’s t-test. Characteristics of pulsatile LH secretion 
were compared in 8 subjects by paired Student’s t-test. Data are presented as mean ± 
SEM. 
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5.4 Results 
5.4.1 Baseline characteristics 
Each subject took part in the control and treatment cycle, which were comparable by 
cycle day on which the study had started, baseline serum LH, FSH and estradiol 
concentrations, and the size of the largest ovarian follicle present at that time (Table 
5.1).  
 
Characteristic Control cycle NK3Ra cycle p value 
Cycle day study commenced 5.6 ± 0.2 5.0 ± 0.2 0.06 
LH (IU) 4.9 ± 0.5  4.8 ± 0.4 0.98 
FSH (IU) 5.1 ± 0.8 5.3 ± 0.9 0.82 
Estradiol (pmol/l) 160 ± 19 126 ± 13 0.07 
Follicle diameter (mm) 8.4 ± 0.4 8.1 ± 0.3 0.54 
Table 5.1 Basic characteristics of the participants.  
5.4.2 NK3R antagonist does not affect basal LH secretion but 
delays mid-cycle LH surge 
NK3R antagonist had no effect on LH secretion during single timepoint analysis 
(Fig. 5.2A) and 8 hours of frequent LH sampling every 10 minutes (Fig. 5.2E). 
However, the LH surge was significantly delayed in the NK3R antagonist cycle by 7 
days, i.e. the duration of treatment (cycle day: 22±1 vs 15±1, p=0.0006) (Fig. 5.2A 
and 5.6A). There was no effect on the magnitude of the peak of mid-cycle LH 
secretion (23.4±4.8 with NK3R antagonist vs 19.7±3.2 IU/l, ns [data not shown]).  
5.4.3 NK3R antagonist has differential effect on FSH secretion 
FSH secretion was unchanged with the NK3R antagonist on single day sampling 
(Fig. 5.2B). To detect subtle changes in hormone secretion over time potentially 
overlooked by performing single time spot blood sampling, a more detailed analysis 
of FSH secretion every hour for 8 hours post NK3R antagonist dose showed an 
increase in FSH secretion throughout the 8 hour-period with the NK3R antagonist 
administration compared to control cycle (ANOVA p<0.03, Fig. 5.2F) with FSH 
concentrations being higher at each hour sampled (p<0.05 at every hour, Fig. 5.2F).  
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Figure 5.2 Reproductive hormone response in premenopausal women in the control and NK3R 
antagonist-treated cycles. 
Mean serum LH (A), FSH (B), estradiol (C) and inhibin B secretion (D) with and without NK3R 
antagonist was compared in premenopausal women (n=13) by repeated measure two-way ANOVA at 
timepoints when paired data was available (i.e. between cycle days 5-16/18 inclusive) followed by 
Bonferroni’s multiple comparisons post hoc analysis. (E) LH concentrations during frequent every 10 
minute blood sampling and (F) FSH concentrations during hourly blood sampling for 8 hours post 
NK3R antagonist administration on day 6-7 compared to no treatment control cycle in premenopausal 
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5.4.4 NK3R antagonist delays estradiol rise, which resumes after 
stopping the treatment 
Estradiol concentration was significantly lower at each timepoint throughout 
treatment (p<0.05 vs pre-treatment) (Fig. 5.2C). At the end of NK3R antagonist 
administration (166±29 vs control 446±86 pmol/l day 12, p<0.0001), estradiol 
concentrations remained similar to baseline levels on cycle day 5 (126±16 pmol/l, 
ns). After NK3R antagonist treatment, estradiol concentrations rose, reaching pre-
ovulatory levels comparable to those in control cycles (690±68 with NK3R 
antagonist vs 699±62 pmol/l, ns [data not shown]) but 7 days later (cycle day 21±1 
vs 14±1, p=0.002) (Fig. 5.6B). 
5.4.5 NK3R antagonist effects on inhibin B secretion 
Inhibin B secretion (a marker of small follicle development) was slightly reduced 
during NK3R antagonist administration, but this did not reach statistical significance 
(Fig. 5.2D). 
5.4.6 NK3R antagonist delays follicle growth, which resumes after 
stopping the treatment 
Follicle growth was suppressed and delayed in the NK3R antagonist treatment 
cycles, closely matching the changes in estradiol secretion. Figure 5.3A shows 
follicle growth until ovulation for each subject in the control and NK3R antagonist-
treated cycle, with mean data in Figure 5.3B. While there was a progressive rise in 
diameter of the leading follicle in control cycles, this did not occur during 7 days of 
NK3R antagonist treatment (ANOVA p=0.0003). The diameter of the leading follicle 
was significantly smaller than in controls at each timepoint throughout 7 days of 
treatment (p<0.05 vs pre-treatment) and at the end of NK3R antagonist i.e. on cycle 
day 12 (9.3±0.4 vs 15.1±0.9 mm, p<0.0001) (Fig. 5.3B). After treatment normal 
follicle development resumed, reaching the same pre-ovulatory follicle size as in 
controls (16.1±0.7 with NK3R antagonist vs 17.2±0.7 mm, ns) but later (cycle day: 
21±1 vs 15±1, p=0.002) (Fig. 5.6C).  
NK3R antagonist delayed ovulation in 11 of 13 subjects. One subject had earlier 
ovulation with NK3R antagonist compared to her control cycle and one subject 
ovulated on the same day with or without the NK3R antagonist treatment (Fig. 5.3C). 
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Figure 5.3 Follicle development in 13 premenopausal women in the control and NK3R 
antagonist-treated cycle until ovulation. 
(A) Follicle growth in each of the 13 premenopausal women showing delayed development with the 
NK3R antagonist treatment (red squares) compared to the control cycle (black circles). (B) Mean 
follicle diameter in the control and NK3R antagonist-treated cycle. Data include all cycles where the 
leading follicle remained i.e. only include women who had not yet ovulated at the later time points. 
(C) Table showing the timepoint in the control and NK3R antagonist cycle at which the leading 
follicle was no longer identified at transvaginal ultrasonography. Data were compared by repeated 
measure two-way ANOVA at timepoints when paired data was available (i.e. between cycle days 5-12 
inclusive) followed by Bonferroni’s multiple comparisons post hoc analysis. Data are presented as 
mean ± SEM. *, p<0.05;  ****, p<0.0001.  
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5.4.7 NK3R antagonist delays endometrial development 
Endometrial development was also affected by the NK3R antagonist treatment 
(p<0.0001), being significantly thinner than in controls at the end of treatment 
(4.6±0.4 vs 7.7±0.5 mm day 12, p<0.0001) (Fig. 5.4).  Thereafter endometrial 
thickness increased, reaching a similar thickness to that in control cycles at the time 
of ovulation (8.9±0.6 vs 9.5±1.0 mm, ns). 
 
 
Figure 5.4 Endometrial development in 13 premenopausal women in the control and NK3R 
antagonist-treated cycle.  
NK3R antagonist was administered from average cycle day 5 for 7 days with the last treatment day on 
average cycle day 11. Mean endometrial thickness was compared by repeated measure two-way 
ANOVA at timepoints when paired data was available (i.e. between cycle days 5-16/18 inclusive) 
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5.4.8 NK3R antagonist delays luteal progesterone rise 
Consistent with the above demonstration of delayed ovulation, NK3R antagonist 
delayed the cycle day of mid-luteal progesterone  (cycle day LH surge +7: 30±2 vs 
22±1, p=0.002) (Fig. 5.6D). However, when standardised against the day of the LH 
surge, luteal function was not affected by the NK3R antagonist (urinary progesterone 
58±10 vs 48±7 pmol/mol creatinine on LH surge day +7, ns) (Fig. 5.5). 
   
 
Figure 5.5 Mean urinary progesterone/creatinine ratio with and without NK3R antagonist in 11 
premenopausal women adjusted to LH surge onset day 0. 
 
 
5.4.9 NK3R antagonist prolongs menstrual cycle length 
Menstrual cycle length was prolonged by approximately 6 days with the NK3R 
antagonist further supporting delayed ovulation in the treatment group (35±1 vs 29±1 
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Figure 5.6 Summary of the delay in timing of key events in female reproduction with the NK3R 
antagonist compared to no treatment control cycle in premenopausal women.  
Individual subject (n=13) response to NK3R antagonist showing delay in menstrual cycle day for LH 
surge (A), peak estradiol (B), appearance of the largest diameter of the pre-ovulatory follicle (C), mid-
luteal urinary progesterone (day at surge +7, n=11) (D), and the length of menstrual cycle (E). Note 
that two subjects in figure (B) and (C) had the same cycle days for the events described.  **, p<0.01; 
***, p<0.001.  
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5.4.10 NK3R antagonist effects on pulsatile LH secretion 
Assessment of pulsatile LH secretion was performed in 8 of the 13 women on day 6 
or 7 of NK3R antagonist treatment and on the equivalent day of the control cycle. An 
example of an LH pulse frequency profile is shown in Figure 5.7A. Although LH 
pulse frequency did not change with the NK3R antagonist (0.69±0.1 vs 0.66±0.1 
pulses/hr, ns), basal (i.e. nonpulsatile) LH secretion was reduced (p<0.05) (Fig. 5.7B 
and C). NK3R antagonist had no overall effect on secretory mass of LH per pulse 
(Fig. 5.7D) and total amount of LH secreted in a pulsatile manner (Fig. 5.7E). A 
slight improvement in the orderliness of LH secretory pattern approached statistical 
significance (p=0.054) (Fig. 5.7F).  
 
 
Figure 5.7 Pulsatile LH secretion in premenopausal women in the control and NK3R antagonist-
treated cycle.  
Illustrative LH pulse profile from one subject (A) undergoing 10 minute blood sampling for LH for 8 
hour with no NK3R antagonist (black circles) and on day 7 of NK3R antagonist treatment (red 
squares). Mean LH pulse frequency (B), basal (nonpulsatile) LH secretion (C), mass of LH per pulse 
(D), pulsatile LH secretion (E) and relative orderliness/regularity of LH secretory pattern (F) were 
compared between the control and NK3R antagonist-treated cycles (n=8). Data are presented as mean 
± SEM. *, p<0.05. 
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5.4.11 Tolerability and safety 
NK3R antagonist was well tolerated with no treatment discontinuations. No subjects 
reported menopausal symptoms whilst on NK3R antagonist, with estradiol remaining 
above 100 pmol/l. Haematology and biochemistry safety parameters remained stable 
in all subjects throughout the study period. All subjects returned to their usual 
menstrual cycle length following NK3R antagonist-treated cycle.  
5.5 Discussion 
This study has investigated the role of neurokinin B in regulating physiological 
follicle development and its hypothalamic action through the modulation of pulsatile 
GnRH/LH secretion in premenopausal women. NK3R antagonism for 7 days in the 
early follicular phase in healthy women suppressed follicle growth and estradiol 
secretion and delayed ovulation by the duration of treatment. Deconvolutional 
analysis of LH secretion showed a reduction of basal LH secretion, without a change 
in pulse frequency, whereas single timepoint analysis did not show an effect on LH 
release, probably because this was 12 hours after the previous NK3R antagonist 
dose. The half-life of AZD4901 is approximately 8.5 hours (Litman et al. 2014). 
However, FSH secretion was increased with the NK3R antagonist when analysed 
during frequent sampling over 8 hours post dosing. Taken together, this suggests that 
selective blockade of NK3R reduces follicular estradiol production and arrests 
follicle growth by reducing basal GnRH/LH secretion, and this effect persisted for 
the duration of treatment. These findings confirm an important role of NKB in 
human reproduction and provide clear evidence for NKB signaling in the 
physiological regulation of normal follicle development in women. 
A further striking finding was that the effect of NK3R antagonist were reversible 
after discontinuation of treatment, with normal follicle estradiol production and 
growth resuming, resulting in a normal LH surge and mid-luteal progesterone rise, 
all of which were delayed by the duration of treatment. This indicates that growth of 
the dominant follicle can be suspended by manipulation of the endocrine 
environment without atresia being inevitable, although oocyte competence for 
fertilisation was not tested. 
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The decreased estradiol secretion for the duration of 7-day treatment in healthy 
women was biologically relevant as shown by absent development of the 
endometrium during NK3R antagonist treatment, with later growth as follicle 
estradiol production increased after drug discontinuation. A recent study using a 
different NK3R antagonist (ESN364) in normal women for 21 days throughout the 
follicular phase failed to detect any significant suppression in follicle growth, despite 
other findings being consistent with our data, particularly a delayed LH surge in 
some women and prolongation of menstrual cycle length (Fraser et al. 2016). It is 
likely that the more variable effect on LH surge possibly due to ESN364 being less 
potent suppressor of basal LH secretion than AZD4901 used here precluded clear 
demonstration of an effect of folliculogenesis. While antral follicle development was 
clearly delayed by treatment with the NK3R antagonist in this study, there was not 
clear evidence of an effect on the growth of smaller follicles, as inhibin B levels were 
not significantly reduced. However, the markedly suppressed estradiol is likely to 
contribute to the increase in FSH secretion observed with the NK3R antagonist. FSH 
secretion is also promoted (relative to LH) by basal rather than pulsatile GnRH 
secretion (McNeilly et al. 2003), thus two mechanisms may contribute to the raised 
FSH concentrations observed. 
The absence of detectable effects of NK3R antagonist on LH secretion in this study 
is consistent with previous data showing only a temporary suppression of LH levels 
lasting few hours post dosing, but no overall decrease in gonadotropin secretion with 
a different NK3R antagonist (ESN364) throughout the follicular phase in normal 
women (Fraser et al. 2016) and in intact female monkeys (Fraser et al. 2015a). These 
findings are similar to minimal suppression on LH secretion observed in 
postmenopausal women in Chapter 4 after 7 days administration of the same dose of 
NK3R antagonist used here. However, marked decrease in LH secretion with the 
NK3R antagonist was shown in ovariectomised ewes (MRK-08) (Li et al. 2015) and 
castrate monkeys (ESN364) (Fraser et al. 2015a), although treatment was 
administered centrally and in much higher concentrations, respectively. It is possible 
that loss of negative feedback with decreased serum estradiol in this study limited the 
ability of NK3R antagonist to suppress LH secretion. Duration and/or dose of NK3R 
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antagonist and sampling regimen acknowledged above may have contributed to the 
lack of effects seen on LH secretion, especially as patients with loss-of-function 
mutations in NKB and its cognate receptor exhibit a significant phenotype of 
hypogonadotropic pubertal delay (Topaloglu et al. 2009). Ovulation was delayed in 
11 of the 13 women with two women being non-responders. This suggests that the 
dose and regimen used in this study may be at the bottom of the dose-response curve. 
It is possible that with higher doses of NK3R antagonist, a more marked inhibitory 
action on LH secretion would be observed. Nevertheless, consistent with the effects 
on pulsatile LH secretion, antagonism of NK3R resulted in marked ovarian effects: 
follicle maturation and ovarian hormone secretion were delayed, postponing the LH 
surge and subsequent luteal progesterone rise. The lower serum estradiol levels with 
the NK3R antagonist suggests that LH dependent secretion of thecal androgens was 
suppressed. Granulosa cell proliferation (and thus follicle growth) is predominantly 
driven by FSH, which was not suppressed but rather increased by the NK3R 
antagonist, an observation not reported in the previous studies. It may be that NK3R 
antagonist therefore exerts direct effects on granulosa cells (Cejudo Roman et al. 
2012, Garcia-Ortega et al. 2014, Garcia-Ortega et al. 2016). Reduction in ovarian 
weight was reported with 35-day administration of NK3R antagonist in intact female 
monkeys, although this was not associated with any histopathological findings in the 
ovary (Fraser et al. 2015a). Stromal atrophy and glandular inactivity in the uterine 
mucosa of those monkeys related to the NK3R antagonist were reversible upon 
cessation of drug treatment (Fraser et al. 2015a). This is consistent with the return of 
pre-treatment ovarian function and menstrual cycle length in women in this study 
after the NK3R antagonist has prolonged it.  Delay in key events in female 
reproductive cycle for the duration of NK3R antagonist administration, which was 7 
days in this study, lends further support for temporary treatment effects.  
The present study has for the first time investigated a hypothalamic mode of action 
of NKB in healthy women, showing that in the follicular phase NK3R antagonist 
reduced basal i.e. nonpulsatile LH and by inference GnRH secretion with no effect 
on pulse frequency. Marked suppression in LH secretion between the pulses is 
consistent with data from men and postmenopausal women shown in Chapter 3 and 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
NKB in different sex-steroid milieu  161 
Chapter 4, respectively. Changes in basal LH/GnRH secretion with no effect on 
pulse frequency in these studies were sufficient to decease LH secretion in 
postmenopausal women and LH and testosterone in men, and in premenopausal 
women suppressed ovarian follicle estradiol production and growth and delayed 
ovulation. This suggests that NKB signalling may be integral in regulating basal 
LH/GnRH secretion, and that the frequency of LH pulses is predominantly controlled 
by another hypothalamic peptide, such as kisspeptin (George et al. 2011, Young et 
al. 2013). In men and postmenopausal women, other parameters of LH secretory 
pattern were affected by the NK3R antagonist, including mass of LH secreted per 
pulse, pulsatile LH release and ApEn. Reduction in the frequency of LH/GnRH 
pulses by the NK3R antagonist has been demonstrated previously but only in state of 
high LH output, such as in women with PCOS (George et al. 2016) and in 
gonadectomised animals (Fraser et al. 2015a, Li et al. 2015). Patients with 
inactivating mutations in NKB pathway had diminished LH pulse frequency (Young 
et al. 2013) and therefore it remains possible that with larger doses of NK3R 
antagonist such effect would be observed in healthy women. There are no other 
published data to compare the effect of NKB antagonism on LH/GnRH pulsatility in 
health, and the only study administering NKB itself as an infusion over 8 hours in 
men showed no effect on any parameters of pulsatile LH secretion (Jayasena et al. 
2014c). Taken together these data suggest that downstream ovarian effects of NK3R 
antagonist in premenopausal women are mediated via modulation of basal GnRH/LH 
secretion.  
The suppressive effect of NK3R antagonist on nonpulsatile GnRH/LH but increased 
FSH release allows ongoing estradiol secretion from granulosa cells with estradiol 
levels remaining above 100 pmol/l in this study. This alleviates concerns of 
unwanted menopausal-like side effects, which are associated with the clinical use of 
GnRH analogues, whereby blockade of GnRH receptor downregulates the HPG axis 
with more marked suppression of estradiol secretion (Maggi et al. 2016). There were 
no reports of hot flushes in premenopausal women whilst taking the NK3R 
antagonist in this study. Selective blockage of NKB signalling might therefore have 
therapeutic potential in the management of sex-steroid disorders, such as 
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endometriosis, fibroids and heavy menstrual bleeding. NK3R antagonist as a novel 
non-steroidal contraceptive is also a possible indication. Although follicle growth 
was arrested during 7 days of NK3R antagonist treatment, it remains unclear if such 
effect would persist with longer use and might be limited by lack of progesterone 
exposure and adverse endometrial outcomes.  
In summary, NK3R antagonism in healthy premenopausal women in the early 
follicular phase of menstrual cycle, supressed follicle growth and estradiol secretion 
and delayed ovulation for the duration of treatment. Those effects were reversible 
after cessation of drug administration with evidence of normal ovulation and luteal 
function. Whilst NK3R antagonist had no effect on LH secretion (by once-daily 
sampling), detailed analysis revealed a marked effect on basal LH secretion in 
normal women, thus providing strong support for the role of NKB signalling in 
modulating GnRH secretion. These data confirm the involvement of NKB in the 
physiological neuroendocrine control of female reproduction. Our studies suggests 
that blockade of NKB-NK3R signalling may have potential therapeutic application in 
non-steroidal contraception and in the management of sex-steroid dependent 
disorders, e.g. endometriosis, fibroids, prostatic hypertrophy (see section 8.5 Clinical 
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Chapter 6. Neurokinin B in the regulation of ovarian function 
in healthy women in the late follicular and luteal 
phases of menstrual cycle 
6.1 Introduction 
In Chapter 5, the role of NKB in regulating reproductive hormone secretion and 
ovarian follicle development in healthy women was investigated. When administered 
in the early follicular phase, NK3R antagonist (AZD4901) prevented ovarian follicle 
development and estradiol secretion and delayed ovulation for the duration of 
treatment. Those effects were reversible upon discontinuation of treatment. This is 
consistent with recently published data using a different NK3R antagonist (ESN364), 
showing delayed pre-ovulatory estradiol rise and variable effects on the LH surge 
with delayed mid-luteal progesterone secretion over 21 day administration in women 
(Fraser et al. 2016) and similar findings in rhesus monkeys (Fraser et al. 2015a). The 
mechanism of action, or at least a part of it, by which NK3R antagonism achieved 
those effects in normal women appears to be by decreasing basal, non-pulsatile LH 
secretion through presumed similar changes in GnRH secretion. These data clearly 
supports a role for NKB in modulating GnRH secretion in the early follicular phase 
in female reproduction. However, in those studies effects of NK3R antagonism later 
in the cycle reflect suppressed estradiol secretion in the early follicular phase.  There 
are no studies investigating the role of NKB signalling in a different sex-steroid 
environment, specifically when administered in the late follicular or luteal phases in 
normal women.   
The involvement of NKB in the mid-cycle LH surge has been suggested in animal 
models (Billings et al. 2010, Navarro et al. 2011a, Ramaswamy et al. 2011). In ewes, 
the NK3R agonist senktide stimulated LH secretion to levels mimicking a surge, 
whilst the NK3R antagonist reduced LH surge amplitude (Billings et al. 2010). 
However, these results have not been reproduced in other species, including humans. 
Recent evidence suggest that NKB is not a prerequisite for positive estrogen 
feedback since centrally administered NK3R antagonist  (MRK-08) failed to abolish 
estradiol-induced LH surge in an ovariectomised sheep, although the onset to peak 
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time of the LH surge was delayed (Li et al. 2015). Unlike an upregulation of Kiss1 at 
the pre-ovulatory LH surge in ewes (Smith et al. 2006b), the expression of Tac3 did 
not change in ovariectomised ewes in response to a surge-inducing estrogen 
challenge (Goubillon et al. 2000).  In the studies in Chapter 5 of NK3R antagonist 
administration from the early follicular phase, the LH surge was delayed secondary 
to reduced estradiol secretion from arrested follicle growth. Whether blockade of 
NK3R antagonism would also suppress the development of a dominant ovarian 
follicle in the late follicular phase and subsequently affect sex-steroid secretion and 
the LH surge remains unknown.  
The role of NKB in regulating the function of the corpus luteum has not yet been 
specifically explored. After ovulation, marked increase in progesterone levels exert a 
profound negative feedback slowing the frequency of GnRH pulses and thus LH 
secretion in the late luteal phase and favouring the rise in FSH necessary to initiate 
the next cycle (Yen et al. 1972, McNeilly et al. 2003). We have shown that NK3R 
antagonist administered early in the cycle postponed mid-luteal progesterone 
secretion, but it affected neither luteal function, nor its duration, consistent with the 
delayed ovulation observed with treatment. Similarly, delayed ovulation and luteal 
progesterone secretion were observed in healthy women with 21-day administration 
of ESN364 (Fraser et al. 2016). In intact female monkeys, mid-luteal progesterone 
rise was attenuated by the NK3R antagonist, but treatment was initiated in the early 
follicular phase and throughout the luteal phase for 35 days, and the results are 
consistent with overall suppression of pre-ovulatory estradiol secretion and hence the 
LH surge (Fraser et al. 2015a). Effects of NK3R antagonist on endometrium were of 
stromal atrophy and glandular inactivity (Fraser et al. 2015a). Menstrual cycle and 
uterine mucosa changes were reversible in those animals after discontinuation of 
treatment (Fraser et al. 2015a). All together, these data suggest that when 
administered in the early follicular phase NK3R antagonist is able to prevent or delay 
the normal events of the menstrual cycle, but it remains to be explored if antagonism 
of NKB-NK3R pathway would interrupt the progression through the menstrual cycle 
when administered in the late follicular phase or affect luteolysis with treatment 
initiated following ovulation.  
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6.2 Objectives 
The objectives of this study were to investigate the effect of NK3R antagonism in 
healthy women during: 
1) the late follicular phase, on gonadotropin and ovarian hormone secretion, 
follicle development and the endometrial response; 
2) the luteal phase, on gonadotropin secretion, luteal function and endometrial 
thickness. 
6.3 Methods  
6.3.1 Participants 
Twelve healthy premenopausal women (eight women being the same participants as 
in previous study), aged 27-45 years and with regular menstrual cycles (26-34 days) 
based on medical history were recruited into the study; all volunteers provided 
informed written consent. Subjects were not taking any hormonal contraception nor 
had a copper intrauterine device in situ. They were eligible based on inclusion and 
exclusion criteria (Table 2.1 Inclusion and exclusion criteria, Chapter 2), had normal 
physical examination and negative urine pregnancy test. Full blood count, renal 
function, electrolytes, liver function and electrocardiogram were within normal 
limits. 
6.3.2 Study drugs 
The specific neurokinin-3 receptor (NK3R) inhibitor AZD4901 was administered 
orally at 40 mg twice daily.  
6.3.3 Protocol 
Study 1: Effects of NK3R antagonism on gonadotropin secretion and ovarian 
function in the late follicular phase.  
Schematic presentation of the protocol is shown in Figure 6.1A. Six subjects were 
administered the NK3R antagonist for 7 days from the day of emergence of a 
dominant (≥12 mm diameter) follicle determined by transvaginal ultrasonography 
performed on alternate days from cycle day 10. All women had a no treatment 
control cycle and a treatment cycle, the order of cycles being randomised. Peripheral 
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venous blood was drawn for spot LH, FSH, estradiol and progesterone assay, and 
transvaginal ultrasonography was performed for the leading follicle diameter and 
endometrial thickness immediately before treatment (pre-treatment), on days 2, 4 and 
6 of NK3R antagonist administration, in the morning following the last dose and then 
6-8 days later. In the control cycle interval timing for blood sampling and 
radiological assessment was equivalent to that in the treatment cycle. Study visits 
took place in the morning: during treatment, this was immediately prior to the next 
dose of NK3R antagonist, i.e. 12 hours after the previous dose.  
Study 2: Effects of NK3R antagonism on gonadotropin secretion in the luteal phase 
and luteolysis.  
Schematic presentation of the protocol is shown in Figure 6.1B. Six subjects were 
administered the NK3R antagonist for 7 days from day 2-3 after ovulation, which 
was defined as either by the disappearance of the dominant follicle or the appearance 
of a corpus luteum at transvaginal ultrasonography performed on alternate days from 
cycle day 12. All women had a no treatment control cycle and a treatment cycle, the 
order of cycles being randomised. Peripheral venous blood was drawn for spot LH, 
FSH, estradiol and progesterone assay immediately before treatment (pre-treatment), 
on days 2, 4 and 6 of NK3R antagonist administration and in the morning following 
the last dose. Endometrial thickness was assessed by transvaginal ultrasonography on 
the same days as interval blood sample timing. Blood sampling and radiological 
assessments were performed in the morning: during treatment, this was immediately 
prior to the next dose of NK3R antagonist, i.e. 12 hours after the previous dose. 
Safety profile.  
Safety blood tests including full blood count, renal function and electrolytes, and 
liver function were checked before commencing the NK3R antagonist, at the end of 
NK3R antagonist administration and 2-3 weeks later. 
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Figure 6.1 Study protocol.  
(A) Study 1: NK3R antagonist AZD4901 was administered in healthy women (n=6) for 7 days in the 
late follicular phase following an emergence of a dominant ≥12 mm follicle. (B) Study 2: NK3R 
antagonist AZD4901 was administered in healthy women (n=6) for 7 days in the luteal phase from 
day 2-3 of ovulation. Reproductive hormones were measured and transvaginal ultrasonography was 
performed throughout the studies and compared to no treatment control cycle, the order of treatment 
and control cycles being randomised. LMP, last menstrual period; NMP, next menstrual period; TV 
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6.3.4 Analytical methods 
Hormone assays and safety blood tests were performed as described in Chapter 2.  
6.3.5 Statistical analysis 
Data were assessed for Gaussian distribution by Shapiro-Wilk normality test (for 
data points ≥7) or Kolmogorov-Smirnov test as appropriate (for data points <7).  
Baseline characteristics between the control and NK3R antagonist-treated cycles 
were compared by Student’s paired t-test (for normally distributed data: follicle size, 
LH, FSH and estradiol) and by Wilcoxon matched-pairs signed rank test (for data 
that did not have a normal distribution: cycle days and progesterone).  
Days to peak reproductive hormone concentrations and to the next menstrual period 
from the start of the study were compared by Wilcoxon matched-pairs signed rank 
test. The null hypothesis of equal variation in the number of days from the start of 
the study visits to the LH surge and peak FSH, estradiol and progesterone 
concentrations was tested by Levene’s test for homogeneity of variance using 
statistical package system R, which was kindly performed by Dr Tom Kelsey at the 
University of St Andrews.  
Mean hormone concentrations, follicle growth and the endometrial thickness 
between the control and NK3R antagonist-treated cycles were compared using 
repeated measure two-way ANOVA followed by Bonferroni’s multiple comparisons 
post hoc analysis. The rate of follicle growth was calculated as change in millimetres 
since last measurement. Peak luteal estradiol and progesterone levels were compared 
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6.4 Results 
6.4.1 Study 1: Effects of NK3R antagonist on gonadotropin 
secretion and ovarian function in the late follicular phase 
6.4.1.1 Baseline characteristics 
Table 6.1 shows that the control and NK3R antagonist-treated cycles were matched, 
with no pre-treatment differences in the diameter of the dominant ovarian follicle, 
serum reproductive hormones or cycle day on which the study commenced in the late 
follicular phase of menstrual cycle.  
 
Characteristic Control cycle NK3Ra cycle p value 
Cycle day treatment 
commenced 
13.7± 1.8 11.3 ± 1.2 0.09 
LH (IU) 6.3 ± 1.3  7.0 ± 1.4 0.35 
FSH (IU) 3.6 ± 0.4 3.6 ± 0.6 0.98 
Estradiol (pmol/l) 393 ± 94 345 ± 62 0.70 
Follicle diameter (mm) 12.9 ± 0.5 12.9 ± 0.2 0.95 
Table 6.1 Basic characteristics of the participants in the late follicular phase of menstrual cycle.  
Control and NK3R antagonist-treated cycles were comparable at pre-treatment by the size of a 
dominant ovarian follicle, reproductive hormone levels and the menstrual cycle day on which the 
study visits had commenced (n=6). Data are presented as mean ± SEM.    
 
6.4.1.2 NK3R antagonist effects on reproductive hormone secretion 
All subjects showed an LH surge in both control and NK3R antagonist cycles. 
However, NK3R antagonist administration in the late follicular phase interfered with 
the timing of the LH surge, increasing the variation in the number of days from the 
emergence of a ≥12 mm follicle to the LH surge (Levene’s test p=0.03) (Fig. 6.2A). 
The LH surge was earlier in three and later in another three subjects during NK3R 
antagonist treatment. There appeared some greater variation in time to peak estradiol 
concentrations preceding the LH surge, but this was not statistically significant 
(p=0.08), and no changes were observed in days to peak FSH secretion, or to 
subsequent peak progesterone concentrations (Fig. 6.2 B-D).  There was no 
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difference in cycle length from the emergence of a dominant follicle to the onset of 
next menstrual period between the control and treatment cycle (NK3R antagonist: 
18±1 vs 17±1 days, ns).  
NK3R antagonist had no effect on basal LH secretion and did not affect the 
magnitude of the mid-cycle LH surge (ANOVA ns), the concentration of which was 
comparable to the control cycle (31.8±7.8 with NK3R antagonist vs 24.0±4.4 IU/l on 
LH surge day 0, ns) (Fig. 6.2E). Pre-ovulatory estradiol levels were not different in 
the NK3R antagonist-treated cycles compared to controls (470±89 with NK3R 
antagonist vs 690±109 pmol/l on LH surge day -2, ns) and no changes were observed 
in FSH secretion  (Fig. 6.2 F and G). Luteal function was also unaffected by the 
NK3R antagonist (ANOVA ns) with equivalent mid-luteal progesterone 
concentrations (NK3R antagonist 37.2±6.7 vs 28.0±2.8 nmol/l day 8-10 of the LH 
surge, ns) (Fig. 6.2H).  
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Figure 6.2 Timing of peak reproductive hormone secretion and mean hormone concentrations 
in the late follicular phase in healthy women with and without NK3R antagonist treatment.  
Variation in the number of days from the emergence of a dominant ≥12mm ovarian follicle until the 
LH surge (A) and peak FSH (B), estradiol (C) and progesterone (D) secretion was tested by Levene’s 
test for homogeneity of variance. Mean reproductive hormone concentrations relative to the LH surge 
day (0) (E-H) in the control and NK3R antagonist-treated women in the late follicular phase were 
compared by unpaired two-way ANOVA with Bonferroni’s multiple comparisons post hoc analysis. 
Data are presented as mean ± SEM. *, p<0.05 Levene’s test.    
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6.4.1.3 NK3R antagonist effects on follicle development and the 
endometrial response 
Individual subject data suggest some variation in the development of a dominant 
follicle, which was delayed in 3 women with the NK3R antagonist treatment (Fig. 
6.3A). The rate of follicle growth appeared smaller in the NK3R antagonist 
compared to the control group but this was not statistically different (ANOVA ns) 
(Fig. 6.3B) with the diameter of the pre-ovulatory follicle being comparable to 
controls (16.5±0.3 vs 18.7±0.8 mm, ns). Endometrial development was unaffected by 
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Figure 6.3 NK3R antagonist effects on the development of a dominant ≥12 mm follicle and the 
endometrial thickness in healthy women in the late follicular phase of menstrual cycle.  
(A) Follicle growth in each of the 6 premenopausal women with the NK3R antagonist treatment (red 
squares) compared to the control cycle (black circles). (B) Growth in follicle diameter until ovulation 
and (C) endometrial thickness relative to the LH surge day (day 0). Mean ± SEM.  
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6.4.2 Study 2: Effects of NK3R antagonist on gonadotropin 
secretion in the luteal phase and luteolysis 
6.4.2.1 Baseline characteristics 
Each participant took part in control and NK3R antagonist cycles, which were 
comparable by cycle day on which the study visits commenced and by pre-treatment 
reproductive hormone profile (Table 6.2).  
Characteristic Control cycle NK3Ra cycle p value 
Days since ovulation (n) 2.7 ± 0.5  2.5 ± 0.2 0.99 
LH (IU) 9.7 ± 1.7 8.2 ± 1.4 0.52 
FSH (IU/l) 3.6 ± 0.7 3.8 ± 0.5 0.79 
Estradiol (pmol/l) 271 ± 44  306 ± 40  0.44 
Progesterone (nmol/l) 22.3 ± 4.8 19.6 ± 4.7 0.99 
Table 6.2 Basic characteristics of the participants  (n=6) in the luteal phase of menstrual cycle. 
Subjects in the control and NK3R antagonist-treated cycles were comparable at pre-treatment based 
on the number of days since ovulation to the start of the at that time. Data are presented as mean ± 
SEM.  
6.4.2.2 NK3R antagonist effects on reproductive hormone secretion 
Luteal LH and FSH concentrations were unchanged with the NK3R antagonist (Fig. 
6.4 A and B). Although estradiol secretion appeared suppressed by the NK3R 
antagonist compared to control cycle, this was not significant statistically (ANOVA, 
ns) (Fig. 6.4C). Luteal function was overall unaffected by the NK3R antagonist with 
no changes observed in peak estradiol (418±41 vs 569±98 pmol/l, ns) and 
progesterone (35.9±3.8 vs 45.9± 5.6 nmol/l, ns) secretion between the control and 
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Figure 6.4 Mean luteal reproductive hormone secretion with and without NK3R antagonist 
administration in women. 
Mean LH (A), FSH (B), estradiol (C) and progesterone (D) secretion and peak estradiol (E) and 
progesterone (F) levels in the luteal phase in healthy pre-menopausal women (n=6). Data are 
presented as mean ± SEM.  
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NK3R antagonist administration post ovulation in healthy women tightened the 
variation in the timing of peak estradiol secretion (Levene’s test p=0.03) (Fig. 6.5A).  
No changes were observed in timing of peak progesterone secretion, and the duration 
of luteal phase was overall unaffected by treatment (Fig. 6.5 B and C).  
 
Figure 6.5 NK3R antagonist effects on the timing of luteal hormone secretion and cycle length. 
Peak estradiol (A) and progesterone (B) secretion and days to the next menstrual period (C) in the 
control and NK3R antagonist cycle (n=6).  Days are counted from the start of the study visits i.e. from 
day 2-3 of ovulation. Data are presented as mean ± SEM. *, p<0.05 Levene’s test.    
6.4.2.3 NK3R antagonist effects on the endometrial thickness 
NK3R antagonist had no effect on the endometrial thickness in the secretory phase 
(Fig. 6.6).  
 
Figure 6.6 Effects of NK3R antagonist on the endometrial response in the luteal phase in healthy 
premenopausal women.  
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6.4.3 Tolerability and safety 
NK3R antagonist treatment was well tolerated with no treatment discontinuations. 
Haematology and biochemistry safety parameters remained stable in all subjects 
throughout the study period. 
6.5 Discussion 
In this study, the effects of NK3R antagonism in the late follicular and luteal phases 
were explored in healthy women. Administration of this and similar drugs at these 
stages of the cycle has not been reported previously.  In the late follicular phase, 
NK3R antagonist administration for 7 days increased the variation in the timing of 
the LH surge but did not abolish it, suggesting that the timing of positive estrogen 
feedback to the hypothalamic-pituitary centres was disrupted. While no clear 
changes were observed in estradiol secretion that triggers the LH surge, the timing of 
estradiol rise appeared more variable during treatment. However, NK3R antagonist 
had no marked effect on the growth of an already selected dominant follicle and 
luteal function, as reflected by progesterone secretion, was also unaffected.  
When administered in the luteal phase, NK3R antagonist reduced the variation in the 
timing of peak estradiol secretion, concentrations of which were also slightly 
reduced, but it had no overall effect on luteal function and its duration. Although no 
changes were seen in LH secretion, this may not be detected by performing single 
timepoint blood sampling, and pulsatile LH secretion was not assessed in this study. 
Thus it remains possible that NKB is involved in regulating LH secretion in the 
luteal phase, as LH is the major determinant of androgen availability for estradiol 
synthesis throughout the menstrual cycle in premenopausal women (Karnitis et al. 
1994, Ben-Chetrit et al. 1996).  
The present data demonstrate a striking difference in NK3R antagonism effects on 
the timing of key events in the female reproduction when administered in the late 
compared to early follicular phase in normal women in Chapter 5. In the early 
follicular phase, NK3R antagonist delayed ovarian follicle growth and estradiol 
secretion, the LH surge and ovulation. This resulted in luteal progesterone rise and 
next menstrual period both being delayed for the duration of 7-day treatment (see 
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Chapter 5). Similarly, the LH surge was postponed and menstrual cycle length was 
prolonged in another study administering a different NK3R antagonist (ESN364) in 
normal women for 21 days throughout the follicular phase (Fraser et al. 2016) with 
comparable data in female rhesus monkeys (Fraser et al. 2015a). Interestingly, in the 
late follicular phase NK3R antagonist did not consistently delay the LH surge but 
perturbed its timing, advancing it in three and delaying it in another three women 
without any effect on overall reproductive hormone concentrations. Taken together 
this suggests that in the early follicular phase NKB modulates basal GnRH/LH 
secretion (as demonstrated by pulsatility studies), but in the late follicular phase 
NKB may have a role in mediating estrogen feedback and thus the timing of the LH 
surge without regulating the surge mode of LH secretion. Consistent with this, some 
variation was seen in the timing of pre-ovulatory estradiol rise but no effect was 
observed on peak estradiol secretion and LH levels on the surge day. Additional data 
supporting a key role of NKB signalling in sensing and mediating estrogen feedback 
are presented in Chapter 7. One explanation for lack of the NK3R antagonist effect 
on the LH surge levels may be the pituitary response to estradiol as seen in patients 
with deficient hypothalamic function, such as Kallmann syndrome, during GnRH 
administration by pump who can show a mid-cycle LH surge without any change in 
GnRH dose (Crowley and McArthur. 1980). In keeping with our findings, central 
administration of another NK3R antagonist (MRK-08) in ovariectomised ewes also 
interfered with the timing of estrogen induced LH surge, delaying the onset-to-peak 
time of LH secretion but not abolishing it (Li et al. 2015). The anatomical location of 
NKB neurones within the infundibular nucleus in humans and the equivalent arcuate 
nucleus in ruminants, the site for positive estrogen feedback in those species, further 
supports the involvement of this neuropeptide in mediating sex-steroid feedback 
(Oakley et al. 2009, Pinilla et al. 2012). This is, however, species specific since NKB 
is thought not to be involved in the pre-ovulatory LH surge in rodents, based on the 
location of NKB neurones in the arcuate nucleus only, but not the anteroventral 
periventricular (AVPV) nucleus, the site for positive estrogen action in those species 
(Oakley et al. 2009, Pinilla et al. 2012). Despite perturbation of the LH surge timing, 
NK3R antagonist administration in the late follicular phase did not increase the 
variation in days to peak luteal progesterone secretion and no difference was 
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observed in length to the next menstrual period between the control and treatment 
cycle. It is possible that more variable baseline cycle length and therefore follicular 
phase between the participants and the small sample size precluded demonstration of 
subtle changes in the timing of luteal sex-steroid secretion and the onset of next 
menstruation with NK3R antagonist treatment. Using a model to standardise the 
onset of LH surge between the participants and even between the different cycles of 
the same participant, would aid clarification for the role of NKB in mediating 
positive estrogen feedback and the LH surge in humans, which is further explored in 
Chapter 7.  
It is a novel finding that NK3R antagonism had no effect on the growth of a 
dominant follicle in the late follicular phase, which is in contrast to clear suppression 
of antral follicle development seen early in the follicular phase before the selection 
process has occurred. It is therefore likely that basal GnRH/LH secretion is 
unaffected by the NK3R antagonist in the late follicular phase as ovarian follicle 
growth was highly sensitive to such changes in the early follicular phase. Both NKB 
and NK3R are expressed at the mRNA and protein level in human granulosa cells of 
the pre-ovulatory follicle obtained after ovarian stimulation during assisted 
conception treatment (Garcia-Ortega et al. 2014, Garcia-Ortega et al. 2016). NKB 
and NK3R immunoreactivity changes throughout follicle maturation, being minimal 
in growing follicles but high in corpora lutea in women (Cejudo Roman et al. 2012). 
The NKB-NK3R system has also been detected in mouse and rat granulosa cells 
(Loffler et al. 2004, Candenas et al. 2005). Therefore, the present lack of ovarian 
effect with the NK3R antagonist administration in the late follicular phase further 
supports the hypothalamic action of NK3R antagonist in mediating suppression of 
follicle development seen in the early follicular phase. Consistent with our findings, 
in cultured human mural granulosa cells from oocyte donors undergoing ovulation 
stimulation treatment, NKB itself had no effect on calcium influx (Garcia-Ortega et 
al. 2014). In the presence of a cocktail of antagonists selective for NK1R, NK2R and 
NK3R, calcium influx was reduced, but this was to a lesser extent with NK3R 
antagonist alone (Garcia-Ortega et al. 2014).  Of note, expression of the NKB-NK3R 
system in the follicles obtained from IVF cycles may not represent that of a normally 
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cycling woman and ovarian stimulation can induce changes in serum and follicular 
fluid and therefore granulosa cell gene and protein expression (de los Santos et al. 
2012). Nevertheless, this suggests that NKB may mediate its local ovarian effects by 
its interaction with different tachykinin receptors, since NKB is known to activate 
any of the three tachykinin group receptors (Maggi. 2000, Almeida et al. 2004, 
Satake et al. 2013).  
The lack of suppressive effect of the NK3R antagonist on the growth of a dominant 
follicle in this study indicates that the NKB-NK3R pathway has limited activity at 
this stage of the menstrual cycle, although only one dose level was investigated and 
the limited effects seen here may be greater if higher doses are used. In keeping with 
this, estrogen exposure decreases TAC3 and TACR3 expression in various tissues, 
including the hypothalamus and uterus (Rance and Young. 1991, Pinto et al. 1999, 
Pinto et al. 2009, Rance. 2009), suggesting that high estrogen levels in the follicular 
phase might have donwregulated hypothalamic NK3R expression, the substrate for 
the AZD4901 antagonist in this study.  
The present study has also investigated effects of the blockade of NKB-NK3R 
pathway on luteal function when administered in both the late follicular and luteal 
phases of the menstrual cycle. When administered in the late follicular phase, NK3R 
antagonist neither affected the time to peak luteal progesterone secretion, nor its mid-
luteal concentration, suggesting that luteal function and its duration was unaffected 
by treatment. A different NK3R antagonist (ESN364) attenuated the mid-luteal 
progesterone rise in rhesus female monkeys, but treatment was initiated in the early 
follicular phase for 35 days (Fraser et al. 2015a). Similarly, delayed luteal 
progesterone secretion was observed in healthy women with 21-day administration 
of NK3R antagonist (ESN364) administration (Fraser et al. 2016). Changes seen in 
luteal sex-steroid secretion in previous human and animal studies therefore reflect 
effects of NK3R antagonism on hormone release earlier in the cycle, but do not 
determine the role of NKB on luteal function. This study demonstrates that when 
administered 2-3 days after ovulation, NK3R antagonist decreased the variation in 
days to peak estradiol secretion and appeared to slightly suppress luteal estradiol 
release, but these effects were modest. This may indicate a locus of action of the 
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NK3R antagonist at the ovarian level in this experimental design, as there is 
abundant expression of NKB-NK3R in the corpus luteum (Cejudo Roman et al. 
2012, Garcia-Ortega et al. 2014, Garcia-Ortega et al. 2016), although GnRH/LH 
pulsatility assessment was not performed here and a dual site of action therefore 
cannot be ruled out. Peak luteal estradiol and progesterone secretion was unaffected 
by the treatment and the duration of luteal phase was unchanged, suggesting overall 
normal luteal function in the presence of NK3R antagonist.  
Local uterine effects were not explored in this study, but this is unlikely since no 
effect was observed on luteal hormone secretion and endometrial thickness with this 
dose of NK3R antagonist in the late follicular and luteal phases in healthy women. 
Nevertheless, the NKB-NK3R pathway is localised to the mammalian uterus (Pinto 
et al. 1999, Patak et al. 2003, Pinto et al. 2009, Cejudo Roman et al. 2012) and its 
expression is dependent on the hormonal state. In the human myometrium the 
immunohistochemical expression of NK3R was weaker in the proliferative compared 
to the secretory phase (Cejudo Roman et al. 2012), consistent with reduced TACR3 
expression in the human and rodents uteruses with estrogen dominance (Pinto et al. 
1999, Patak et al. 2003, Pinto et al. 2009). The presence of NKB and NK3R in 
uterine mast cells and vascular smooth muscle suggests that the system may be a link 
between the uterus and immune system, the involvement of which has been 
increasingly recognised in heavy menstrual bleeding (Maybin et al. 2011a, Maybin et 
al. 2011b). Furthermore, the expression of TAC3 and TACR3 was significantly 
upregulated and their cyclical variation was reduced in uterine fibroids following 
hysterectomy, suggesting that dysregulation of NKB-NK3R signalling might 
contribute to symptoms seen in women with fibroids (Canete et al. 2013). In rhesus 
monkeys, endometrial assessment showed moderate stromal atrophy and mucosal 
glandular inactivity with NK3R antagonist treatment throughout the menstrual cycle, 
the effects of which were reserved in the next menstrual cycle upon treatment 
cessation (Fraser et al. 2015a). Histological analysis of endometrium exposed to 
NK3R antagonist has not yet been performed in humans. Manipulation of NKB-
NK3R system clearly opens new paradigms for therapeutic application in the 
regulation of female reproduction, including birth control and management of sex-
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steroid dependent disorders. Nevertheless, there remains a necessity to ensure normal 
endometrial function in women of reproductive age post NK3R antagonist exposure 
before translational application of NK3R blockade.  
In summary, NK3R antagonism in the late follicular phase in healthy premenopausal 
women altered the timing of the LH surge but there were no detected effects on pre-
ovulatory LH secretion, or late follicle growth and estradiol production. This 
suggests the involvement of NKB in positive estrogen feedback and the timing of the 
mid-cycle LH secretion but a more limited role in basal LH secretion in the late 
follicular phase (although pulsatility analysis was not performed). This is in contrast 
to the early follicular phase, where basal GnRH/LH secretion was reduced and 
ovarian follicle development was suppressed. When administered in the luteal phase, 
this dose and course of NK3R antagonist administration affected neither luteal 
function, nor its duration. Taken together, these data confirm the involvement of 
NKB in physiological regulation of female reproduction in the normal dynamics of 
the menstrual cycle but the extent of which is dependent on the phase of the cycle, 
possibly reflecting changes in the sex-steroid environment. Our studies add further 
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Chapter 7. Interactions between neurokinin B and kisspeptin 
in mediating estrogen feedback in healthy women 
The work in this chapter has been published in the Journal of Clinical Endocrinology 
and Metabolism:  
Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA. Interactions 
between neurokinin B and kisspeptin in mediating estrogen feedback in healthy 
women. JCEM 2016:101(12); 4628-4636.  
Acknowledgements and author contributions for the above manuscript are detailed in 
Chapter 1. 
7.1 Introduction 
In Chapters 5 and 6, the role of NKB in regulating gonadotropin secretion and 
ovarian function and the influence thereon of varying sex-steroid milieu across the 
menstrual cycle in healthy women was investigated. In the early follicular phase, 
NKB action on LH secretion was identified, and found to be by modulation of basal 
GnRH release, which was decreased by the NK3R antagonist also suppressing 
ovarian estrogen secretion and delaying LH surge and ovulation. When administered 
in the late follicular phase, NK3R antagonist interfered with the timing of LH surge 
but did not inhibit pre-ovulatory estradiol or LH secretion. Similarly, LH surges were 
observed in all ovariectomised estrogen challenged sheep following an 
administration of a different NK3R antagonist (MRK-08), but the time from LH 
surge onset to peak was significantly delayed (Li et al. 2015). This suggests 
differential action of NKB in regulating downstream GnRH/LH secretion across the 
menstrual cycle, which might be dependent on sex-steroid feedback. Although NKB 
controls basal GnRH/LH secretion early in the cycle when estrogen feedback is 
negative and estradiol levels are relatively low, the role of NKB at the switch to 
positive estrogen feedback remains unclear. We observed no changes in LH secretion 
with the NK3R antagonist in the late follicular phase in healthy women, but LH 
pulsatility assessment was not performed and subtle effects on LH release may have 
been overlooked. Furthermore, timing of the physiological LH surge was variable 
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between the participants, introducing difficulty in accurate assessment. We have 
therefore used a model of exogenous estradiol (transdermal) administration 
developed by Baird et al., (Baird et al. 1995) standardising estrogen exposure and the 
onset of increased LH secretion to further explore the role of NKB in regulating sex-
steroid feedback at the time of the switch from negative to positive, and pulsatile LH 
secretion during this feedback in healthy women.  
NKB neurones in the infundibular nucleus in humans, equivalent to the arcuate 
nucleus in rodents and other species, also co-express kisspeptin, and the functions of 
those neuropeptides are closely interlinked (Pinilla et al. 2012). NKB and kisspeptin 
are essential for normal GnRH and gonadotropin secretion as inactivating mutations 
in NKB, kisspeptin and their receptors are associated with hypogonadotropic 
pubertal delay (de Roux et al. 2003, Seminara et al. 2003, Topaloglu et al. 2009, 
Topaloglu et al. 2012), whilst activating mutations in kisspeptin-kisspeptin receptor 
pathway cause precocious puberty (Teles et al. 2008). Experimental characterisation 
of the relative roles played by kisspeptin and NKB, as well as their functional 
hierarchy, has been largely carried out in non-human models (Billings et al. 2010, 
Corander et al. 2010, Navarro et al. 2011a, Ramaswamy et al. 2011, Garcia-Galiano 
et al. 2012). The first human study demonstrating the interaction between kisspeptin 
and NKB was in a disease model, where in patients with loss of function mutations 
in NKB and its receptor, kisspeptin-10 infusion increased LH secretion and restored 
its pulsatility (Young et al. 2013). This, and concordant data from animal models 
(Corander et al. 2010, Garcia-Galiano et al. 2012), has led to the conclusion that 
central NKB signalling is functionally upstream of kisspeptin. However, there are no 
equivalent data on this in humans in health. We have shown that in states of slow LH 
output, NK3R antagonist suppressed LH and testosterone secretion in men by 
modulating nonpulsatile GnRH secretion, but did not abrogate stimulatory 
kisspeptin-10 response (Chapter 3). In postmenopausal women with high LH output, 
gonadotropin response to kisspeptin-10 and pharmacological blockade of NK3R was 
rather limited (Chapter 4). Taken together our data support the overall hierarchy 
whereby NKB is functionally upstream of kisspeptin, but suggest that this interaction 
is complex and may be influenced by the sex-steroid milieu. Indeed, in another 
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study, the stimulatory effect of kisspeptin-54 on LH and testosterone secretion was 
greater than that observed with co-infusion of NKB itself and kisspeptin-54 
(Narayanaswamy et al. 2015). LH response to exogenous kisspeptin is greatest in the 
late follicular phase (Dhillo et al. 2007, Jayasena et al. 2011, Chan et al. 2012) and is 
positively related to endogenous estradiol levels (Narayanaswamy et al. 2015), 
implicating kisspeptin in mediating positive sex-steroid feedback on LH release. 
However, there are no studies exploring the interaction between kisspeptin and NKB 
at this stage of the menstrual cycle. The antagonistic effect of neurokinin B and its 
interaction with kisspeptin was explored during exogenous estrogen administration, 
aiming to reveal the functional hierarchy of kisspeptin and NKB at the time of 
positive estrogen feedback and the LH surge in women. 
7.2 Objectives 
The objectives of the study were, using a model of estrogen-induced LH secretion in 
healthy premenopausal women: 
1) To determine the effect of KP-10 on gonadotropin secretion; 
2) To determine the effect of NK3R antagonist on gonadotropin secretion; 
3) To investigate the effect of NK3R antagonist on LH pulsatility; 
4) To determine if KP-10 stimulated LH secretion is abrogated in the presence 
of NK3R antagonist, thereby revealing the functional hierarchy of neurokinin 





Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
NKB/kisspeptin in estrogen feedback   186 
7.3 Materials and Methods 
7.3.1 Participants 
Twenty healthy women, aged 18-45 years with regular menstrual cycles (25-35 days) 
were recruited from the community to this study, which was approved by South East 
Scotland Research Ethics Committee (Ref: 09/S1101/67); all volunteers provided 
informed written consent. Subjects were not taking steroidal contraception, had 
normal physical examination, and full blood count, renal function, electrolytes, liver 
function and electrocardiogram were within normal limits.  
7.3.2 Study drugs 
Kisspeptin-10 was custom synthesized under GMP standards (Bachem GmBH, Weil 
am Rhein, Germany) (George et al. 2011). 1 mg kisspeptin-10 was dissolved in 5 ml 
sterile normal (0.9%) saline immediately before infusion. The syringe and line for 
infusion were first coated for 30 min with kisspeptin-10 to minimise peptide loss 
from adherence to the plastic. Sterile normal saline was infused as vehicle. The 
specific neurokinin-3 receptor (NK3R) inhibitor AZD4901, formulated as 20 mg 
tablets, was gifted by AstraZeneca, UK. Transdermal patches releasing 200 μg 17β 
estradiol per 24 hours (Janssen-Cilag Buckinghamshire, UK) were used as 
exogenous estradiol treatment (Medicines.org. 2015). 
7.3.3 Protocol 
To standardise estrogen exposure and the onset of increased LH secretion, we used a 
model of follicular phase administration of transdermal estradiol (200µg/day), which 
initially suppresses then at 48 hours increases LH secretion (Baird et al. 1995).  We 
confirmed that LH secretion at 48 hours is increased to the same extent if the patches 
were removed at 32 hours or continued till 72 hours: for the main study therefore 
patches were removed at 32 hours (Fig. 7.1). Sample size was based on previous 
proof of concept mechanistic studies (George et al. 2011, George et al. 2012).  
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Figure 7.1 Model of estrogen-induced LH secretion.  
Estradiol (A), LH (B) and FSH (C) levels in a model of estrogen-induced LH secretion at 48 hours 
with ten women receiving estrogen for 32 hr (black bars) and four women receiving estrogen 
treatment for 72 hr (grey bars). No kisspeptin-10 or NK3R antagonist was administered. Two estradiol 
patches releasing a total of 200 μg estradiol/day were applied at 0  hours. Gonadotropin levels were 
equivalent between estrogen exposure for 32 and 72 hours. Data presented as mean ± SEM. *, p<0.05; 
**, p<0.01; ****, p<0.0001 vs 0 hours, except where a difference between groups is indicated in 
estradiol concentrations. 
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Twenty women were randomly allocated to NK3R antagonist (AZD4901) 40mg oral 
twice daily starting from cycle day 4-6 for 6 days, or no treatment (Fig. 7.2). Two 
transdermal estradiol patches were administered after 5 days (time 0 hours), in the 
late follicular phase (cycle day 9-11, according to the day of starting AZD4901). At 
24 hours of estradiol treatment volunteers attended our clinical research facility for 8 
hours. After an hour of baseline sampling, volunteers were randomised (using sealed 
envelopes) to receive a continuous intravenous infusion of kisspeptin-10 
(4µg/kg/hour) or vehicle for 7 hours. In the NK3R antagonist treatment group, the 
last dose of AZD4901 was on the morning of kisspeptin-10 or vehicle 
administration. Estradiol patches were removed at the end of the infusion i.e. 32 
hours after application. Volunteers attended for further measurement of reproductive 
hormones at 48 and 72 hours. In a subsequent menstrual cycle, all women returned to 
receive the alternate infusion of kisspeptin-10 or saline.  Those receiving NK3R 
antagonist had at least one wash out cycle between treatment cycles.  To compare the 
effect of exogenous vs endogenous estrogen on kisspeptin-10 response, another 
group of ten women received intravenous kisspeptin-10 (4µg/kg/hour) infusion for 7 
hours on cycle day 10-12 without exogenous estrogen treatment, with reproductive 
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Figure 7.2 Study protocol diagram.  
Follicular phase administration of transdermal estradiol was used to induce LH secretion 48 hours 
later as a model of the mid-cycle LH surge in women. Ten healthy women were administered NK3R 
antagonist AZD4901 from cycle day 4-6 for 6 days, matched to ten women having no treatment. 
Transdermal estradiol was applied after 5 days. 24 hours later, women were randomised to 7 hour of 
kisspeptin-10 or vehicle infusion, returning in a subsequent cycle for the alternate infusion. 
Reproductive hormones were measured throughout the study and LH pulsatility assessed during 10 
minute blood sampling for 8 hours.  
7.3.4 Blood sampling and hormone assays 
Peripheral venous blood was sampled for LH, FSH and estradiol in the treatment 
group on the day of commencing NK3R antagonist and in both control and treatment 
groups before estradiol treatment (0 hour) and then at 24, 32, 48 and 72 hours. 
During the 8 hour visit, blood samples were collected via an indwelling iv cannula at 
10 min intervals for assessments of LH pulsatility; FSH was measured hourly.  Blood 
samples were centrifuged at 4°C for 10 min at 3000 rpm and serum frozen at -20°C 
or below until analysis. LH and FSH were determined by ELISA as previously 
described (George et al. 2011). 17β-estradiol was measured by ELISA (Demeditec 
Diagnostics, Kiel, Germany). Inter-assay and intra-assay coefficient of variation for 
all hormones was <5% at the concentrations measured. Lower detection limit for LH 
and FSH was 0.1 IU/l and for estradiol 20pmol/l.  
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7.3.5 Statistical analysis 
Analysis of variance (ANOVA) was used to analyse preliminary data on LH changes 
with time in the model. For the primary endpoints, hormone concentrations were 
compared between the four treatment groups at specific time points using ANOVA 
with repeated measures as appropriate. If there was overall significance, post hoc 
analysis was performed with Bonferroni’s correction for multiple comparisons, 
comparing all four treatments simultaneously at each time point. The relationship 
between the timing of peak LH and treatment was assessed by chi-square test. 
Pearson correlation coefficient was computed to assess the relationship between 
estradiol concentrations and LH response to kisspeptin-10.  
The number of LH pulses, secretory mass of LH per pulse, basal (nonpulsatile) and 
pulsatile (integral of dual amplitude and frequency regulation) LH secretion were 
identified by an established deconvolutional algorithm with cluster analysis (93% 
sensitivity and specificity) (Veldhuis et al. 2008, Liu et al. 2009) blinded to treatment 
allocation. Approximate entropy (ApEn), a measure of orderliness, was also 
estimated for the pattern of LH secretion. Deconvolutional estimates and mean 
hourly hormone changes were not calculated for one woman in each group, as full 8 
hour sampling data were not obtained. ANOVA was used to assess changes in LH 
pulsatility parameters between the 4 groups, with post hoc testing as above.  
Data are presented as mean ± SEM. Data not normally distributed were log-
transformed prior to statistical analysis, resulting in a distribution that approximated 
a normal distribution. Differences were regarded as significant at a two-sided p<0.05. 
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7.4 Results 
Baseline age, BMI and the menstrual cycle length were comparable between the 
subjects in the control and the treatment group, as were baseline LH, FSH and 
estradiol levels in vehicle and kisspeptin-10 cycles within the group (Table 7.1).  
 












Cycle length (days) 
10 
35 ± 1.8 
25 ± 1.4 
29 ± 0.6 
  
10 
35 ± 1.7 
28 ± 2.2 





















9.2 ± 0.2 
4.8 ± 0.7 
4.3 ± 0.4 
274 ± 40 
9.4 ± 0.3 
5.6 ± 0.6 
5.3 ± 0.8 





4.4 ± 0.2 
5.0 ± 0.6 
6.2 ± 0.6 
121 ± 17 
4.8 ± 0.2 
4.9 ± 0.6 
5.5 ± 0.4 





Table 7.1 Baseline characteristics of women in the control and the treatment group undergoing 
vehicle and kisspeptin-10 infusion.  
Data are shown as mean ± SEM; ns, not significant. Note that baseline data on control and treatment 
groups in lower part of the table reflect sampling at different stages of the menstrual cycle. 
 
 
7.4.1 Model validation for estrogen-induced LH secretion 
Treatment with exogenous estrogen for 32 hours increased serum estradiol 
concentrations as expected (p<0.0001) (Fig. 7.1). Serum LH was initially suppressed 
at 32 hours of estrogen treatment, then increased at 48 hours which persisted at 72 
hours (all p<0.05 vs 0 hours). FSH concentrations were significantly lower at 24 
(p<0.01) and 32 hours (p<0.0001) but were not higher at 48 and 72 hours compared 
to baseline. This confirms that with this regimen, estrogenic negative feedback is 
followed by increased LH secretion, thus standardising estrogen exposure and the 
time course of changes in LH secretion. 
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7.4.2 Kisspeptin-10 stimulates gonadotropin secretion 
During estrogen administration, kisspeptin-10 stimulated LH secretion to 16.4±3.9 
IU/l at the end of infusion vs 2.9±0.3 IU/l following vehicle administration 
(p<0.0001) (Fig. 7.3A). The time course of this response is shown in Fig 7.4A. 
Kisspeptin-10 induced LH secretion persisted beyond the discontinuation of the 
infusion with higher peak LH compared to controls at 48 hours (9.3±0.7 vs 21.6±5.8 
IU/l, p=0.007) (Table 7.2). Clarification of the impact of exogenous estradiol on this 
response was demonstrated in a separate group of women receiving kisspeptin-10 
infusion only in the late follicular phase without exogenous estrogen administration, 
who showed a similar acute increase in LH secretion correlating positively with 
estradiol concentration (r2=0.63, p=0.006), but of a shorter duration (48 hours: 
6.8±1.8 IU/l vs 15.0±3.6 with estrogen treatment, p<0.01; Fig. 7.5). All subjects in 
the endogenous estrogen group had peak LH at the end of kisspeptin-10 infusion, 
whereas in exogenous estrogen-treated subjects the kisspeptin-10 induced peak LH 
persisted beyond kisspeptin-10 infusion with 50% of women having peak LH at 32 
hours and 50% at 48 hours (p<0.01, Table 7.2). 
FSH secretion was also significantly higher at the end of kisspeptin-10 infusion 
compared to vehicle in the control group (p<0.05) but not different to baseline (0 
hours; Fig. 7.3B, 7.4B).  As expected with this model of exogenous estradiol 
administration, estradiol concentrations were similar in kisspeptin-10 and vehicle-
infused controls (Fig. 7.3C).  
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Figure 7.3 Reproductive hormone response to kisspeptin-10 and NK3R antagonist 
administration in the model of estrogen-induced LH secretion.  
Comparison of mean LH (A), FSH (B) and estradiol (C) response to an infusion of kisspeptin-10 and 
vehicle in ten control and ten NK3R antagonist-treated cycles in the model of estrogen-induced LH 
secretion. Two estradiol patches releasing a total of 200 μg estradiol/day were applied between 0 and 
32 hours. The infusion period of kisspeptin-10 and vehicle was between 24 and 32 hours. Data 
presented as mean ± SEM. *, p<0.05;  ****, p<0.0001. 
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Figure 7.4 Time course analysis of reproductive hormone secretion during 8 hours of frequent 
blood sampling during vehicle or kisspeptin-10 infusion with and without the NK3R antagonist.  
LH (A) and FSH (B) levels an hour pre and during 7 hours of vehicle or kisspeptin-10 infusion in the 
control group (n=9) and in the treatment (NK3R antagonist) group (n=9). The infusion period of 
kisspeptin-10 and vehicle was between 24 and 32 hours of estrogen administration. Data presented as 
mean ± SEM. Statistical analysis by 2-way ANOVA determined statistically lower LH levels between 
vehicle and NK3Ra-treated women (p<0.0001), although Bonferroni’s post hoc multiple comparison 
test found no significant changes at specific time points. For vehicle vs kisspeptin-10 infused controls: 
*p<0.05, ****p<0.0001. For kisspeptin-10 infusion in controls vs NK3Ra: λλp<0.01. For vehicle vs 
NK3Ra: κp<0.05, κκp<0.01. For vehicle vs kisspeptin-10 in NK3Ra-treated women: Ψp<0.05, 
ΨΨp<0.01, ΨΨΨp<0.001, ΨΨΨΨp<0.0001.  
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Figure 7.5 The effect of endogenous compared with exogenous estrogen on response to 
kisspeptin-10 infusion.  
LH (A), FSH (B) and estradiol (C) levels in women receiving kisspeptin-10 infusion (between 24 and 
32 hours) without (black bars, n=10) and with (grey bars, n=10) transdermal estradiol treatment. Two 
estradiol patches releasing a total of 200 μg estradiol/day were applied between 0 and 32 hours. Data 
presented as mean ± SEM. **, p<0.01; ****, p<0.0001. 
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Timing and mean of peak LH and FSH  
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n peak LH 
LH IU/l 
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Table 7.2 The timing and peak LH and FSH concentration in kisspeptin-10 and vehicle infused 
subjects in control and treatment (NK3Ra) group.  
Numbers in parentheses indicate row percentages. Peak LH and FSH was determined for each 
participant during 32, 48 or 72 hour time points and mean ± SEM calculated a: vehicle vs kisspeptin-
10); b: kisspeptin-10 with and without exogenous estrogen); c: vehicle vs kisspeptin-10 in NK3Ra-
treated group); d: kisspeptin-10 with and without NK3Ra). *, p<0.05; **, p<0.01; ***, p<0.001. 
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7.4.3 NK3R antagonist has differential effects on LH and FSH 
secretion 
Serum LH levels did not change after 5 days of NK3R antagonist treatment (before 
the estradiol patches were applied) when compared to either pre-treatment 
concentrations (pre NK3Ra 5.0±0.6 vs 5 days NK3Ra 6.6±1.3 IU/l, ns) or to controls 
(Fig. 7.3A). Overall there was no difference in LH concentrations and the timing of 
peak LH in controls vs NK3Ra-treated women (Table 7.2 and Fig. 7.3A). To detect 
subtle changes in hormone secretion potentially overlooked by single time point 
blood sampling, analysis of hourly LH for 8 hours post dose showed that overall LH 
secretion was lower in NK3Ra-treated women compared to controls (p<0.0001, Fig. 
7.4A), although post hoc analysis indicated no significant differences in LH levels at 
any individual hourly time point.  
FSH concentrations appeared higher throughout treatment with NK3R antagonist 
compared to controls (Fig. 7.3B) and were significantly higher in NK3Ra-treated 
women throughout the eight-hour period (i.e. during saline infusion, p<0.0001) (Fig. 
7.4B). This may reflect that serum estradiol concentrations were significantly lower 
after 5 days of treatment with NK3R antagonist compared to controls (p<0.05) (Fig. 
7.3C) and comparable to estradiol levels before NK3R antagonist administration (pre 
NK3Ra: 121±17 vs 145±27 pmol/l after 5 days NK3Ra, ns).  
7.4.4 Effect of NK3R antagonist on the gonadotropin response to 
kisspeptin-10 
NK3R antagonist non-significantly increased kisspeptin-10 stimulated LH secretion 
at 32 hours (21.6±5.6 with NKB antagonist vs 16.4±3.9 IU/l kisspeptin-10 alone, 
p=0.41) (Fig. 7.3A, 7.4A). The FSH response to kisspeptin-10 was however 
significantly more pronounced in the presence of NK3Ra (10.7±3.5 vs 5.0±1.1 IU/l 
at 32h, p<0.05 Fig. 7.3B; and throughout the 7 hour infusion: p<0.0001 Fig. 7.4B).  
However, NK3Ra blunted the duration of kisspeptin-10 induced LH secretion, with 
significantly lower LH at 48 hours (15.0±3.6 vs 7.5±1.5 IU/l, p<0.05) when 
compared to kisspeptin-10 infused controls, whereas FSH showed no significant 
difference (Fig. 7.3). There were related changes in the timing of the LH peak 
(although not statistically significant), which was at 32 hours in 9/10 NK3Ra-treated 
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women in response to kisspeptin-10 infusion, compared with kisspeptin-10 treated 
controls whose LH peak timing was evenly divided between 32 and 48 hours (Table 
7.2).  
7.4.5 NK3R antagonist impedes estradiol dependent kisspeptin-10 
response 
The relationship between LH response to kisspeptin-10 and estradiol exposure, and 
the influence thereon of NK3Ra treatment, was investigated by analysing LH 
concentration at the end of kisspeptin-10 infusion in relation to endogenous estradiol 
concentrations at 0 hours (i.e. before transdermal estradiol application). There was a 
strong positive correlation in controls (r2=0.75, p=0.001) (Fig. 7.6). However, in 
NK3Ra-treated women, the LH response to kisspeptin-10 showed no such 
relationship (r2=0.007, ns). Very similar results were obtained when the analysis was 
based on estradiol concentrations after 24 hours of patch administration (r2=0.65, 
p=0.005 in controls; r2=0.03, ns in NK3Ra-treated women).  
 
Figure 7.6 Correlation between endogenous estradiol and LH response to kisspeptin-10 in 
controls and NK3R antagonist treated women.  
Kisspeptin-10 response on LH secretion is positively related to endogenous estradiol levels, whilst 
this correlation is not seen during NK3R antagonist treatment.  
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7.4.6 Interaction between NK3R antagonist and kisspeptin-10 in 
regulating LH pulsatility 
LH pulse frequency increased from 0.7±0.1 pulses/hour in vehicle cycle to 1.0±0.1 
pulses/hour during kisspeptin-10 infusion (p<0.01) (Fig. 7.7 A and B). NK3R 
antagonist reduced LH pulsatility to 0.5±0.1 pulses/hour (p<0.05 vs vehicle-infused 
controls), but administration of kisspeptin-10 to NK3Ra-treated women restored LH 
pulse frequency to that observed in kisspeptin-10-infused controls. Thus while 
NK3Ra slowed LH pulsatility in estrogen treated women, it did not affect the 
response to kisspeptin-10, indicating that kisspeptin effects are downstream of NKB 
signalling. 
Secretory mass of LH per pulse was increased similarly during infusion of 
kisspeptin-10 compared with vehicle in both control (p<0.05) and NK3R antagonist 
treated women (p<0.01) (Fig. 7.7C). NK3Ra antagonist did not reduce LH secretory 
mass per pulse.  
Consistent with increased LH pulse frequency, basal LH secretion decreased and 
pulsatile LH secretion increased during kisspeptin-10 infusion in the control group 
(p<0.05 vs vehicle; Fig 7.7 D and E). Basal LH secretion appeared lower in NK3Ra-
treated women when compared to controls but there was no effect on pulsatile LH 
secretion. Kisspeptin-10 induced the same changes in NK3Ra treated women as in 
controls, with no change in basal and an increase in pulsatile LH secretion 
(p<0.0001).  
The regularity of LH secretory pattern was assessed by approximate entopy (ApEn). 
Both kisspeptin-10 infusion and NK3Ra separately imposed greater orderliness 
(lower ApEn) in LH secretion (p<0.05; Fig 7.7F).  This was increased further in 
NK3Ra- treated women during kisspeptin-10 infusion (p<0.0001 vs NK3Ra alone; 
Fig. 7.7F). 
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Figure 7.7 Analysis of 8 hour LH secretory pattern during vehicle and kisspeptin-10 in controls and NK3Ra-treated women.  
(A) Illustrative LH pulse profile from one subject undergoing vehicle (green triangles), NK3R antagonist (purple circles), kisspeptin-10 (red diamonds) and NK3R 
antagonist followed by kisspeptin-10 (blue squares) treatment visits. Mean LH pulse frequency (B), secretory mass of LH per pulse (C), basal (nonpulsatile) LH 
secretion (D), pulsatile LH secretion (E) and the relative orderliness/regularity of LH secretory pattern (F) during vehicle and kisspeptin-10 infusion with (n=9) and 
without (n=9) pre-treatment with NK3R antagonist. Mean ± SEM. *, p<0.05; **, p<0.01; ****, p<0.0001. 
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7.5 Discussion 
In a model of LH modulation by estrogen administration in women, exogenous 
kisspeptin-10 stimulated LH secretion, the extent of which directly reflected estradiol 
concentrations. Pharmacological blockage of NKB-NK3R signalling slowed LH 
pulsatility and shortened the duration of kisspeptin-mediated LH secretion with 
‘sharpening’ of the LH response and strikingly abolished the relationship between 
estradiol and LH response to kisspeptin.  Taken together, these data support a central 
role for kisspeptin in the modulation of GnRH/LH secretion, and whilst NKB 
signalling is largely upstream of kisspeptin as previously reported (Young et al. 
2013), both pathways interact in determining the timing and characteristics of 
estrogenic negative and positive feedback on LH secretion.  
The stimulatory effect of exogenous kisspeptin on LH secretion in women is 
dependent on the sex steroid environment (Dhillo et al. 2007, Jayasena et al. 2011, 
Chan et al. 2012, George et al. 2012). This response is initially limited but increases 
markedly in the late follicular phase of the menstrual cycle when estradiol levels are 
rising (Dhillo et al. 2007, Jayasena et al. 2011, Chan et al. 2012). For most of the 
cycle, GnRH and thus LH secretion are inhibited by negative feedback from estradiol 
(and progesterone in the luteal phase), thus the low responsiveness to kisspeptin 
administration in previous studies is consistent with endogenous kisspeptin 
signalling being suppressed by steroid feedback. Conversely, the enhanced LH 
response in the later follicular phase may indicate the development of increased 
endogenous kisspeptin signalling in the lead up to the mid-cycle surge. This is 
supported by animal studies, where kisspeptin expression is highest following an 
estrogen challenge in the anteroventral periventricular nucleus (the site of positive 
estrogen feedback in rodents) in ovariectomised mice (Smith et al. 2005a) and at the 
time of GnRH/LH surge in sheep (Smith et al. 2006b), but is prevented by 
administration of kisspeptin receptor antagonist (Pineda et al. 2010, Smith et al. 
2011). The present data suggests a role of estradiol in modulating LH response to 
kisspeptin-10 infusion, which persisted well beyond the pharmacokinetic clearance 
of the exogenous kisspeptin-10. The striking positive relationship between estradiol 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
NKB/kisspeptin in estrogen feedback   202 
concentration in the late follicular phase and the LH response to kisspeptin-10 
infusion lends further support for the involvement of kisspeptin in estrogen feedback, 
as recently demonstrated for kisspeptin-54 (Narayanaswamy et al. 2015).  
The present data demonstrate that NK3R antagonist treatment, in an environment of 
high estrogenic negative feedback, reduced LH secretion and pulse frequency, whilst 
in the presence of kisspeptin-10 had a stimulatory effect on the secretion of both 
gonadotropins, but with a shorter duration of LH response. Hitherto, NK3R 
antagonists have been demonstrated to suppress LH secretion in states of high LH 
output, such as in women with PCOS (George et al. 2016), or in the ovariectomised 
ewe and castrate monkeys (Fraser et al. 2015a, Li et al. 2015), and in intact female 
monkeys a delay of surge-like but no decrease in basal LH secretion was observed 
(Fraser et al. 2015b). Although it appears that the suppression of LH secretion by the 
present dose and regimen lasted only a few hours, this was sufficient to significantly 
lower estradiol concentrations after 5 days of NK3R antagonist treatment (i.e. prior 
to the estrogenic treatment) compared to controls. This is consistent with data in the 
early follicular phase of the menstrual cycle (Chapter 5), where marked suppression 
in follicle estradiol secretion was observed with no detectable changes in serum LH 
concentrations when measured once a day. Gonadotropin secretion was also 
unaffected by NK3R antagonism from the late follicular phase of the menstrual cycle 
(Chapter 6) as well as in postmenopausal women (Chapter 4). This suggests that in 
women irrespective of the sex-steroid milieu NKB action is not critical for 
maintaining circulating baseline LH concentrations, although it is involved in 
modulating the pulsatile pattern of GnRH/LH secretion. Indeed, in this model of 
estrogen-modulated LH secretion the frequency of LH pulses was reduced by the 
NK3R antagonist and in the early follicular phase the amount of LH secreted in 
between those pulses was suppressed (Chapter 5). This is however in contrast to 
men, where NK3R antagonist markedly suppressed LH and testosterone secretion by 
decreasing nonpulsatile GnRH/LH release whilst having no effect on the frequency 
of LH pulses (Chapter 3). This may reflect sexual dimorphism, where changes in 
GnRH/LH pulsatility throughout the menstrual cycle are a physiological feature for 
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normal reproductive function in women (Filicori et al. 1986) but not in men 
(Veldhuis et al. 2012). 
In this thesis the role of NKB at the mid-cycle LH surge has been investigated in two 
models in healthy women. When administered in the late follicular phase, NK3R 
antagonist did not abolish the mid-cycle LH surge but did affects its timing, being 
more variable in the treatment compared to control cycle (Chapter 6), suggesting that 
NK3R antagonist perturbed the switch to positive estrogen feedback. However, no 
changes in peak estradiol secretion were detected and cycle length between the 
participants was variable, making it difficult to draw clear conclusions. We have 
therefore used exogenous estrogen exposure to standardise increased LH secretion, 
aiming to mimic the mid-cycle LH surge (Baird et al. 1995). NK3R antagonist had 
no effect on the timing of peak LH secretion in this model of estrogen 
administration, which is consistent with a lack of effect of NK3R antagonist on the 
estrogen induced LH surge seen in ovariectomised ewes (Li et al. 2015). The 
mechanisms critical for progression to positive estrogen feedback therefore appear to 
be largely independent of NKB but are dependent on kisspeptin, consistent with 
rodent neuroanatomical data (Smith et al. 2005a, Burke et al. 2006). A recent study 
using a different NK3R antagonist in normal women also showed a temporary 
suppression of LH levels lasting few hours post dosing, but no overall decrease in 
basal LH secretion following treatment throughout the follicular phase (Fraser et al. 
2016). NK3Ra did, however, delay LH surge in some women, probably as a 
consequence of delayed pre-ovulatory estradiol rise, but the study did not assess the 
effect of neurokinin B antagonism at the time of the switch from negative to positive 
estrogen feedback, when NKB might be no longer critical (Fraser et al. 2016). Unlike 
in the present study, no effect of NK3Ra on FSH secretion was observed (Fraser et 
al. 2016). 
Infusion of kisspeptin-10 can restore LH pulsatile secretion in men and women with 
inactivating mutations in NKB signalling, indicating that kisspeptin is functionally 
downstream of NKB in LH pulse generation (Young et al. 2013). This is supported 
by the inability of the NK3R agonist senktide to stimulate LH secretion in Kiss1r 
knockout mice (Garcia-Galiano et al. 2012).  Consistent with this overall hierarchy, 
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NKB antagonism (active during kisspeptin-10 administration as half life of 
AZD4901 is 8.5 hours (Litman et al. 2014)) did not prevent the stimulatory effect of 
kisspeptin-10 infusion on LH secretion. NKB antagonist however shortened the LH 
response to kisspeptin-10, affecting its timing by reducing the variability of peak LH 
secretion, and disrupted the relationship between LH response and estradiol 
concentrations. These findings suggest a more complex interaction than a linear 
pathway between those neuropeptides at the time of the mid-cycle LH surge, but are 
also consistent with NK3R antagonist reducing endogenous kisspeptin stimulation of 
GnRH as a contribution to the observed effect.  
LH pulse frequency increases in the late follicular phase, culminating in the mid-
cycle LH surge (Yen and Tsai. 1971). Exogenous kisspeptin stimulates pulsatile LH 
secretion (George et al. 2011, George et al. 2013, Jayasena et al. 2013b, Young et al. 
2013, Jayasena et al. 2014b), but its role as a potential contributor to positive 
estrogen feedback has not been previously investigated. In this study, the increase in 
LH secretion during kisspeptin-10 infusion included increased LH pulse frequency 
and mass-per-secretory pulse. This resulted in a larger proportion of total LH 
secretion occurring in pulsatile bursts, and the regularity of LH secretory pattern 
showed greater orderliness in the lead up to the stimulatory phase of response to 
estrogen.  Deconvolution analysis also indicated changes in the nature of the 
pulsatile LH secretion following NK3R antagonist administration, with reduced basal 
secretion and ApEn, indicating a more orderly, slowed pattern of LH and by 
inference GnRH secretion.  The increase in LH pulse frequency resulting from 
kisspeptin-10 infusion and the slowing in LH pulsatility with NK3R antagonist 
administration both increased the regularity and orderliness of LH secretion and may 
be the basis for the reduced variability in the timing of peak LH secretion as well as 
shortened duration of stimulated LH secretion in response to kisspeptin-10. 
Consistent with some aspects of our findings, estrogen-induced LH surges were 
preserved in ovariectomised NK3R antagonist-treated ewes, although the onset-to-
peak time was delayed (Li et al. 2015). In sheep, the NK3R agonist senktide 
increased LH secretion, resembling ‘surge-like’ LH levels (Billings et al. 2010), 
whilst in monkeys, NK3R antagonist abolished LH surge, ovulation and subsequent 
Kisspeptin and neurokinin B in the regulation of the human HPG axis 
 
NKB/kisspeptin in estrogen feedback   205 
progesterone rise (Fraser et al. 2015b). While our data primarily indicate that NKB 
signalling is largely upstream of kisspeptin signalling in mediating estrogenic 
positive effects, it clearly has a modulatory role in determining the pattern and 
duration of GnRH secretion during estrogen positive feedback. 
A stimulatory effect of kisspeptin alone on FSH has been minimal and inconsistent 
in previous studies (Dhillo et al. 2007, Jayasena et al. 2011, Chan et al. 2012, 
Skorupskaite et al. 2014), but was robustly demonstrated in this model and was not 
prevented by NK3R antagonist treatment. NK3R antagonist also increased FSH 
secretion, and markedly augmented stimulation by kisspeptin-10. Higher serum FSH 
concentrations were also observed with the NK3R antagonist in the early follicular 
phase of the menstrual cycle (Chapter 5). These findings with the NK3R antagonist 
are consistent with well-established data from animal models showing that high 
GnRH pulse frequency favours LH secretion while low pulse frequency favours FSH 
secretion (McNeilly et al. 2003), and that this is the main drive to follicular estrogen 
production, the reduction in both of which (and presumed reduced inhibin 
production, not determined here) is likely to have resulted in the observed increased 
FSH secretion. The differential effects of NK3Ra on FSH vs LH response to 
kisspeptin-10 are also similar to the effects in patients with NKB defects (Young et 
al. 2013). This does not explain the increased FSH secretion in response to kisspeptin 
with NK3R antagonist, when pulse frequency was not suppressed.  This may indicate 
the importance of other aspects of pulsatile GnRH section in the differential 
regulation of LH and FSH, such as its regularity, as ApEn was decreased by both 
NK3R antagonist and kisspeptin, and further by the two in combination. 
While the present study has clear strengths (the use of specific neurokinin-3 receptor 
antagonist, detailed LH pulse profiling and blinded pulse analysis), there are 
weaknesses. The sample size is small, and placebo was not administered to the 
control group receiving no NK3Ra. The limited LH suppression by the NK3R 
antagonist might be due to the small sample size and the dose of AZD4901 may be 
low compared to those used in animal studies, limiting the response (Fraser et al. 
2015b). Statistical analyses included adjustment for alpha for multiplicity of 
comparisons but studies such as these should be regarded as mechanistic 
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explorations. Although our model of estrogen-stimulated LH secretion may be 
limited in representing the physiological LH surge, taken together with late follicular 
phase data, our results suggest a role for neurokinin B in mediating negative estrogen 
feedback, and the timing and pattern of the surge mode of GnRH/LH secretion in 
which kisspeptin is a key modulator. 
In summary, using estrogen to standardise LH secretion in women to model the mid-
cycle LH surge, we have shown that the increase in LH secretion by kisspeptin-10 
infusion is related to estradiol exposure. We show that NK3R antagonist reduced LH 
pulsatility in healthy women. Assessment of the interaction between kisspeptin and 
NKB showed that the duration of kisspeptin-mediated LH secretion was shortened 
by the NK3R antagonist, and the quantitative relationship with estradiol exposure 
abolished. These data thus indicate that NKB pathways regulate GnRH/LH secretion 
in women, are predominantly upstream of kisspeptin signalling in mediating estrogen 
feedback, but modify this kisspeptin response. This extends our understanding of 
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Chapter 8. General discussion and conclusions 
In this thesis, the interaction and functional hierarchy between kisspeptin and 
neurokinin B in the control of human reproduction was investigated in states of fast 
and slow LH pulsatility and in varying sex-steroid environments in healthy men and 
women. Using pharmaceutical manipulation of NKB-KP-GnRH pathways we have 
demonstrated that neurokinin B is involved in the physiological regulation of 
reproductive function in men and women and that this is via the modulation of 
GnRH/LH pulsatility. Whilst neurokinin B signalling is predominantly proximal to 
kisspeptin, the hierarchy is more complex than simply linear in the control of human 
HPG axis, with the importance of the NKB pathway varying in different states. 
Primary results have been discussed in Chapters 3 to 7, with key themes emerging 
when the findings from those mechanistic studies are considered together.  
8.1 Kisspeptin and neurokinin B interaction is complex 
In patients with genetic mutations inactivating the TAC-TACR3 pathway, 
characteristically low LH pulse frequency was restored by exogenous kisspeptin 
administration, demonstrating for the first time in the human model that central 
neurokinin B signalling is functionally upstream of kisspeptin (Young et al. 2013). 
Whilst this is consistent with data from animal models (Billings et al. 2010, Corander 
et al. 2010, Navarro et al. 2011a, Ramaswamy et al. 2011, Garcia-Galiano et al. 
2012), there are no previous studies investigating the hierarchy of kisspeptin and 
neurokinin B in the control of GnRH secretion in health rather than a disease setting, 
and in different states of LH pulsatility and sex-steroid environment across the 
reproductive cycle. This has been explored in this thesis with key findings 
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LH pulsatility Slow Fast LH surge model 
Sex-steroid 
feedback 
Negative Loss of sex-steroid 
stimulus 
Negative then positive 
NK3Ra response Decreased LH 
and FSH  
Decreased T  
Marginal LH 
decrease 
No FSH effect 
Marginal decrease in 
basal LH  
No effect on peak LH 
Increased FSH  
KP-10 response Increased LH No LH/FSH effect Increased LH and FSH 
KP-10 response 
in presence of 
NK3R 
antagonist 
Increased LH No LH/FSH effect Shorter KP response 
Abrogated positive E2 
feedback 
Table 8.1 Summary table showing effects of kisspeptin and NK3R antagonism on gonadotropin 
secretion in different states of LH pulsatility and sex-steroid environments across human 
reproductive cycle.  
Gonadotropin response to kisspeptin-10 and NK3R antagonist alone and in combination has been 
investigated in healthy men, postmenopausal women and in pre-menopausal women under estrogen 
administration to enhance LH secretion.  
 
By using a consistent protocol of NK3R antagonism for 7 days and exogenous 
kisspeptin administration, we have shown that in men, postmenopausal women and 
in a model of LH surge in premenopausal women, there is a consistent functional 
hierarchy of those neuropeptides. This has been demonstrated at the level of both 
gonadotropin secretion and hypothalamic GnRH pulsatility, where a decreased LH 
pulse frequency with the NK3R antagonist was increased by kisspeptin infusion in 
healthy women. In men, LH secretion was decreased with the NK3R antagonist, but 
this did not affect an immediate stimulatory LH response to kisspeptin. Limited 
effect on LH secretion with kisspeptin administration has been shown in 
postmenopausal women previously (George et al. 2012) but its stimulatory role 
following potential LH suppression by NK3R antagonism has not been assessed. We 
have shown a different gonadotropin response in hypoestrogenic postmenopausal 
women, where the HPG axis was refractory to manipulation by kisspeptin and NK3R 
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antagonist. These data raise the possibility that with the loss of negative estrogen 
feedback in menopause, the system in not responsive to central manipulation. This is 
in keeping with the hypertrophy of kisspeptin and neurokinin B expressing neurones 
seen in the hypothalamus of postmenopausal women (Rance et al. 1990, Rance and 
Young. 1991) with similar findings in aging monkeys (Eghlidi et al. 2010). 
Supporting a role for neurokinin B in sex-steroid feedback, in a model of estrogen-
induced LH secretion in premenopausal women, NK3R antagonist prevented the 
positive correlation between serum estradiol and LH response to kisspeptin, and 
furthermore shortened but did not abolish kisspeptin-stimulated LH secretion. Whilst 
being consistent with the overall hierarchy, this suggests an additional level of 
interaction between kisspeptin and neurokinin B at least in this model, whereby 
neurokinin B is having downstream effects modifying the kisspeptin response. 
Further evidence of a role for the NKB pathway in mediating estrogen feedback is 
provided by the increased variation in the timing of the LH surge in normal women 
administered NK3R antagonist in the late follicular phase. 
This complexity is somewhat consistent with another study in healthy men, where 
stimulatory LH response to co-infusion of kisspeptin (KP-54) and neurokinin B itself 
was significantly lower than with kisspeptin alone, indicating potential inhibitory 
action of neurokinin B (Narayanaswamy et al. 2016c). Indeed, both stimulatory and 
inhibitory effects of exogenous neurokinin B administration have been reported in 
animal studies (Navarro et al. 2009, Billings et al. 2010, Ramaswamy et al. 2010, 
Navarro et al. 2011a). In a model of mid-cycle LH surge in women, the orderliness 
and regularity of LH secretion was greater with co-administration of kisspeptin-10 
and NK3R antagonist than with either treatment alone, suggesting further the effects 
of NKB on kisspeptin signalling. Having investigated kisspeptin-neurokinin B 
interaction in regulating GnRH and thus gonadotropin secretion across different 
stages of reproductive health in men and women, this suggests that the interaction 
between these neuropeptides is complex with potential dual stimulatory and 
inhibitory actions of neurokinin B on downstream kisspeptin signalling, which may 
be dependant on sex-steroid environment.  
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8.2 NKB-KP pathway shows sexual dimorphism 
In the present study, gonadotropin response to pharmacological blockade of 
neurokinin-3 receptor and exogenous kisspeptin administration was observed to be 
different between men and women, suggesting sexual dimorphism in NKB-KP 
pathways. Gender differences in their response to kisspeptin are well recognised in 
literature (Jayasena et al. 2011, Chan et al. 2012). This is further supported by the 
findings here, showing marked increase in LH with kisspeptin administration in men, 
but variable response in women, having no effect in estrogen deficient 
postmenopausal women in contrast to enhanced LH secretion in women under high 
estrogen exposure. Apart from some anatomical data, evidence for sexual 
dimorphism in neurokinin B signalling is less clear. In this thesis, LH secretion was 
assessed every 10 minutes for up to 8 hours post 6-7 days of NK3R antagonist 
administration in men, postmenopausal women and in premenopausal women during 
the follicular phase as well as in a model of estrogen-induced LH secretion. We have 
demonstrated that NK3R antagonist markedly suppressed LH secretion in men but 
this response in women was marginal. In the follicular phase and postmenopause, 
NK3R antagonist had no significant effect on LH secretion when sampled at single 
timepoints. Although overall LH secretion was lower with the NK3R antagonist 
treatment between 24 and 32 hours of estrogen exposure in a model LH surge, post 
hoc analysis indicated no significant differences in LH levels at any individual 
hourly timepoint over 8 hours, and no change in LH concentrations was observed 
throughout 7 days of NK3R treatment. These are novel findings in humans, 
indicating sexual dimorphism in neurokinin B signalling, but rather at variance with 
animal data showing greater abundance of neurokinin B expressing neurones in ewes 
than rams (Goubillon et al. 2000, Cheng et al. 2010) and earlier maturation of 
neurokinin B signalling in female rats (Ciofi et al. 2007). Our data in men are 
consistent with another study published during the preparation of this thesis, where a 
different NK3R antagonist (ESN364) decreased LH and testosterone secretion in 
healthy men (Fraser et al. 2016) with concordant results in castrate monkeys (Fraser 
et al. 2015a). ESN364 was also administered to healthy women throughout the 
follicular phase for 21 days, with the authors suggesting that baseline LH secretion 
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was also inhibited (Fraser et al. 2016). However, this effect was very short-lived 
showing significant LH inhibition at 4 and 6 hours only post dosing with no clear 
suppression following treatment throughout the follicular phase, but a delay in LH 
surge in some women likely as a consequence of delayed estradiol rise (Fraser et al. 
2016). Furthermore, in intact female monkeys, NK3R antagonist administered at 
significantly higher doses did not show marked suppression in LH secretion 
throughout 35 day treatment but also delayed LH surges (Fraser et al. 2015a). 
Decrease in LH secretion in females has been demonstrated previously, but this was 
with central infusion of NK3R antagonist (MRK-08) in ovariectomised ewes (Li et 
al. 2015), and in women with PCOS, where LH hypersecretion is a part of the 
pathophysiology (George et al. 2016). Nevertheless, even if there is scope for 
manipulating LH secretion in women by the NK3R antagonist, this response is 
strikingly different to that observed in normal men in this and other published 
studies. Taken together, this suggests there may be gender different mechanisms by 
which neurokinin B modulates GnRH/LH secretion and this is consistent with sex 
differences observed in the KNDy neuronal network (Oakley et al. 2009). Inability to 
clearly manipulate LH secretion in women may reflect normal physiology where it is 
the cyclical change in GnRH/LH pulsatility that is prerequisite for normal gonadal 
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8.3 Kisspeptin and neurokinin B modulate GnRH pulsatility 
It is well established that pulsatile GnRH secretion is pivotal for normal reproductive 
function (Herbison. 2015). Mechanisms for the GnRH pulse generator are not fully 
understood but kisspeptin and neurokinin B have been recently implicated as 
potential upstream modulators of this ‘clock’ (Herbison. 2015, Plant. 2015a). The 
role for kisspeptin in this has been demonstrated in normal men and women and in 
disease models (reviewed in (Skorupskaite et al. 2014, Clarke and Dhillo. 2016)). 
Administration of the same NK3R antagonist (AZD4901) to women with PCOS 
(George et al. 2016) and different NK3R antagonists (ESN364 and MRK-08) to 
ovariectomised ewes (Fraser et al. 2015a, Li et al. 2015) reduced the frequency of 
LH pulses, suggesting the role of neurokinin B in regulating GnRH/LH pulsatility at 
least in states of high LH output. However, there are no known studies exploring the 
role of neurokinin B and its interaction with kisspeptin in modulating pulsatile 
GnRH/LH release in health in humans.  
The present study has shown for the first time that in normal men and women NK3R 
antagonist affected the pulsatile nature of LH secretion (a marker of GnRH release) 
but that this was variable across the groups studied (Table 8.2). This indicates that 
whilst neurokinin B acts centrally to modulate GnRH pulsatility, its interaction with 
GnRH is complex and influenced by additional factors. In keeping with published 
data, NK3R antagonist decreased LH pulse frequency but with the dose and regimen 
used here, this was only seen in women during estrogen-induced LH secretion and in 
those postmenopausal women with symptomatic hot flushes, but not in men or 
during other stages of the menstrual cycle. It is possible that there is a threshold to 
which a maximal suppression of pulse frequency can be achieved.  Lower LH pulse 
frequency in men (0.5 pulses/hour in this study) may have precluded further pulse 
reduction by the NK3R antagonist in contrast to increasing LH pulsatility throughout 
the late follicular phase with observed decrease in LH pulse frequency from 0.7 
pulses to 0.5 pulses/hour in this model of the LH surge. However, this does not seem 
to be an absolute determinant for LH pulse modulation since in the early follicular 
phase mean LH pulse frequency was 0.7/hour and in all postmenopausal women 
irrespective of their flush status was approximately 0.9 pulses/hour. Estrogen 
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feedback appears to be at least one candidate affecting neurokinin B modulation on 
pulsatile GnRH/LH secretion.  In a model of LH surge, NK3R antagonist slowed LH 
pulsatility and abolished the correlation between estradiol and LH response to 
kisspeptin, which is in contrast to the absence of effect on LH pulse frequency 
observed in women with lower estradiol levels in the early follicular phase and in 
hypoestrogenic postmenopausal women in a group as a whole. Sex-steroids are 
known to regulate LH pulse frequency (Veldhuis et al. 2008), thus the fall in serum 
testosterone in men and estradiol in women is likely to have counteracted any 
suppressive effect of NK3R antagonism on pulsatile LH secretion. Furthermore, 
inability to manipulate LH pulse frequency in men and menopausal women may 
reflect normal physiology in that changes in LH pulse frequency are not essential for 
normal testicular function in men (Veldhuis et al. 2012) and the prolonged estrogen 
deficiency in postmenopausal women may have affected its role, unlike its key role 
in regulating menstrual cycle in women of reproductive age (Filicori et al. 1986).  
In addition to the frequency of LH pulses most commonly assessed in previous 
studies, other parameters of the pattern of LH/GnRH secretion were analysed in this 
thesis (Table 8.2). The amount of LH secreted in between the pulses (basal secretion) 
was affected most consistently by the NK3R antagonist, being reduced in men, 
postmenopausal women and in women in the early follicular phase with a non 
statistically significant decrease in a model of the mid-cycle LH surge (when pulse 
frequency was reduced). In men, the total amount of LH released in pulsatile bursts 
was also reduced by the NK3R antagonist, and LH secretory pattern was more 
regular (decreased ApEn), which were sufficient to induce a testicular response with 
markedly decreased testosterone secretion, despite no observed changes in LH pulse 
frequency. This suggests that these parameters of pulsatile LH/GnRH release are 
important in mediating Leydig cell function. Similarly, ovarian estradiol secretion 
was decreased and follicle development was arrested during early follicular phase 
administration of NK3R antagonist, where basal (nonpulsatile) LH secretion was the 
only parameter of GnRH/LH secretory pattern affected. Increased orderliness of 
GnRH/LH secretion was a relatively consistent effect of NK3R antagonism, 
indicating a role for NKB signalling in reducing that orderliness in its stimulatory 
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effects on the regulation of GnRH secretion.  Taken together, manipulation of 
pulsatile GnRH/LH secretion by the NK3R antagonist in normal men and women 
and the downstream effects on gonadal function, suggest a key role of neurokinin B 
in modulating GnRH pulsatility and thus reproductive function in humans but with 
the details of the impact on GnRH secretion varying between men and women and 
between different physiological states.   
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Table 8.2 Effects on NK3R antagonism, kisspeptin-10 infusion and their combination on various parameters of pulsatile nature of LH and by inference 
GnRH secretion in healthy men and women in different stages of reproductive life.   
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8.4 Strengths and limitations 
The studies described in this thesis were proof-of-principal mechanistic studies in 
human volunteers, exploring the physiology of hypothalamic regulation of 
reproductive function. We have used the same protocol of administration of a 
specific neurokinin-3 receptor antagonist (AZD4901) and exogenous kisspeptin-10 
(iv bolus or an infusion) across different stages of reproductive health reflecting 
states of high and low LH pulsatility and various sex-steroid milieu. Effects on 
reproductive hormone secretion and detailed LH pulse profiling with blinded pulse 
analysis was performed, forming a comprehensive series of studies to support the 
role of NKB and its complex interaction with kisspeptin in regulating human 
reproductive function through the modulation of pulsatile nature of GnRH secretion.  
It is important to acknowledge that the sample size is small in the present studies. A 
sample size of up to 10 volunteers is commonly used in such mechanistic studies by 
others (Dhillo et al. 2005, Dhillo et al. 2007, Jayasena et al. 2011) and in previous 
work by our group (George et al. 2011, George et al. 2012), demonstrating 
significant changes in reproductive hormone secretion and LH pulsatility. However, 
small sample size may have affected statistical power to detect subtle effects of 
NK3R antagonism on LH secretion in women. Furthermore, limited LH suppression 
and variable effects on LH pulse frequency by the NK3R antagonist might be due to 
80mg of AZD4901 being at the bottom of the dose response curve, this was the 
lowest dose that had an effect on LH secretion in women with PCOS (George et al. 
2016). It has to be noted that marked effects on LH pulsatility and serum 
concentrations achieved in animal studies were often with central administration of 
NK3R antagonist and with larger doses (Fraser et al. 2015a, Li et al. 2015). In 
addition, there are anatomical and therefore likely physiological differences in NKB-
KP pathway in animals compared to humans, making direct comparisons difficult, 
and there are to date limited human data on the interaction between kisspeptin and 
neurokinin B in regulating the HPG axis. Peripherally administrated drugs in this 
study may not have fully reached the hypothalamic regions of their action, although 
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KNDy neurones send projections to the median eminence and the arcuate nucleus, 
which have an incomplete blood-brain-barrier (Rodriguez et al. 2010).  
Compliance with taking the NK3R antagonist was not formally assessed, such as by 
using drug diaries. Participants were asked to return drug bottles after the study, and 
although the tablet count was correct this is not a reliable indicator alone. We have 
no reason to suspect non-compliance, as reproductive hormone profiles during 
treatment were consistent with the overall pattern of effect between individuals.  
The present study was an open label one and placebo was not administered to the 
control group receiving no NK3R antagonist. This may have particularly influenced 
demonstration of reduction in flush symptoms by the NK3R antagonist in 
postmenopausal women. However, paired data were obtained for the control period 
and administration of NK3R antagonist in most studies, and the order of those was 
randomised (in women in early and late follicular, luteal phase and model of pre-
ovulatory LH surge) as was the infusion of kisspeptin-10 or saline, using a sealed 
envelope technique. The same operator performed all ultrasound assessments 
throughout the study. Reproductive hormone samples were analysed in duplicate by 
the operator blinded to treatment allocation, and deconvolution analysis was also 
blinded to treatment allocation.  
We have used a model of exogenous estradiol administration previously 
demonstrated to induce LH secretion at 48 hours mimicking positive estrogen 
feedback by Baird and colleagues (Baird et al. 1995). This model may not fully 
replicate the physiological system of the pre-ovulatory state. Nevertheless, it allowed 
us to standardise estrogen exposure in women and gain some insight into neurokinin 
B and kisspeptin interaction in positive estrogen feedback, which is otherwise 
challenging to study in normal women with variable timing and extent of follicle 
development and estrogen production. Although the LH increase at 48 hours might 
be in part secondary to loss of negative estrogen feedback with exogenous estradiol 
removal at 32 hours, we have shown that continuing estrogen administration at 48 
hours had no effect in serum LH concentration at that time. This is therefore 
suggestive of positive estrogen feedback triggering LH secretion in our model.  
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8.5 Clinical application of NKB-KP manipulation and future work 
GnRH analogues are used extensively in clinical practice mainly to downregulate 
gonadal function in sex-steroid dependent disorders, e.g. in breast and prostate 
cancer, endometriosis, uterine fibroids, and in assisted conception. Although 
effective, GnRH analogues suppress gonadal steroids to near castrate levels, giving 
rise to menopausal-like side effects, such as hot flushes, loss of libido and reduced 
bone mass density. Classification of reproductive endocrine conditions into the states 
of high (PCOS, menopause, precocious puberty), low (delayed puberty, 
hypothalamic amenorrhoea, hypogonadism in diabetes) and normal (endometriosis, 
fibroids, prostate hypertrophy) GnRH/LH pulsatility makes manipulation of NKB-
KP pathways a novel therapeutic approach in managing various reproductive 
endocrine states (Fig. 8.1). 
 
Figure 8.1 Potential therapeutic application of manipulation of kisspeptin and neurokinin B 
based LH secretion.  
Kisspeptin and neurokinin B antagonists have therapeutic potential to decrease LH pulsatility in 
health and in reproductive endocrine disorders where LH pulse frequency is high, whilst kisspeptin 
and neurokinin B agonists and opioid antagonists may increase pulsatile LH secretion where it is low. 
Adapted from Skorupskaite et al. (2014).  
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8.5.1 Manipulation of NKP-KP pathways to suppress HPG axis 
Manipulation of KNDy neurones to supress the stimulatory action of kisspeptin and 
neurokinin B by their receptor antagonists, and to stimulate the inhibitory action of 
dynorphin by its agonists, offers therapeutic potential to reduce gonadotropin and 
thus sex-steroid secretion where GnRH/LH pulsatility is normal or high (Fig. 8.1). 
Therapeutic potential in states of normal GnRH/LH pulsatility 
In the present study, NK3R antagonist in healthy women halted ovarian follicle 
development and pre-ovulatory estradiol rise, thereby delaying the mid-cycle LH 
surge and ovulation. Our data suggest potential therapeutic application of neurokinin 
B antagonism in non-steroidal contraception, being specifically advantageous in 
women where estrogen is contraindicated. Moreover, a delay in ovulation for the 
duration of treatment may be also applied as pro-contraceptive. Similar effects were 
observed with a different NK3R antagonist (ESN364) administration for 21 days 
delaying positive estrogen feedback and LH surge, although, in contrast to our data, 
no changes in ovarian follicle growth were demonstrated (Fraser et al. 2016). 
Importantly, we have shown that after treatment was discontinued, follicle 
development resumed with evidence of normal ovulation and luteal function. Luteal 
function was consistently unaffected by NK3R antagonist administration in the late 
follicular and luteal phases. However, possible effects on endometrium remain to be 
established since NKB-NK3R pathway is expressed in human uterine epithelium 
(Cejudo Roman et al. 2012). Indeed, uterine stromal atrophy with inactive glands 
was observed with NK3R antagonism (ESN364) in monkeys but those changes were 
reversible after treatment discontinuation (Fraser et al. 2015a) and it is unclear 
whether these findings merely reflect the changed endocrine environment. Clinical 
application of NK3R antagonism might be limited by the resulting lack of 
progesterone exposure and potential adverse endometrial effects associated with it. 
In the present study, treatment was for 7 days only but whether such effects would 
persist with longer NK3R antagonist administration is yet to be determined.  
Potentially more subtle decrease in LH than FSH secretion by antagonism of 
kisspeptin and neurokinin B signalling contrasts with profound suppressive effects of 
GnRH analogues, which decrease gonadotropin and sex steroid secretion to near 
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castration levels with consequent side effects, including vasomotor symptoms, loss 
of libido and decreased bone mineral density (Roseweir et al. 2009). Whilst complete 
downregulation of gonadal steroids is necessary in some conditions, such as prostate 
cancer, partial suppression is more desirable in sex-steroid dependent disorders, such 
as benign prostatic hyperplasia, endometriosis, uterine fibroids and heavy menstrual 
bleeding. Estradiol levels were above castrate levels with the NK3R antagonist in our 
female studies and those reported by others (Fraser et al. 2016), avoiding the 
unwanted side effects of estrogen deficiency. Clinical advantage of incomplete 
suppression of the HPG axis is further illustrated in the management of 
endometriosis and uterine fibroids, where selective progesterone receptor modulators 
and/or GnRH analogues with sex-steroid add back are often used. Furthermore, the 
NKB-NK3R pathway is upregulated in human uterine fibroids (Canete et al. 2013) 
and a randomised placebo controlled trial is currently underway investigating NK3R 
antagonism in in this setting. The thinner endometrium observed with NK3R 
antagonist administration in the early follicular phase in our study is a foundation for 
assessment of menstrual blood loss, which could translate into therapies to reduce 
heavy menstrual bleeding.  
A similar therapeutic approach might support the use of kisspeptin and neurokinin B 
inhibition in benign prostatic hypertrophy. In men, NK3R antagonist suppressed 
testosterone levels and this was more profound in men compared to estradiol 
reduction in women. Testosterone concentrations were markedly reduced after 24 
hours of treatment but then remained at the lower end of normal for the duration of 
NK3R antagonist administration, with one man reported reduced libido, which 
recovered after treatment. Similarly, kisspeptin analogues were shown to decrease 
testosterone into the castration range in healthy men (Maclean 2013, Scott 2013), 
potentially limiting the clinical use of antagonism of the actions those neuropeptides.  
Therapeutic potential in states of high GnRH/LH pulsatility 
It is a novel observation that postmenopausal women administered NK3R antagonist 
reported subjective reduction in their hot flush frequency and severity. Indeed, LH 
pulses were shown to coincide with hot flushes (Casper et al. 1979, Oakley et al. 
2015), the expression of kisspeptin and neurokinin B is unregulated postmenopause 
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(Rance. 2009), and in premenopausal women 30-minute infusion of neurokinin B 
induced the sensation of hot flushes (Jayasena et al. 2014c). We have shown that 
NK3R antagonist reduced the frequency of LH pulses in those postmenopausal 
women reporting flush symptoms. Taken together this data support a link between 
GnRH/LH pulsatility and vasomotor symptoms (Casper et al. 1979, Rance et al. 
2013) and NK3R antagonism as a potential therapeutic approach. We do appreciate 
lack of placebo in the present study but this warrants further exploration in the form 
of a randomised placebo controlled trial and an objective measure of hot flushes, 
such as by using sternal conductance monitoring.  
In the present study, both exogenous kisspeptin and NK3R antagonist have been 
shown to increase and decrease LH pulse frequency, respectively, and to affect other 
parameters of pulsatile nature of LH/GnRH secretion. Slowing down GnRH pulse 
frequency, which preferentially determines LH secretion (McNeilly et al. 2003), by 
kisspeptin and/or neurokinin B receptor antagonists may selectively suppress 
hypersecretion of LH seen in PCOS. Indeed, a recent phase 2 trial administered the 
same NK3R antagonist (AZD4901) to anovulatory hyperandrogenaemic women with 
PCOS, demonstrating suppression in LH pulse frequency and subsequent decrease in 
serum LH and testosterone levels (George et al. 2016). The rate of ovulation was 
equivalent between the control and treatment groups, and it was not possible to 
distinguish if this was a spontaneous or potentially treatment-induced ovulation 
(George et al. 2016). A randomised controlled trial administering higher NK3R 
antagonist doses for longer in women with PCOS is currently underway to determine 
effects of neurokinin B antagonism on resumption of folliculogenesis and 
menstruation as well as its role in the treatment of hirsutism. Although the inhibitory 
role of opioids on GnRH and LH pulsatility is well known chronic opioids exposure 
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8.5.2 Manipulation of NKB-KP pathways to stimulate HPG axis 
Manipulation of KNDy neurones to enhance the stimulatory action of kisspeptin and 
potentially neurokinin B by their cognate agonists, and to suppress the inhibitory 
tone of dynorphin by its antagonists, offers therapeutic potential to increase 
gonadotropin secretion where it is low (Figure 8.1).  
Therapeutic potential in states of low GnRH/LH pulsatility 
In addition to the stimulatory role of kisspeptin on gonadotropin release in healthy 
men and women, kisspeptin has been shown to increase LH secretion and pulse 
frequency in women with hypothalamic amenorrhoea (Jayasena et al. 2014b), 
hypogonadal men with diabetes (George et al. 2013) and in patients bearing 
inactivating TAC3/TACR3 mutations (Young et al. 2013), but with suboptimal 
effects on gonadal steroid secretion.  
In women with hypothalamic amenorrhoea twice-weekly administration of 
kisspeptin (KP-54 6.4 nmol/kg) maintained gonadotropin secretion for 8 weeks with 
no significant increase in estradiol levels, suggesting that ovarian activity remained 
quiescent, as confirmed by unchanged follicle size and endometrial thickness on 
ultrasound scan (Jayasena et al. 2010). FSH response to kisspeptin has been minimal 
and inconsistent in previous studies (Dhillo et al., 2007, Jayasena et al., 2011, Chan 
et al., 2012), and may account for this lack of androgen aromatisation. An inhibitory 
action of NKB has been suggested following the observation that co-infusion of 
NKB and kisspeptin had lesser stimulatory response on LH secretion than kisspeptin 
alone (Narayanaswamy et al. 2016c). Dual administration of kisspeptin and NK3R 
antagonist may stimulate LH and FSH secretion sufficiently to increase estradiol 
secretion in women with hypothalamic amenorrhoea. Kisspeptin may need to be 
administered more frequently, for longer and by a more potent route to achieve 
longer-term effects on gonadal function. Indeed, intravenous infusion of the highest 
dose of kisspeptin-54 (1.0 nmol/kg/hour) in those women for 10 hours increased 
pulsatile LH secretion with serum estradiol continuing to increase for the duration of 
the infusion (Jayasena et al. 2014b). However, a gradual decline in LH secretion was 
observed after 5 hours of kisspeptin infusion (Jayasena et al. 2014b), as it was with 
twice daily subcutaneous injections for 2 weeks (6.4 nmol/kg) (Jayasena et al. 2009), 
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indicating possible tachyphylaxis. The opioid antagonist, naltrexone, has been 
administered in women with hypothalamic amenorrhoea, where it increased LH 
pulse amplitude and circulating estradiol levels and restored menstruation in some 
patients (Genazzani et al. 1995a). The role of opioid antagonism in stimulating 
gonadotropin secretion in other cases of abnormally low LH secretion remains to be 
elucidated.  
Lack of gonadal steroid effect by exogenous kisspeptin has also been demonstrated 
in other causes of hypogonadotropic hypogonadism. In men and women with defects 
in neurokinin B pathway, testosterone and estradiol secretion did not reach 
physiological levels, respectively, despite increased LH pulse frequency by 
kisspeptin administration (KP-10 1.1 nmol/kg/hour for 12 hours) (Young et al. 
2013). Whilst kisspeptin-10 normalised serum testosterone in diabetic hypogonadal 
men, baseline testosterone levels were above castrate compared to other studies 
(George et al. 2013). Therapeutic benefits of NKB-KP pathway manipulation in 
patients with low GnRH/LH pulsatility will be determined by the ability to bring 
about gonadal function without desensitisation when used for a longer period of 
time. 
The role of neurokinin B in patients with abnormally low LH secretion has not been 
investigated, which is likely to stem from lack of stimulatory or inhibitory effect of 
neurokinin B on reproductive hormone secretion seen in healthy men and women 
(Jayasena et al. 2014c). In animal models kisspeptin and neurokinin B has been 
shown to advance pubertal maturation (Navarro et al. 2004b, Plant et al. 2006, 
Nakahara et al. 2013) but neither of these neuropeptides have been administered to 
children with delayed puberty. Nevertheless, pubertal induction with kisspeptin and 
neurokinin B may be more physiological in stimulating LH pulses compared with 
sex hormone therapy used currently in girls and boys with delayed puberty.   
Hyperprolactinaemia inhibits pulsatile GnRH/LH release and results in 
hypogonadotropic anovulation and infertility, both of which are reversed by pulsatile 
GnRH infusion (Bouchard et al. 1985, Lecomte et al. 1997), suggesting a 
hypothalamic action of prolactin. Whilst only few GnRH neurones express prolactin 
receptors (Grattan et al. 2007), they are present on kisspeptin neurones (Kokay et al. 
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2011). Prolactin-induced anovulation in mice is associated with diminished 
kisspeptin expression in the AVPV and the arcuate nucleus (Sonigo et al. 2012), 
suggesting that prolactin mediates its actions upstream of GnRH and via kisspeptin 
signalling. Indeed, intraperitoneal administration of Kp-10 restored suppression of 
gonadotropin secretion and ovarian acyclicity in hyperprolactinaemic mice (Sonigo 
et al. 2012). There are no published data on kisspeptin administration in patients with 
hyperprolactinaemia, but it may be an alternative therapy to restore fertility in those 
who are resistant or intolerant to dopamine agonists.  
Kisspeptin therapy has the potential to finesse in vitro fertilization (IVF) techniques. 
Kisspeptin-54 increased LH secretion sufficiently to induce oocyte maturation in a 
FSH/GnRH antagonist superovulation protocol with achievement of live term births 
(Jayasena et al. 2014a). Furthermore, the LH response to exogenous kisspeptin is of 
much shorter duration that following hCG administration, reducing the risk of life-
threatening ovarian hyperstimulation syndrome (OHSS). Indeed, women at risk of 
OHSS, who received kisspeptin-54 following ovarian stimulation, developed no 
moderate, severe or critical OHSS (Abbara et al. 2015). These are preliminary but 
promising insights into alternative agents used in assisted reproduction and a large 
randomised controlled trial is required to determine potential advantages and 
disadvantages over current approaches.  
Nevertheless, the discovery of kisspeptin and neurokinin B has revolutionised our 
understanding of the neuroendocrine signals controlling reproductive axis. The 
potential for translational application of kisspeptin and neurokinin B analogues is 
being explored in several clinical trials and it is likely that the manipulation of NKB-
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